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ABSTRACT 
MECHANISMS OF FATIGABILITY IN PEOPLE WITH TYPE 2 DIABETES AND 
PREDIABETES 
Jonathon Senefeld, B.S. 
Marquette University, 2018 
 Dynamic fatiguing exercise of limb muscles is the basis of exercise training and a 
cornerstone of management of type 2 diabetes mellitus (T2D) and prediabetes. Little is 
known however, about the fatigability of limb muscles (the acute exercise induced 
reduction in force or power) and the involved mechanisms in people with T2D and 
prediabetes.  Current evidence suggests that people with T2D have reduced muscle 
strength and power, are more fatigable after static contractions, and have physical 
impairments affecting activities of daily living. However, impaired function in people 
with T2D compared with controls is larger for dynamic than static tasks. The purpose of 
this dissertation was to determine the magnitude and mechanisms of fatigability in people 
with T2D and prediabetes after a dynamic exercise task with the knee extensor muscles. 
Importantly, these studies matched people with T2D and prediabetes to controls based on 
age, sex, physical activity and body size. 
 
The first studies determined the magnitude of fatigability and the neural and 
muscular mechanisms in people with T2D and controls (Study 1) and in prediabetes 
(Study 2). People with T2D had approximately twice the decline in both power 
(fatigability) and electrically-evoked muscle contractile properties than controls after the 
six-minute dynamic task with the knee extensor muscles. People with prediabetes also 
had greater fatigability (~50%) and reductions in contractile properties than controls, but 
less than people with T2D. The reduction in voluntary activation (neural drive to the 
muscle) after fatiguing exercise was not different between people with T2D, prediabetes 
and controls. Thus, the greater fatigability in people with T2D was due to mechanisms 
within the skeletal muscle rather than neural drive.  
 
Study 3 determined whether skeletal muscle blood flow could explain the greater 
fatigability in people with T2D. People with T2D had greater fatigability and lower blood 
flow after exercise than controls, and there was an association between fatigability and 
the exercise-induced increase in muscle blood flow after exercise. Collectively, these data 
suggest that people with T2D and prediabetes have greater fatigability during dynamic 
exercise with knee extensor muscles due to mechanisms effecting muscle contractile 
properties, including impaired skeletal muscle blood flow.  
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CHAPTER 1: INTRODUCTION AND REVIEW OF THE LITERATURE 
1.1 Epidemiology and Etiology of Diabetes and Prediabetes 
Type 2 diabetes mellitus (T2D) is characterized by chronically elevated blood 
glucose and is the costliest chronic disease in the United States (Trogdon et al., 2015). 
T2D affects approximately 13% of the US population (Menke et al., 2015), and is rapidly 
growing in prevalence with an expected increase in incidence by 70% in the next 20 
years (Shaw et al., 2010). The leading cause of disability among people with T2D is 
diabetic polyneuropathy, which affects ~50% of people with T2D and causes gait 
instability, muscle atrophy, weakness, and/or increased susceptibility to fatigue (Allen et 
al., 2013; Allen et al., 2014a; Allen et al., 2014b; Allen et al., 2015a; Allen et al., 2015b; 
Senefeld & Hunter, 2016; Stino & Smith, 2017). The most effective intervention to delay 
onset of T2D and impede the progression of T2D is lifestyle intervention including 
regular exercise training (Knowler et al., 2002; Diabetes Prevention Program Research et 
al., 2009; Herman et al., 2017). However, there is little scientific evidence to characterize 
physical performance and the factors that might limit physical performance (neural and 
muscular factors) during a single bout of exercise. To address this gap in scientific 
knowledge, the aim of this dissertation is to compare performance of dynamic exercise 
and determine the contribution of neural and muscular factors that potentially limit 
exercise performance in people with T2D and prediabetes compared to people without 
T2D (i.e. controls). The following provides an in-depth review of the epidemiology and 
etiology of T2D and a pre-cursor condition known as prediabetes, the clinical 
manifestations of T2D, a brief review of the benefits of exercise training, and a review of 
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the scientific literature examining the limitations to a single bout of exercise in people 
with diabetes mellitus.  
Diabetes mellitus is a group of metabolic disorders resulting in chronically 
elevated blood glucose levels (American Diabetes, 2015a) because the islet cells of the 
pancreas produce inadequate insulin and or tissues in the body develop resistance to the 
action of insulin. T2D is a clinical distinction of diabetes mellitus. People with T2D have 
impairments in glucose disposal that require clinical treatment and have considerable risk 
of developing clinical-symptoms (e.g. sensory loss) associated with chronically high 
glucose (American Diabetes, 2015a). The pancreas in people with T2D typically retains 
the ability to produce insulin but to a reduced capacity, which is in stark contrast to type 1 
diabetes in which the pancreas can no longer produce insulin (American Diabetes, 
2015a). Approximately 95% of cases of diagnosed diabetes mellitus are T2D (American 
Diabetes, 2018). Additionally, beginning in 1997, the Expert Committee on Diagnosis 
and Classification of Diabetes Mellitus (1997) officially recognized people who did not 
meet clinical criteria for diagnosis of diabetes, but had elevated clinical markers that 
indicated increased risk of developing T2D—i.e. increased fasting blood glucose and 
HbA1c. This patient population is now referred to as people with prediabetes (American 
Diabetes, 2015a).  
T2D and prediabetes have become global pandemics (Ogurtsova et al., 2017), 
estimated to currently affect 13% and 37% of Americans, respectively (Menke et al., 
2015). However, a considerable portion of these people with T2D (~25%) and 
prediabetes (~90%) are undiagnosed (American Diabetes, 2018). Diabetes mellitus 
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(including prediabetes) is the most common chronic condition in the United States 
(Buttorff et al., 2017).  
The primary diagnostic criteria for diabetes mellitus are glucose concentration and 
glucose regulation. The gold standard for diagnosis is the two-hour oral glucose tolerance 
test (OGTT) whereby endogenous action of insulin is estimated by measuring plasma 
glucose levels two hours after a bolus of glucose (e.g. 75 g). This test (OGTT) can 
demonstrate insulin resistance and β-cell dysfunction that are the pathophysiological 
basis of diabetes (Bartoli et al., 2011).  
Another diagnostic criterion for diabetes mellitus is glycated hemoglobin, 
commonly known as HbA1c. HbA1c is an assessment of the proportion (%) of hemoglobin 
molecules that have bound glucose (Roszyk et al., 2007), which is often considered an 
indication of average blood glucose levels over the previous 120-day period because 120 
days is the average lifespan of an erythrocyte (Bode et al., 2007). Assessment of HbA1c is 
relatively inexpensive (Bode et al., 2007), is predictive of diabetes risk factors and 
prognosis of diabetes (Diabetes Prevention Program Research Group et al., 2014; 
Vijayakumar et al., 2017), and has high concordance with the oral glucose tolerance test 
(Kim et al., 2016). Therefore, HbA1c assessment is often used to determine T2D or 
prediabetes for research purposes, but the OGTT remains the clinical gold standard for 
diagnosis (Kim et al., 2016).  
Another diagnostic criteria for diabetes is the assessment of plasma glucose after 
an 8-hour fast (Kim et al., 2016). The American Diabetes Association has suggested 
values for the diagnostic criteria of T2D and prediabetes, as demonstrated in Table 1.1 
(American Diabetes, 2015a). For diagnostic purposes, the HbA1c and fasting glucose 
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must be determined by lab measurement and not by point of care testing (American 
Diabetes, 2018). 
 T2D Prediabetes Control 
Oral Glucose Tolerance Test (mmol·L-1) ≥ 11.1 7.8 – 11.0 ≤ 7.7 
HbA1c (%) ≥ 6.5 5.7 – 6.4 ≤ 5.6 
Fasting Plasma Glucose (mg·dL-1) ≥ 126 100 – 125 ≤ 99 
Table 1.1. Classification criteria for type 2 diabetes and prediabetes. Oral glucose 
tolerance test, glycated hemoglobin (HbA1c) and fasting plasma glucose are used to 
demarcate type 2 diabetes (T2D) and prediabetes; however, the oral glucose tolerance test 
is the clinical gold standard for diagnosis (Kim et al., 2016). 
1.2 Development and Complications of Type 2 Diabetes 
The factors leading to a predisposition of T2D are multifactorial including 
environmental factors (e.g. obesity, non-adherence to diet, smoking and lack of physical 
activity) (Hu et al., 2001) and genetic variants (Vassy et al., 2014). In the largest known 
cohort study (Nurses’ Health Study), risk of developing T2D was prospectively evaluated 
in ~85,000 women after a 16-year observation period (Hu et al., 2001). Approximately 
3,300 women developed T2D (~4% incidence) and the two risk factors most predictive of 
developing T2D were physical activity and body mass index (BMI). Relative to the most 
physically active (7 or more hours of exercise per week), women with the least amount of 
physical activity (≤ 30 minutes of exercise per week) were twice as likely to develop T2D 
(Hu et al., 2001). Similarly, women with the highest BMI (≥ 35.0 kg·m-2) were 2.5 times 
more likely to develop T2D compared to women with the lowest BMI (<23.0 kg·m-2) (Hu 
et al., 2001).  
Additionally, there are several genetic variants that have been identified to be 
associated with T2D and models based on genetic risk scores can predict relative risk for 
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development of T2D (Vassy et al., 2014). However, compared to simple demographic 
and clinical prediction models (BMI, systolic blood pressure, fasting plasma glucose and 
family history of T2D) without genetic information, the addition of genetic information 
has a small impact on relative risk prediction for T2D (Vassy et al., 2014). Collectively, 
these data highlight the importance of modifiable risk factors—particularly physical 
activity and body mass— in the development of T2D. As discussed in this introduction, 
physical activity may also be a panacea for many of the complications that develop as a 
result of T2D and prediabetes.  
There are three primary pathophysiological complications of T2D, 1) diabetic 
polyneuropathy, 2) metabolic dysfunction and 3) vascular dysfunction. Each of these 
pathophysiological complications results in multiple clinical manifestations and marked 
variability between people; however, one commonality is that greater insulin resistance is 
associated with worsening of each complication—diabetic polyneuropathy (Lee et al., 
2016), metabolic dysfunction (Jelenik & Roden, 2013) and vascular dysfunction 
(Montero et al., 2013; Mahmoud et al., 2016). 
Diabetic Polyneuropathy 
Diabetic polyneuropathy can manifest in nerve dysfunction among motor, sensory 
and autonomic nerves (Senefeld & Hunter, 2016). Diabetic polyneuropathy often 
manifests in a symmetrical and length-dependent pattern affecting distal portions of long 
peripheral nervous of people with DM (Said, 2007), and can contribute to the 
pathogenesis of foot ulcers (Papanas et al., 2007) and axonal loss and demyelination 
(Severinsen & Andersen, 2007). Excessive glucose in the blood, a hallmark feature of 
T2D, contributes to hyperglycemic milieu in the soma of cells in tissue of the nervous 
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system (Hasselbalch et al., 1999; Chung et al., 2003), resulting in oxidative stress in the 
nerve axons (Souayah et al., 2009). This oxidative stress causes withdrawal of the longest 
(typically most distal) nerve axons from the innervated tissue without cellular death 
(Souayah et al., 2009), providing the potential for recovery from structural damage of the 
axon prior to death of the nerve soma (Kennedy & Zochodne, 2005). Although in some 
cases small fiber injury (autonomic and sensory) is the sole pathology of diabetic 
polyneuropathy (Moghtaderi et al., 2006; Papanas & Ziegler, 2011), there can be 
significant damage to motor nerve function in people with diabetic polyneuropathy. 
Diabetic polyneuropathy can manifest as motor nerve axon degeneration (Souayah et al., 
2009) and result in as muscle atrophy, weakness, and/or increased susceptibility to 
fatigue (Allen et al., 2013; Allen et al., 2014a; Allen et al., 2014b; Allen et al., 2015a; 
Allen et al., 2015b). Motor dysfunction occurs as a result of alterations to the motor nerve 
axon, motor nerve soma, and motor unit neuromuscular junctions (Fahim et al., 2000; 
Kaji, 2003). In human diabetes and experimental diabetes in rodent models, diabetic 
polyneuropathy is associated with slowing of motor nerve conduction velocity (Hansen & 
Ballantyne, 1977; Sima et al., 1993; Kaji, 2003; Kikkawa et al., 2005; Almeida et al., 
2008), reduced muscle contractile function (Fahim et al., 1998; Allen et al., 2014b), 
increased neuromuscular transmission failure (Miglietta, 1973; Chang & Chuang, 1996; 
Fahim et al., 2000; Marques & Santo Neto, 2002; Allen et al., 2015a), muscle atrophy 
(Andersen et al., 1997; Severinsen et al., 2007) and muscle weakness (Andersen et al., 
1997; Andreassen et al., 2006; Allen et al., 2013).  Importantly, people with T2D and no 
clinical signs of diabetic polyneuropathy also demonstrate reduced maximal strength of 
limb muscles, impaired mobility, and quality of life compared to controls (Ijzerman et al., 
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2011; IJzerman et al., 2012); and diabetic polyneuropathy has a moderate additional 
effect to cause greater reductions in strength, mobility and quality of life in these people 
(Ijzerman et al., 2011; IJzerman et al., 2012).  
In addition to direct effects on motor function, T2D and diabetic polyneuropathy 
may affect commands from the motor cortex. It has been demonstrated that people with 
T2D and diabetic polyneuropathy have lower estimated number of motor units and 
reduced mean motor unit firing rates in the tibialis anterior and first dorsal interosseous 
(Allen et al., 2014a) compared with age-matched control participants. In a group of 
people with diabetes mellitus (type 1 or type 2), people with symptomatic diabetic 
polyneuropathy demonstrated reduced compound muscle action potential, reduced motor 
nerve conduction velocity and reduced muscle strength of the ankle dorsiflexors and knee 
extensors compared to people with diabetes and absent or asymptomatic diabetic 
polyneuropathy (Andersen et al., 1998). Additionally, both groups (people with diabetes 
with or without diabetic polyneuropathy) demonstrated these impairments (reduced 
compound muscle action potential, conduction velocity and strength) relative to healthy 
controls without diabetes (Andersen et al., 1998). Similarly, people with type 1 diabetes 
mellitus demonstrated reduced contractile force, slower conduction velocity and lower 
mean motor unit discharge rate (Almeida et al., 2008).  
There is more recent evidence examining motor unit firing patterns of the vastus 
lateralis in men with T2D but without diabetic polyneuropathy compared with age-
matched control men (n = 8 vs 8), demonstrating that men with T2D and no diabetic 
polyneuropathy had lower and more variable motor unit instantaneous firing rates 
(Watanabe et al., 2013). Using high-density surface electromyography (EMG) of the 
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vastus lateralis during sustained (2-minute) submaximal (10% maximum), isometric 
exercise with the knee extensors, it has been demonstrated that men with T2D have a 
reduced area of activation within the knee extensors and fewer changes (less 
heterogeneity) in the area of muscle activation during the 2-minute exercise (Watanabe et 
al., 2012). These data may suggest that people with T2D may activate limited numbers of 
motor units continuously during sustained exercise (Watanabe et al., 2012). Collectively, 
these data suggest that people with T2D may have reduced and more variable motor unit 
firing rates and reduced number of active motor units during sustained contractions 
(which are exacerbated in people with T2D and diabetic polyneuropathy) and may 
contribute to increased fatigability for people with T2D. 
Metabolic Dysfunction 
 Skeletal muscle plays a major role in energy metabolism, and this metabolically 
active tissue is responsible for at least 80% of insulin-stimulated glucose disposal 
(Szendroedi & Roden, 2008). Mitochondria, the organelle responsible for oxidative 
phosphorylation in skeletal muscle, plays such a prominent role in glucose metabolism 
that some researchers insist that insulin resistance is a proxy for reduced mitochondrial 
quality or quantity (Porter & Wall, 2012). There are three primary molecular pathways 
thought to be impaired in people with T2D, which impair the metabolism of glucose in 
mitochondria and skeletal muscle causing slowed glucose disposal.  
The first pathway that can impair glucose metabolism in people with T2D is 
reduced efficacy of the translocation of GLUT4 glucose transporter from intracellular 
compartments to the extracellular membrane to allow insulin-stimulated glucose uptake 
(Goodyear & Kahn, 1998). This translocation of GLUT4 occurs via insulin receptor 
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substrate 1, at a specific domain referred to as IRS1-P13K and subsequent 
phosphorylation of TBC1D4 (Goodyear & Kahn, 1998; Maarbjerg et al., 2011; Cartee, 
2015). Although the pathway is debated (Petersen & Shulman, 2002) and more intricate 
than originally proposed (Hue & Taegtmeyer, 2009), a second pathway thought to impair 
glucose metabolism in the mitochondria among people with T2D is increased 
concentrations of acetyl-CoA, which inhibits pyruvate dehydrogenase and therefore 
reduces glucose oxidation via reduced activity of the tricarboxylic acid (TCA) cycle—in 
a process called the ‘Randle cycle’ (Randle et al., 1963). The third pathway which 
impairs glucose metabolism in people with T2D is reduced expression of the PGC1 
protein (PPARγ coactivator-1), which is a master regulator of mitochondrial biogenesis 
(Montgomery & Turner, 2015). Reduced expression of PGC1 will reduce the generation 
of mitochondrial via reduced transcription of genes responsible for mitochondrial 
biogenesis. These three pathways are highlighted in the Figure 1.1, reprinted from 





Figure 1.1. Schematic of the potential sites of metabolic dysfunction in people with 
type 2 diabetes. Skeletal muscle is responsible for an enormous amount of metabolism, 
responsible for at least 80% of insulin-stimulated glucose disposal. However, people with 
T2D often present with metabolic dysfunction within the myocyte and mitochondria 
within the myocyte. The metabolic dysfunction in people with T2D is often seen at the 
sites of glucose transport into the cell (e.g. myocyte) via GLUT4 at the IRS1-P13K 
domain, reduced genetic transcription and protein expression of PGC1, and increased 
concentrations of Acteyl-CoA, each of which reduce the magnitude and rate of glucose 
oxidation. The figure was reprinted from (Szendroedi & Roden, 2008).  
 These impairments in metabolic function would directly shift metabolic processes 
during exercise, resulting in a net shift toward increased anaerobic processes 
(phosphocreatine/creatine kinase system and anaerobic glycolysis) and reduced aerobic 
metabolic processes (TCA cycle and oxidative phosphorylation) (Kelley et al., 2002). 
Importantly, this potential shift in metabolic processes for people with T2D could result 
in greater concentrations of anaerobic metabolic by-products (e.g. hydrogen ion and 
inorganic phosphate) which are known to impair skeletal muscle contractile function and 
increase fatigability in healthy muscle (Fitts, 1994; Kent-Braun et al., 2012; Debold et 
al., 2016), and stimulate Group III and IV afferents which reduce voluntary activation 
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from the motor cortex (Taylor et al., 2016; Hunter, 2017). However, there is substantial 
research to support that these three pathways (GLUT4 pathway, acetyl-CoA pathway and 
PGC1 pathway) can be altered during sustained, acute bouts of exercise and prolonged 
exercise training, which creates a stimulus for enhanced action of insulin (Goodyear & 
Kahn, 1998; Holloszy, 2005; Stanford & Goodyear, 2014; Kim et al., 2015), and 
although weight loss can accompany exercise training, these observations are likely not 
due to weight loss alone (Weiss et al., 2007).  
Vascular Dysfunction 
 Although there is no definitive conclusion that muscle oxygen delivery is 
impaired in people with T2D, there is strong evidence to support abnormal skeletal 
muscle blood flow regulation in people with T2D at rest and during exercise (for review, 
see (Poitras et al., 2018)). As a broad concept, blood flow is required to support sustained 
exercise to deliver airborne oxygen to the exercising skeletal muscle for substrate 
metabolism (Saltin et al., 1998) and clear exercise-stimulated metabolic by-products from 
the muscle tissue that inhibit contractile function of the exercising muscle in high 
concentrations (Fitts, 1994). The increase in blood flow during exercise, termed exercise-
induced hyperemia, closely matches the metabolic demands of the contracting muscle 
(Andersen & Saltin, 1985). The blood flow redistribution that occurs during maximal 
exercise may represent the largest physiological stress on the cardiovascular system, 
resulting in 8× greater blood flow during exercise compared to rest (Joyner & Casey, 
2015). The regulation of blood flow distribution is mediated systemically by sympathetic 
nervous system activity (Joyner & Casey, 2015); however, blood flow to the exercising 
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muscle is primarily mediated by reactivity of the vasculature supplying blood to the 
exercise muscles (Casey & Joyner, 2011). 
Peripheral blood flow is primarily regulated by the diameter of the vasculature, 
and much of the dynamic control of blood flow during exercise occurs in smaller 
vasculature (termed resistance vessels) (Sarelius & Pohl, 2010). The exercise-induced 
hyperemia is circulated and gas exchange occurs within the exercising muscle(s) via 
capillaries in small terminal arteriole trees to replenish substrates for metabolic processes, 
and upstream of these terminal arteriole trees are four to six orders of artery branch sizes 
that are perfused from one major feed artery to the muscle (Joyner & Casey, 2015). Thus, 
although these large-conduit feed arteries to muscles are typically measured to determine 
vascular health or function (as discussed below) (Thijssen et al., 2011), the vasoreactivity 
of these conduit arteries is not functionally significant for the regulation of blood flow to 
the exercising muscle (Joyner & Casey, 2015). 
 From a bottom-up perspective, the vasodilator response to skeletal muscle 
contraction is conducted upstream after being initiated within the terminal arteriole trees 
(a.k.a. microcirculation) (Segal et al., 1989), and this vasodilatory response begins within 
~1s of initiation of exercise (VanTeeffelen & Segal, 2006). The signaling process 
mediating the vasodilatory response to exercise is still actively debated; however, there is 
convincing evidence that vasodilation is primarily mediated by chemical factors released 
from the contracting muscles or endothelium with minimal contributions of neutrally-
mediated or muscle pump-mediated vasodilation (for review, see (Joyner & Casey, 
2015)). The chemically-mediated vasodilation during exercise is highly redundant and 
most vasoactive chemicals also stimulate the release of nitric oxide, thereby making it 
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difficult to determine the contribution of nitric oxide or another vasoactive chemical 
(Joyner & Casey, 2015). The primary vasoactive chemicals released during skeletal 
muscle contraction include: potassium ion (K+), nitric oxide (NO), hydrogen ion (H+), 
and adenosine (Joyner & Casey, 2015). In addition to these vasodilatory substances, two 
other underlying vasoactive processes occur during exercise: 1) the brief compression of 
arterioles due to skeletal muscle contraction initiates a reactive hyperemia response 
(Laughlin, 1987) causing vasodilation and 2) increased sympathetic nerve activity due to 
exercise leads to global vasoconstriction and can blunt the exercise-induced vasodilation 
in the large conduit arteries but likely not small arterioles (Segal et al., 1999). 
 Although the vasoreactivity of large conduit arteries is not functionally significant 
for the regulation of blood flow to the exercising muscle (Joyner & Casey, 2015), the 
vasoreactivity of these arteries is commonly used as a proxy of vascular health (Thijssen 
et al., 2011). This common clinical indication of vascular health is a flow-mediated 
dilation study consisting of measuring conduit artery diameter before and after a 5-minute 
bout of complete arterial occlusion downstream of the conduit artery. Flow-mediation 
dilation studies may reflect the bioavailability of nitric oxide, and these studies provide 
important prognostic information for endothelial health and cardiovascular disease risk 
(Thijssen et al., 2011). A recent systematic review and meta-analysis (Montero et al., 
2013) demonstrated impaired endothelial function in non-exercising vasculature in 
people with T2D compared to age matched controls in 28 out of 29 studies—see Figure 
1.2.  Despite these robust differences in a proxy for vascular health, there is sparse data to 
examine blood flow (to infer endothelial function) during or after exercise in people with 
T2D. Moreover, there is no data to examine blood flow during or after exercise in people 
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with T2D compared to controls matched for age, sex, BMI and physical activity, so the 
independent effects of T2D and BMI or physical activity on blood flow during exercise 
are unknown. Our understanding of the potential association between blood flow 
regulation and fatigability is paramount in people with T2D, because this potential 
relationship may highlight a clinical target for improvement in people with T2D which 
could ameliorate increased exercise intolerance and reduced exercise training adherence 




Figure 1.2. Forest Plot of standard mean differences in resting endothelial function 
(assessed as dilation mediated by flow, acetylcholine, methacholine or serotonin) 
between controls and people with type 2 diabetes. Each data point represents the mean 
difference of endothelial function between people with T2D and controls, with the 
vertical grey line denoting no difference between the groups. The filled circles denote 
data in favor of better endothelial function in controls and the unfilled circles denote data 
in favor of better endothelial function in people or animals with T2D. Collectively, these 
data provide strong evidence that people with T2D have impaired endothelial function 
compared to the controls. This figure was adapted from  (Montero et al., 2013), and 
includes data from the following studies: (Cipolla et al., 1996; Williams et al., 1996; Pitei 
et al., 1997; Enderle et al., 1998; Lim et al., 1999a; Lim et al., 1999b; Makimattila et al., 
1999; Anderson et al., 2001a; Heitzer et al., 2001; Kimura et al., 2001; Ma et al., 2001; 
van de Ree et al., 2001; Ihlemann et al., 2002; Matsumoto et al., 2002; Tan et al., 2002; 
van Etten et al., 2002; Woodman et al., 2002; Ifrim & Vasilescu, 2004; Vehkavaara & 
Yki-Jarvinen, 2004; Woodman et al., 2005; Woodman et al., 2006; Karabag et al., 2007; 
Sivitz et al., 2007; Sokolnicki et al., 2007; Beer et al., 2008; Brooks et al., 2008; Bruno 




1.3 Treatment of Type 2 Diabetes 
The primary clinical goals of T2D treatment are to reduce HbA1c and systolic and 
diastolic blood pressures; improve lipid profile; and limit complications of T2D 
(including diabetic polyneuropathy, metabolic dysfunction, and vascular dysfunction) 
(American Diabetes, 2015b). Due to public interest and research funding, vast 
improvements in diabetes management and quality of care have led to reductions in 
diabetes-related complications and mortality (Narayan, 2016). Better management of 
T2D, however, is overshadowed by alarming and rapidly increasing numbers of people 
with T2D— providing rationale to focus on the interventions that can prevent T2D as 
opposed to treat complications (Narayan, 2016). According to US and international 
treatment guidelines (Czupryniak, 2009; Garber et al., 2018), metformin is the first 
prescribed medication to treat T2D. However, as T2D progresses, insulin sensitivity and 
secretion are reduced, and it is commonly accepted that people with T2D will eventually 
need insulin secretagogues and exogenous insulin therapy (Home et al., 2014). Although 
insulin secretagogues and basal insulin are effective interventions for management of 
T2D symptoms (Sasali & Leahy, 2003), the reversion rate of T2D among people that are 
prescribed insulin secretagogues or basal insulin is very low (<2%) (Karter et al., 2014). 
Therefore, studies that examine the potential remission of T2D or prevention of T2D 
among people with prediabetes focus on the potential utility of metformin.  
 In 1996, a randomized, controlled clinical trial involving 27 clinical centers across 
the United States (called the Diabetes Prevention Program or DPP) enrolled 3,149 
participants who had prediabetes and were at high risk of progression to T2D and 
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randomly assigned participants to one of the following groups for a 4-year period 
(Knowler et al., 2002): 
Lifestyle Group: Participants exercised at least 150 minutes per week, attempted 
to lose 7% body weight, maintained a healthy diet, and had regular meetings with 
nurses and counselors. 
Metformin Group: Participants took 850 mg of metformin twice daily and were 
provided standard advice about diet and physical activity. 
Placebo Group: Participants took a placebo pill twice daily and were provided 
standard advice about diet and physical activity. 
This on-going longitudinal study sponsored by the National Institutes of Diabetes and 
Digestive Kidney Diseases continues to monitor the participants enrolled in the initial 
trial in 1996 and represents the most comprehensive dataset to determine the efficacy of 
metformin on the delay or prevention of T2D. The initial studies demonstrated that after a 
3-year period, participants in the metformin group had a 31% reduction in risk of 
developing T2D compared to participants in the placebo group (Knowler et al., 2002). 
After 15 years, of those participants that continued to take metformin there was a 18% 
reduction in the incidence of T2D compared to placebo, and it was estimated that daily 
metformin allowed for two additional healthy years before development of T2D 
compared to placebo (Herman et al., 2017). Although metformin was successful in the 
management and prevention of T2D, the lifestyle intervention group had a 58% and 27% 
reduction in risk of developing T2D at 3- and 15-year follow up and an additional four 
healthy years before development of T2D compared to placebo—providing evidence that 
lifestyle interventions are nearly twice as effective as metformin for prevention of T2D 
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(Knowler et al., 2002; Herman et al., 2017). The intensive lifestyle treatment worked best 
in older individuals and those without marked obesity. 
Exercise is Medicine for People with T2D and Prediabetes 
In light of the results of the Diabetes Prevention Program described above, and 
similar research, exercise training has become a cornerstone of T2D management and 
T2D prevention for those with prediabetes (Sigal et al., 2006). The American Diabetes 
Association, International Diabetes Federation, and nearly all other organizations 
associated with diabetes and endocrinology suggest lifestyle therapy (diet, weight loss 
and exercise training) as the first intervention for the prevention and management of T2D 
(Czupryniak, 2009; Garber et al., 2018). Regular exercise training can ameliorate 
pathophysiological biomarkers of T2D (e.g. fasting blood glucose) and can accomplish 
the primary goals of management of T2D: reduce HbA1c (Umpierre et al., 2011); reduce 
systolic and diastolic blood pressures (Chen et al., 2015); improve lipid profile (Chen et 
al., 2015); and lower BMI (Chen et al., 2015). Additionally, regular exercise training is 
beneficial for acute glycemic control (Reynolds et al., 2015), insulin sensitivity 
(Holloszy, 2003, 2005), has a protective influence on cardiovascular health (Padilla et al., 
2015), and is the only intervention that can improve aerobic fitness which is one of the 
best predictors of all-cause mortality in older adults (Trappe et al., 2013) and people with 
T2D (Church et al., 2004). However, people with T2D (and possibly prediabetes) have 
disproportionately high rates of exercise intolerance compared to controls (Reusch et al., 
2013; Poitras et al., 2018). The potential exercise intolerance in people with T2D and 
prediabetes is primarily suggested to be due to: metabolic dysfunction (Stanford & 
Goodyear, 2014), cardiovascular and endothelial dysfunction (Poitras et al., 2018), 
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clinical symptoms of depression/fatigue (Fritschi & Quinn, 2010), and possibly 
impairments in contractile properties of muscle (IJzerman et al., 2012; Allen et al., 2016). 
These four symptoms can contribute to a decline in a decline in muscle force or power 
during exercise—often termed ‘fatigability’ (Kluger et al., 2013; Enoka & Duchateau, 
2016). Fatigability can be more generally defined as any decline in an objective measure 
of muscle performance over a discrete period, which we commonly measure in the 
research laboratory as a reduction in muscle force or power (Kluger et al., 2013; Enoka & 
Duchateau, 2016). 
Currently, no data exist that examine fatigability in humans with prediabetes; 
however, there are studies determining fatigability in people with T2D. General findings 
from these studies suggest that people with T2D have greater or equivalent fatigability 
compared to lean, healthy controls after isometric and isokinetic fatiguing tasks, and 
these studies are described in the next section. However, there is a dearth of conclusive 
data on fatigability during dynamic contractions in people with T2D nor comparing 
fatigability in people with T2D with controls matched for anthropometry and physical 
activity. This line of investigation has scientific merit because exercise training is the 
first-line of prevention and treatment of T2D, yet fatigability and the contributing 
mechanisms are not well understood. 
1.4 Fatigability in People with Type 2 Diabetes 
The symptoms contributing to reduced exercise performance are globally termed 
fatigue and can be categorized into two domains: perceived fatigability and performance 
fatigability (Kluger et al., 2013; Enoka & Duchateau, 2016). Perceived fatigability is 
defined as self-reported symptoms of exertion, exhaustion, and enervation, can be 
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assessed at rest or during exercise performance  (Kluger et al., 2013). In the absence of 
exercise (at rest), perceived fatigability is a common symptom in people with T2D, and 
has been associated with limitations in physical exercise and a lack of motivation to 
perform exercise (Fritschi & Quinn, 2010). The mechanisms for perceived fatigability in 
people with T2D in the rested state may be related to poor glucose control (hypo- or 
hyper-glycemia or glucose fluctuations) (Sommerfield et al., 2004), diabetic 
polyneuropathy (Rijken et al., 1998), impaired sleep quality (Cuellar & Ratcliffe, 2008), 
emotional distress from daily disease management (de Sonnaville et al., 1998), 
depression (Anderson et al., 2001b), and obesity (Pickup, 2004). Although increased 
perceptions of fatigability may contribute to impaired physical function (Singh et al., 
2016), the association between perceived and performance fatigability in people with 
T2D and prediabetes is unknown.   
Performance fatigability is the decline in an objective measure of performance 
over a discrete period that limits human performance (Kluger et al., 2013; Enoka & 
Duchateau, 2016)—which is often measured as the decline in expected force or power of 
limb muscles during a single bout of limb exercise (Kluger et al., 2013; Hunter, 2017) in 
a controlled laboratory setting. The mechanisms contributing to performance fatigability, 
also known as fatigability or muscle fatigue, are dependent on the demands of the task 
being performed (i.e. task dependent) (Enoka & Stuart, 1992)—and thus may differ with 
type of muscle contractions. For example, there is substantial evidence to demonstrate 
that healthy women have less fatigability than men during submaximal, isometric 
fatiguing exercises (Hunter, 2009, 2014); however, women may have greater fatigability 
than men during submaximal, dynamic fatiguing exercises (Hunter, 2016a, b). This 
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paradoxical example, in combination with data presented below, provide the primary 
rationale for examining fatigability in people with T2D during dynamic fatiguing exercise 
and including cohorts of participants large enough to quantify sex-related differences in 
fatigability in the studies contributing to this dissertation. As discussed below, there is 
little evidence to examine fatigability in people with T2D or prediabetes during high 
velocity dynamic contractions or potential sex-related differences in fatigability among 
people with T2D or prediabetes. 
In general, the mechanisms that contribute to fatigability can originate from many 
different tissues along the motor pathway, and are generally categorized into neural 
(mechanisms upstream of the neuromuscular junction) and muscular (mechanisms within 
the muscle) (Gandevia, 2001; Debold et al., 2016), see Figure 1.3. Current scientific 
evidence (as discussed below) demonstrates that neural mechanisms (supraspinal and 
spinal; observed as a loss in voluntary activation and altered motor unit behavior) and 
muscular mechanisms (e.g. mitochondrial and endothelial dysfunction) could contribute 
to greater fatigability in people with T2D. Although these mechanisms may be 
exacerbated by diabetic polyneuropathy (Allen et al., 2016; Senefeld & Hunter, 2016), 
this work in this dissertation focuses on the any impairments that may occur prior to 
clinically-detectable and symptomatic diabetic polyneuropathy. Additionally, these 
neural and muscular mechanisms are exacerbated in the presence of other co-morbidities 
(e.g. sedentary lifestyle and obesity), thus these co-morbidities were accounted for in the 





Figure 1.3. Schematic of the potential sites of fatigability in healthy people (reprinted 
from Hunter (Hunter, 2017)), and that may be relevant to people with type 2 diabetes 
During muscle contractions, activation of skeletal muscle is governed by complex 
interactions between activation of the motor cortex, descending drive through the ventral 
horn of the spinal cord, activation of motor neurons, propagation of the action potential 
across the neuromuscular junction, and cross-bridge cycling of the myofilaments. 
However, activation of skeletal muscle is regulated by interactions of excitatory and 
inhibitory inputs at each level of activation. During volitional exercise, it is estimated that 
reductions in contractile function of skeletal muscle are responsible for approximately 
75% of the observed fatigability with up to 25% of the observed fatigability due to neural 
(spinal and supraspinal) mechanisms (Gandevia et al., 1996; Taylor et al., 2016).  
There is growing evidence that people with T2D have greater fatigability 
compared with healthy controls; however, the effects of T2D per se (excluding the effects 
of insulin, diabetic polyneuropathy, physical activity and body size) are unknown. A 




 Recently, Allen and colleagues (Allen et al., 2015a) demonstrated that people 
with T2D and diabetic polyneuropathy have greater fatigability than controls after 
isometric contractions. Ten people with T2D (6 men; 64 ± 11 years) and diabetic 
polyneuropathy and 10 controls matched for age and sex (6 men; 62 ± 12 years) 
performed a sustained maximal voluntary isometric contraction (MVIC) until the 
isometric torque dropped by 40% with the ankle dorsiflexor muscles, with peroneal nerve 
stimulations performed before and after the fatiguing task. The time to task failure was 
~20% shorter (56.4 ± 14.2s vs. 71.1 ± 11.7s) in people with T2D and diabetic 
polyneuropathy compared with controls (i.e. greater fatigability in T2D) and there was 
evidence of failure in neuromuscular transmission (reduced maximal compound muscle 
action potential, Mmax) in people with T2D and diabetic polyneuropathy. Because 
controls were not matched for physical activity or BMI—both of which may be 
associated with fatigability (Bogdanis, 2012; Mehta & Cavuoto, 2017)— these results 
may not reflect greater fatigability due to T2D per se, these data demonstrate that people 
with T2D may have greater fatigability and neuromuscular transmission or motor unit 
properties may play a role.  
Similarly, Almeida and colleagues (Almeida et al., 2008) examined motor unit 
properties and fatigability in people with type 1 diabetes (T1D) and diabetic 
polyneuropathy. Intramuscular EMG was inserted into the belly of the vastus lateralis and 
participants performed an intermittent (6s contraction, 4s rest) at 50% MVIC until the 
50% MVIC could not be held for 3 s. The time to task failure was ~twice as long (786.4 ± 
654 s vs. 358.6 ± 124.5 s) and motor conduction velocities were ~40% faster (66.7 ± 1.68 
m·s-1 vs. 48.2 ± 2.8 m·s-1) in controls compared to people with T1D and diabetic 
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polyneuropathy. Additionally, people with T1D and diabetic polyneuropathy had a 
reduction in motor unit discharge frequencies during the fatiguing task whereas controls 
had maintained motor unit discharge frequencies. These data suggest that people with 
T1D and diabetic polyneuropathy have greater fatigability, which may be associated with 
reductions in activation of the motor neuron pool for the knee extensor muscles. 
Collectively, these two studies (Almeida et al., 2008; Allen et al., 2015a) suggest that 
people with diabetes and diabetic polyneuropathy have greater fatigability due to 
impairments in activation of motor units; however, the effects of diabetes itself are 
unknown because controls were not matched for physical activity or BMI and people 
with diabetes also had polyneuropathy. 
Fatigability has also been assessed among cohorts of people with T2D and no 
signs of diabetic polyneuropathy. In a study from Bazzucchi and colleagues (Bazzucchi 
et al., 2015), eight sedentary men with T2D and eight sedentary, age-matched men 
performed an isometric fatiguing task with the knee extensor muscles and (separately) 
with the elbow flexors, holding 80% MVIC until torque dropped below 72% MVIC for 3 
s. People with T2D had a shorter time to task failure (i.e. more fatigable; 20.1 ± 0.7s vs. 
26.9 ± 1.3s) compared to controls for the knee extensors, but there was no group-
difference in fatigability for the elbow flexors. Thus, group-differences (T2D vs. control) 
in fatigability may be specific to the limb used to perform the fatiguing exercise (upper 
vs. lower extremity)—a commonly observed phenomenon referred to as task specificity 
(Hunter, 2017). However, the “controls” that participated in this study had a mean HbA1c 
value in the prediabetes range (5.7 ± 0.1%), and the prediabetes condition may predispose 
participants to susceptibility to fatigability.  
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Another study of fatigability in people with T2D and no clinical signs of 
neuropathy from Petrofsky and colleagues (Petrofsky et al., 2005) enrolled 10 people 
(five men, five women; 38 ± 9.7 years) with T2D and matched these people with 10 
controls (five men, five women; 33.8 ± 3.5 years) based on age and sex. Each group 
performed two isometric fatiguing contractions (40% MVIC with 5 minutes between 
each fatiguing contraction) with the finger flexors of their right hand. Each group 
performed the first fatiguing contraction for a similar time (~130 s); however, the second 
fatiguing contraction was shorter for people with T2D (i.e. greater fatigability) compared 
to controls (62.1 ± 13.7 s vs. 89 ± 14.5 s). Limb blood flow was estimated using venous 
plethysmography, and the exercise-induced increase in blood flow was blunted (less than 
half) in people with T2D compared to controls. Thus, the greater fatigability for people 
with T2D may have been due to a blunted increase in blood flow during the isometric 
exercise, indicative of possible impairments in vascular function. Collectively, the results 
from these studies suggest that people with diabetes have greater fatigability after 
isometric contractions.  However, these studies are limited due to inclusion of people 
with diabetes and diabetic polyneuropathy or “controls” with elevated HbA1c. 
Additionally, for each study there was no specific assessment/matching of physical 
activity so that the activity levels which are likely to be lower in people with diabetes, 
were not controlled.  
There are two studies that examined group-related differences in fatigability 
during moderate-velocity dynamic (isokinetic) contractions. As part of an intensive 
insulin treatment study, Halvatsiotis and colleagues (Halvatsiotis et al., 2002) enrolled 
three cohorts of people— eight people with T2D and no diabetic polyneuropathy, eight 
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weight-matched controls, and eight lean healthy controls, with the groups matched for 
age. Each cohort performed 30 maximal voluntary concentric contractions (180 °·s-1) 
with the knee extensors. People with T2D had greater reductions in knee extensor muscle 
power (52.5 ± 7%) compared with weight-matched (43 ± 3%) and lean controls (41 ± 
7%), with no differences between the control groups. Thus, obesity may not be the factor 
mediating greater fatigability in people with T2D, although this study did not examine or 
control for physical activity levels between groups which may explain the lack of 
difference between lean and obese controls.  
In another study examining fatigability during dynamic contractions (IJzerman et 
al., 2012), 39 people (20 men) with T2D and no diabetic polyneuropathy, 98 people (80 
men) with T2D and diabetic polyneuropathy, and 19 “controls” (15 men)— each group 
matched for age but not BMI, sex or physical activity—  performed 20 maximal 
concentric and eccentric isokinetic contractions (120 °·s-1) with the plantar- and 
dorsiflexors and the knee extensors and flexors. The “controls” had an average HbA1c 
within the prediabetes range (6.0 ± 0.5%). For three muscle groups (ankle dorsi- and 
plantar flexors and knee extensors), fatigability was similar between the three groups 
(T2D without diabetic polyneuropathy, T2D with diabetic polyneuropathy, control); 
however, for the knee flexor muscles, “controls” were less fatigable (22 ± 9% reduction 
in power) than both T2D groups i.e. those with diabetic polyneuropathy (29 ± 10% 
reduction in power) and those without diabetic polyneuropathy (30 ± 11% reduction in 
power). Additionally, there was no difference in fatigability between people with T2D 
with or without diabetic polyneuropathy, thus, suggesting that diabetic polyneuropathy 
may not exacerbate fatigability when performing dynamic contractions.  
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Collectively, the results from both isometric and isokinetic contraction literature 
do not demonstrate a clear finding regarding differences in fatigability between people 
with T2D and healthy controls. As denoted in Table 1.1, six of the 10 datasets 
demonstrated that people with T2D had greater fatigability compared to controls, but 
40% of the datasets demonstrated no group-related differences. 
Study Task 
 Fatigability  
 LHC Other DM  
(Allen et al., 2015a) ISOM, 100%; DF  71.1 (11.7s) -- 56.4 (14.2s) * 
(Almeida et al., 2008) ISOM, 50%; KE  786.4 (654s) -- 358.6 (124.5) * 
(Bazzucchi et al., 2015) ISOM, 80% 
KE  26.9 (1.3s) -- 20.1 (0.7s) * 
EF  N/A -- N/A  
(Halvatsiotis et al., 2002) ISOK, 30×180 º·s-1; KE  41 (7%) 43 (3%) 52.5 (7%) * 




PF  35 (14%) 43 (14%) 39 (20%)  
DF  53 (14%) 61 (14%) 58 (16%)  
KE  30 (8%) 34 (13%) 37 (13%)  
KF  22 (9%) 30 (11%) 29 (10%) * 
(Petrofsky et al., 2005) ISOM, 40%; FF  89.3 |(14.5s) -- 62.1 (13.7s) * 
Table 1.2 Summary of fatigability data between people with diabetes mellitus and 
healthy controls. These data summarize the fatiguing task— including agonist muscle, 
type of contraction, intensity of contraction and number of repetitions when applicable—
as well as the fatigability data between lean, healthy controls (LHC) and people with 
diabetes mellitus (DM). In two studies more than 2 experimental groups were included: 
Halvatsiotis and colleagues (Halvatsiotis et al., 2002) included people with T2D and 
diabetic polyneuropathy, weight-matched controls (‘Other’) and LHC and Ijzerman and 
colleagues (IJzerman et al., 2012) included people with T2D and without diabetic 
polyneuropathy (‘Other’), people with T2D and with diabetic polyneuropathy, and 19 
LHC. ISOM, isometric; ISOK, isokinetic; DF, dorsiflexor; KE, knee extensor; EF, elbow 
flexor; PF, plantar flexor; KF, knee flexor; FF, finger flexor. *, people with DM have 
greater fatigability compared to LHC.  
To critically appraise and formally synthesize the data from these studies, the data 
were transformed into standard mean differences (Table 1.3) to create a Forest Plot of 
standard mean differences in fatigability (Figure 1.4). Although there is variability 
between the study designs which varied for experimental groups, fatiguing task, muscle 
group, and age, each study provided evidence that people with T2D had greater 
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fatigability than controls when the data were transformed. Thus, when the current body of 
literature is considered in a new light, there is general evidence that people with diabetes 
mellitus have greater fatigability than lean healthy controls for isometric and isokinetic 
fatiguing contractions in velocities up to 180 º·s-1.  However, there is no understanding of 
whether people with T2D are more fatigable for high velocities contractions (for limb 
velocities that commonly occur during walking), when the load does not vary (isotonic 
contractions) which most closely mimic activities of daily living (Senefeld et al., 2017).  
Furthermore, it is not clear whether the greater fatigability of limb muscles is merely due 
to difference in activity levels between controls and people with T2D.    
Study 
T2D  Control SMD 
x (SE) x SD n  x SD n 
(Allen et al., 2015a) 56.4s 14.2 10  71.1s 11.7 10 26.1 (5.8) 
(Almeida et al., 2008) 358.6s 124.5 10  786.4s 654 10 119.3 (210.6) 
(Bazzucchi et al., 2015) 20.1s 0.7 8  26.9s 1.3 8 33.8 (0.5) 
(Petrofsky et al., 2005) 62.1s 13.7 10  89.3s 14.5 10 43.8 (6.3) 
(Halvatsiotis et al., 2002) 47.5% 7 8  59% 7 8 24.2 (3.5) 
(IJzerman et al., 2012) 
61% 20 39  65% 14 19 6.6 (5.1) 
42% 16 39  47% 14 19 11.9 (15.4) 
63% 13 39  70% 8 19 11.1 (3.3) 
61% 10 39  78% 9 19 27.9 (9.9) 
Total   202    128 33.8 (26.9) 
Table 1.3. Summary of standard mean differences (SMD) in fatigability between 
people with diabetes mellitus and healthy controls. The standard mean differences in 
fatigability between people with diabetes mellitus compared to controls for each muscle 
group within each study was generated based on the data presented in Table 1.2. The 
equations listed below (equations 1.1, 1.2 and 1.3) were used for calculations, where x is 
the mean, n is the sample population, s is the standard deviation, and subscript Arabic 
numerals denote the referenced sample population. The positive mean values for each 
dataset demonstrates that people with diabetes mellitus have greater fatigability compared 
to lean healthy controls. 
 
xdifference = (xControl -  xT2D) · (xControl)






       equation 1.2 
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      equation 1.3 
 
 
Figure 1.4. Forest Plot of standard mean differences in fatigability between people 
with diabetes mellitus and controls. Represented are mean data from isometric 
contraction studies and isokinetic studies (120 & 180°·s-1). The group difference in 
fatigue (% controls) is plotted, calculated as the mean difference in fatigability (equation 
1.1). Each data point is positive, indicating that controls were less fatigability than people 
with diabetes mellitus for these studies. Data from Almeida and colleagues (Almeida et 
al., 2008) is not shown because the mean difference (786 ± 654%) was an outlier from 
this group of studies.  
 Thus, the purpose of this dissertation was to quantify fatigability of the knee 
extensor muscles for a dynamic fatiguing contraction task and identify the contributing 
mechanisms in healthy controls, people with prediabetes (Study 2; Chapter 4) and people 
with T2D (Study 1 - 3; Chapters 3 - 5). The purpose of Study 3 (Chapter 5) was to 
examine the potential contribution of vascular kinetics (flow-mediated dilation and 
exercise-induced dilation) to fatigability among healthy controls and people with T2D.  
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1.5 Specific Aims 
Aim 1: Compare fatigability of both men and women with T2D (without clinically-
evident neuropathy) with age-, BMI- and physical activity-matched controls in 
response to a high-velocity dynamic fatiguing task with the knee extensor muscles 
and determine the contribution of neural and muscular mechanisms.  
Hypothesis 1.1: Fatigability of the knee extensor muscles would be greater in 
people with T2D compared with healthy controls. 
Hypothesis 1.2: Both neural and contractile mechanisms would contribute to the 
greater fatigability in people with T2D compared with healthy control 
participants. 
Aim 2: Determine the group-related difference (T2D, prediabetes, control) in and 
associations between [performance] fatigability and perceived fatigability.  
Aim 2.1: Compare [performance] fatigability and the contributing neural and 
muscular mechanisms in men and women with prediabetes compared to those 
with T2D and healthy controls matched for age, BMI and physical activity after a 
high-velocity dynamic fatiguing task with the knee extensor muscles. 
Hypothesis 2.1: Fatigability of the knee extensor muscles would be similar 
between people with T2D and prediabetes but greater compared with healthy 
controls. 
Aim 2.2: Compare perceived fatigability, baseline and in response to dynamic 
fatiguing task, between people with T2D and prediabetes with controls.  
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Hypothesis 2.2: People with T2D and prediabetes would have greater perceived 
fatigability at baseline and larger increases in perceived fatigability compared 
with controls. 
Aim 2.3: Determine the association between indices of perceived fatigability and 
performance fatigability. 
Hypothesis 2.3: Greater perceived fatigability would be associated with greater 
performance fatigability among people with T2D and prediabetes 
Aim 3: Determine the contributions of impaired exercise-induced hyperemia and 
flow-mediated dilation to greater fatigability among people with T2D compared to 
age-, BMI- and physical activity-matched controls.  
Hypothesis 3.1: Impaired exercise-induced hyperemia and flow-mediated dilation 





CHAPTER 2: METHODOLOGICAL CONSIDERATIONS 
2.1 Exclusion Criteria 
HbA1c and plasma glucose are two diagnostic criteria for people with T2D and 
prediabetes (Kim et al., 2016), and were used to inform participant allotment into 
experimental groups (T2D, prediabetes and control). Participants included in the T2D 
group were physician-diagnosed, had no clinically-diagnosed diabetic polyneuropathy, 
were not prescribed insulin or an insulin secretagogue, and had stable glycemic control 
(HbA1c < 10%). T2D was managed by diet, exercise and oral hypoglycemic medications 
for all participants included in the studies of this dissertation. HbA1c and fasting plasma 
glucose measures were used to confirm diagnosis of T2D and assure HbA1c < 10%. 
However, because approximately 90% of people with prediabetes are unaware of 
their undiagnosed,  underlying disorder (CDC, 2014), HbA1c and plasma glucose tests 
were used to classify “controls” into the control or prediabetes groups. Importantly, we 
informed all participants of the results of the assays to measure HbA1c and fasting plasma 
glucose and provided American Diabetes Association  classification criteria (American 
Diabetes, 2015a); however, no diagnoses of T2D or prediabetes were made in the 
research laboratory. Participants were provided their results written and orally and 
participants were group based on these results, but participants were encouraged to visit 
their respective physicians for clinical diagnoses.  
Blood samples were taken and assessed after a 4-hour fast, using standard point of 
care assessment tools for HbA1c (Siemens Healthcare Diagnostics, DCA 2000+) and 
plasma glucose (Alere Cholestech LDX System). The Siemens DCA 2000+ HbA1c point 
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of care instrument is an easy to use technology and is accepted by the National Glycated 
Hemoglobin Standardization Program (NGSP) (Bode et al., 2007).  
Screening for Diabetic Polyneuropathy 
 Participants, regardless of group allotment, were carefully screened for the 
presence of nerve dysfunction or diabetic polyneuropathy, and participants with nerve 
dysfunction or diabetic polyneuropathy were excluded. There is substantial evidence to 
suggest that sensory and autonomic nerve function is affected prior to motor nerve 
involvement (Allen et al., 2016), therefore, diabetic polyneuropathy screening was 
focused on sensory and autonomic nerve function. Participants were informed (oral and 
written) of the results of the diabetic polyneuropathy screening and were encouraged to 
seek a clinical opinion or diagnosis from their physician if participants were excluded due 
to suspected diabetic polyneuropathy.  
Sensory Dysfunction Screening 
 Screening for sensory neuropathy included a monofilament test and a vibratory 
sensation test. A neuropathy questionnaire (Michigan Neuropathy Screening Instrument) 
(Moghtaderi et al., 2006) was administered and a standard physical evaluation was 
performed according to standards suggested by the Health Resources and Services 
Administration in the Lower Extremity Amputation Prevention (LEAP) resources (1998). 
The monofilament screening examination entailed sensation testing at 12 sites on each 
foot of the participant using 10-g monofilament with sufficient pressure applied to bend 
the monofilament. Participants were excluded if the monofilament could not be sensed on 
two or more sites. Six participants were excluded due to poor sensation of 10-g 
monofilament and each participant missed ~ 50% of the sites on each foot.  
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Detection of vibration was assessed using a 128 Hz tuning fork, applied after a 
standardized perturbation, over the right and left medial malleoli and the head of the 1st 
metatarsal of each foot. Participants were required to advise the tester whether they could 
feel the instrument and the vibration and when they could no longer detect vibration. 
Participants were excluded if vibrations could be sensed by the examiner for more than 
10 s longer than the participant. No participants were excluded based on vibration 
sensation. 
Achilles tendon reflex was tested in each leg in the seated position with the leg 
resting over the edge of a plinth, and participants were excluded if tendon jerk was 
absent. No participants were excluded based on Achilles tendon reflex. 
Autonomic Dysfunction Screening 
 Autonomic nerve function was assessed via assessment of blood pressure in 
upright vs. supine posture and electrocardiogram (ECG) during a submaximal exercise 
test. Blood pressure was manually auscultated in supine vs. upright posture, and 
participants were excluded if there was a sustained decrease in systolic pressure (≥ 30 
mmHg) and diastolic pressure (≥ 30 mmHg) (Barbato, 1990). ECG was used to assess 
arrhythmias during the aerobic fitness test (as described below), and participants were 
excluded if arrhythmias were consistently present (5 or more occurrences in the 30 
minutes of ECG), if potentially dangerous arrhythmias were observed, or if an 
appropriate heart rate response was not achieved during the test. Two people were 
excluded due to potentially dangerous arrhythmias— atrial flutter and first degree 
atrioventricular block. One person was excluded due to bradycardia during exercise, the 
participant achieved a maximal heart rate of 100 beats per minute during exercise that 
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resulted in shortness of breath and rating of perceived exertion of 18 out of 20— the 
participant did not report a prescription to β-blocker medication; however, this test was 
suggestive of β-blocker use.  
2.2 Recruitment 
 Recruitment for this dissertation encompassed five years. Recruitment was 
extensive due to the specific inclusion and exclusion criteria. Over the course of the five-
year period, approximately 500 people were phoned from the laboratory. Nearly 200 of 
those 500 people were immediately excluded due to blunt reasons, for example, previous 
stroke or transient ischemic attack, current medical treatment (cancer, depression, etc.), or 
a lack of interest after hearing a description of the study. However, 304 people were fully 
screened via telephone, and of those people, 166 people were excluded—52 people due 
to physician diagnosis of diabetic polyneuropathy, 54 people due to treatment with 
insulin or an insulin secretagogue, 56 people due to overt medical conditions undisclosed 
previously (e.g. osteoarthritis in both knees), and 4 people chose to not be included 
during the phone screening.  
 After enrolling and completing a portion of a study, an additional 14 people were 
excluded: 1 person was intoxicated upon arrival to the laboratory, 9 people were 
suspected of having diabetic polyneuropathy (6 people scored poorly on LEAP screening 
and 3 people had suspected autonomic neuropathy), 2 people were excluded due to non-
compliance with study guidelines (e.g. overnight fasting), and 2 people were excluded 
due to poor glycemic control (HbA1c > 10.0%). Thus, although 138 people were 
consented, only 124 people completed one or more of the studies incorporated in this 
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dissertation, including 60 people with T2D, 20 people with prediabetes and 44 healthy 
controls. See Figure 2.1 and Figure 2.2. 
 
Figure 2.1. Diagram of participant recruitment. This schematic denotes the participant 






Figure 2.2. Diagram of participation within each study. This Venn diagram 
demonstrates the allotment of participants with each study and denotes which participants 
completed one or more studies that are included in this dissertation. Eleven people 
completed all three studies.  
2.3 Matching Criteria 
 For each study, groups of participants were matched according to age, sex, body 
mass index (BMI) and physical activity (steps·day-1). These matching criteria in 
combination with inclusion/exclusion criteria resulted in homogenous groups across 
many different baseline assessments, including: baseline muscle function (voluntary and 
electrically-evoked), body size, and physical function. This control population is a unique 
aspect of these studies, and a novel approach to examine fatigability in people with T2D 
and prediabetes. This experimental approach and control group differs to the typical 
studies of fatigability in people with T2D where control groups are typically lean, healthy 
controls (Petrofsky et al., 2005; IJzerman et al., 2012; Allen et al., 2015a; Bazzucchi et 
al., 2015) or people with diabetes that have diabetic polyneuropathy or insulin 
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prescription (Almeida et al., 2008; Allen et al., 2015a). This is a robust experimental 
approach to examine the effects of T2D per se. 
Age 
 People age 40 and older were recruited for these studies. The onset of T2D at 
young ages is typically accompanied by increased risk for vascular complications at an 
earlier stage and require a more aggressive and supportive disease management (Wilmot 
& Idris, 2014; Al-Saeed et al., 2016), and age 40 is common to delineate young-onset 
T2D (Song, 2015). Additionally, because fatigability can differ across the lifespan 
(Hunter et al., 2016), age was used as a matching criterion between people with T2D and 
healthy controls. 
Sex 
 There are known sex-related differences in fatigability (Hunter, 2016a, b), thus 
near equivalent numbers of men and women were tested within each group and sex was 
used as a matching criterion between people with T2D and healthy controls. Additionally, 
the potential sex-related differences among people with T2D are unknown, therefore, a 
tertiary aim of each study included in this dissertation was to quantify sex-related 
difference in fatigability among people with T2D. Also, the National Institutes of Health 
recommends testing sufficient numbers of men and women to explore potential sex-




Body anthropometry included measurements of height, body mass and waist 
circumference. Lean tissue mass was determined using a dual-energy X-ray 
absorptiometry (DEXA) scan (Lunar Prodigy full-body scanner, Madison, WI, USA) 
(Smith-Ryan et al., 2017). The scanner was calibrated prior to each scan. The analyzed 
data was recorded offline (Encore 2008 software by GE Health care). In the case of 
participants with artificial joints, the artificial joint was excluded via encore software. 
Participants were matched according to body anthropometry, see Table 2.2. 
        Control   Prediabetes   Type 2 Diabetes 










 Fat Mass kg   26.8 ± 8.6   26.6 ± 7.0   31.0 ± 13.6 
Lean Mass kg   51.3 ± 12.1   46.7 ± 9.1   52.6 ± 10.9 








Fat Mass kg   4.1 ± 1.7   4.1 ± 1.4   4.3 ± 2.4 
Lean Mass kg   8.5 ± 2.3   8.0 ± 1.7   8.7 ± 2.1 
Fat Mass %   31.2 ± 11.9   32.3 ± 10.0   30.7 ± 11.9 
Table 2.1. Anthropometrics of controls and people with prediabetes and type 2 
diabetes. Data for all participants included in the studies in this dissertation are included. 
Fat mass (kg and %) and lean mass for the whole body and dominant leg (dom. leg) were 
measured via dual X-ray absorptiometry. There were no group-related differences in 
these measures. Values are reported as mean ± standard deviation of the mean. 
Physical Activity 
Accelerometry data were collected using the Actigraph GT3X+ (ActiGraph, 
Pensacola, FL, USA) that was worn on the hip by each participant for 4 days (2 weekdays 
and 2 weekend days). Sixty-second epochs of data were collected and analyzed. Wear-
time authentication was performed on each participant’s dataset to determine whether 
data were to be included in the analysis. Acceptable wear-time was set a priori and 
defined as ≥ 3 days of ≥ 9 hours (540 minutes) per day. To determine if each participant’s 
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dataset met these criteria, data were filtered.  Data were excluded if there were 60 or 
more consecutive minutes of zeros (indicating non-use), or if counts exceeded 15,000 per 
minute (indicating malfunction). The daily accelerometry data and the data recorded by 
the participant in the activity log were compared for obvious inconsistencies (e.g. 
equipment failure) and data considered erroneous were not included in the analysis. Wear 
time was recorded to be all data that did not meet exclusion criterion. No data was 
excluded due to malfunction or obvious inconsistencies.  
Data were grouped by kcounts indicated by ActiLife v4 software. The cut-points 
to delineate each level of physical activity were defined according to (Freedson et al., 
1998; Crouter et al., 2006; Hart et al., 2011a). Data were analyzed as a percent of wear 
time (540+ minutes of wear time). Delineations were made as follows: sedentary time 
was considered 50 kcounts or less per minute, light lifestyle time was considered 51-759 
kcounts, moderate lifestyle time was considered 760-1951 kcounts, light physical activity 
time was considered 50-1951 kcounts (this encompassed light lifestyle and moderate 
lifestyle times), moderate physical activity time was considered 1952- 5724 kcounts, and 
vigorous physical activity time was considered 5725-14999 kcounts. Step count was also 
recorded (ActiLife Software v4) and analyzed.  
Acceptable data were analyzed to determine daily activity count and step counts, 
and were analyzed using cut points to determine period of time and percentage of wear-
time spent in various intensities of physical activity. Moderate and vigorous activity data 
were conflated to generate data for moderate-to-vigorous activity; and bouts of moderate 
to vigorous physical activity were defined as lasting at least 10 minutes with allowance 
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for 2 minutes of below moderate intensity activity. Participants were matched according 
to daily physical activity, see Tables 2.2 and 2.3. 
      Control   Prediabetes   Type 2 Diabetes 
      n = 36   n = 20   n = 57 
Daily PA steps·day-1   7,994 ± 2,956   8,283 ± 3,311   8,195 ± 4,090 
Sedentary % WT   65.2 ± 10.7   63.7 ± 6.3   64.4 ± 12.9 
Light PA % WT   31.0 ± 10.3   31.8 ± 5.6   31.7 ± 11.8 
Moderate PA % WT   3.5 ± 2.9   4.0 ± 2.2   3.8 ± 3.2 
Vigorous PA % WT   0.3 ± 0.8   0.5 ± 1.3   0.1 ± 0.2 
MVPA % WT   3.8 ± 3.4   4.5 ± 2.5   3.9 ± 3.3 
Table 2.2. Physical activity assessed with accelerometry of controls and people with 
prediabetes and type 2 diabetes. Data for most participants included in the studies in 
this dissertation are included; however, some data were excluded due to a priori 
exclusion criteria. Data were measured via triaxial accelerometry (GT3X). There were no 
group-related differences in these measures. Values are reported as mean ± standard 
deviation of the mean. PA, physical activity; MVPA, moderate-to-vigorous physical 
activity; WT, wear time. 
 In addition to triaxial accelerometry, physical activity was estimated using two 
validated questionnaires: the Physical Activity Questionnaire (Kriska et al., 1990) and the 
Physical Activity Scale for the Elderly (Washburn et al., 1993).  
      Control   Prediabetes   Type 2 Diabetes 
      n = 44   n = 20   n = 60 
PAQ MET·hr·week-1   34.1 ± 29.4   42.6 ± 42.2   47.9 ± 49.4 
PASE AU   176 ± 99   189 ± 97   187 ± 94 
Table 2.3. Physical activity estimated with questionnaires of controls and people 
with prediabetes and type 2 diabetes. Data for all participants included in the studies in 
this dissertation are included. There were no group-related differences in estimated 
physical activity. Values are reported as mean ± standard deviation of the mean. PAQ, 
Physical Activity Questionnaire; PASE, Physical Activity Scale for the Elderly; 




2.4 Perceptions and Medications 
 The most common perceptions among people with T2D and prediabetes that may 
affect assessments of performance fatigability include perceived fatigability, symptoms 
of depression and impaired sleep quality (Fritschi & Quinn, 2010; Fritschi et al., 2012)— 
which were assessed with the Fatigue Impact Scale (Fisk et al., 1994), Short Form 
Geriatric Depression Scale (Parmelee & Katz, 1990; Snowdon, 1990; Burke et al., 1991), 
and Pittsburgh Sleep Quality Index  (Buysse et al., 1989), respectively. Participants were 
matched according to perceptions that may contribute to perceived fatigability, see Table 
2.4. 
    Control   Prediabetes   Type 2 Diabetes   
    n = 44   n = 20   n = 60   
FIS Cognitive   3.5 ± 4.7   3.2 ± 4.2   4.9 ± 5.7   
FIS Physical   2.9 ± 4.3   3.9 ± 5.5   6.6 ± 6.9 *† 
FIS Psychological 4.5 ± 6.3   5.5 ± 10.0   8.4 ± 6.1   
FIS Total   10.9 ± 13.9   12.6 ± 18.6   19.5 ± 22.8   
GDS   0.61 ± 0.93   0.92 ± 1.09   1.18 ± 1.70   
PSQI   3.84 ± 2.24   4.67 ± 2.60   4.80 ± 2.35   
Table 2.4. Reports of clinical symptoms of fatigue, depression and sleep quality in 
people with prediabetes and type 2 diabetes. Data for all participants included in the 
studies in this dissertation are included. The physical domain of the Fatigue Impact Scale 
was greater for people with T2D compared to prediabetes and controls; however, there 
were no other group-related differences. Values are reported as mean ± standard 
deviation of the mean. FIS, Fatigue Impact Scale; GDS, Geriatric Depression Scale; 
PSQI, Pittsburgh Sleep Quality Index. Tukey’s HSD post-hoc: *, T2D vs. control, P < 
0.05; †, T2D vs. prediabetes, P < 0.05. 
 The standard treatment algorithm for people with T2D, as put forth by the 
International Diabetes Federation (IDF) (Czupryniak, 2009), includes metformin as 
second line treatment after lifestyle interventions (exercise, diet and weight 
management). In addition to metformin, statins and angiotensin converting enzyme 
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(ACE) inhibitors are commonly prescribed medications among people with T2D. Thus, 
the prescriptions of these medications were quantified, see Table 2.5.   
      Control   Prediabetes   Type 2 Diabetes 
Diabetes Duration years --   --   7.7 ± 6.9 
Metformin 
  n 0   1   60 
Daily Dose mg --   1,000   1,155 ± 586 
Duration years --   7.0   4.6 ± 5.1 
Statin* 
  n 8   5   34 
Daily Dose mg 20.6 ± 24.6   13.0 ± 6.7   19.8 ± 21.0 
Duration years 5.5 ± 6.0   7.2 ± 4.3   4.8 ± 4.9 
ACE 
inhibitor# 
  n 4   3   21 
Daily Dose mg 11.3 ± 7.5   10.0 ± 5.0   25.2 ± 24.7 
Duration years 5.8 ± 7.6   9.0 ± 5.8   6.5 ± 7.1 
Table 2.5. Prescriptions of daily doses of metformin, statins, and angiotensin 
converting enzyme (ACE) inhibitors. Data for all participants included in the studies in 
this dissertation are included. These data are descriptive and were not analyzed 
statistically. Values are reported as mean ± standard deviation of the mean. *Statin data 
are reported using an Atorvastatin equivalent dose per published drug information 
accessed via: http://www.globalrph.com/statins_comparisons.htm. #ACE inhibitor data 
are reported using a Lisinopril equivalent dose per published drug information accessed 





CHAPTER 3: MECHANISMS FOR THE INCREASED FATIGABILITY OF THE 
LOWER LIMB IN PEOPLE WITH TYPE 2 DIABETES 
This published article was reproduced with permission from American Physiological 
Society. The full citation is listed below. 
Senefeld J, Magill SB, Harkins A, Harmer AR, Hunter SK. Mechanisms for the 
Increased Fatigability of the Lower Limb in People with Type 2 Diabetes 
Journal of applied physiology. 2018: (in press). 
3.1 Introduction 
Type 2 diabetes mellitus (T2D) has become a global pandemic and is estimated to 
currently affect 8% of the world’s population (Ogurtsova et al., 2017). Physical activity is 
a cornerstone of T2D management and along with diet is the first intervention used to 
treat T2D (Sigal et al., 2006). Incidence of T2D can be reduced by 58% with lifestyle 
interventions (diet, weight loss and exercise), and these lifestyle interventions were 
almost twice as effective as pharmacological treatment (metformin), which reduced the 
incidence of diabetes by 31% (Knowler et al., 2002). Fatiguing contractions of limb 
muscles are the foundation of exercise training and the neuromuscular adaptations that 
accompany regular exercise (Kraemer & Ratamess, 2004). However, there is minimal 
understanding of the mechanisms that limit a single bout of fatiguing exercise in people 
with T2D.  
Fatigability of limb muscles is a reversible, short-term and activity-induced 
reduction in muscle strength or power (Gandevia, 2001; Hunter, 2017), and can limit 
performance of daily tasks that require repeated or sustained contractions (Enoka & 
Duchateau, 2016; Senefeld et al., 2017). Mechanisms that contribute to limb fatigability 
45 
 
in healthy adults include deficits in neural drive to the muscle, impairments in 
neuromuscular propagation, reduced force capacity of skeletal muscle fibers, and 
impaired blood flow to the muscle (Gandevia, 2001; Debold et al., 2016; Hunter, 2017). 
Few studies have examined the mechanisms of fatigability among people with diabetes. 
Several studies have shown that for isometric contractions with lower limb muscles 
(ankle dorsiflexor and knee extensor muscles), people with type 1 diabetes and diabetic 
polyneuropathy and people with T2D, were more fatigable than controls (Almeida et al., 
2008; Allen et al., 2015a; Bazzucchi et al., 2015). The mechanisms contributing to 
greater fatigability in the people with type 1 diabetes who had diabetic polyneuropathy 
included disruption of neuromuscular transmission indicated by a concomitant decrease 
in the maximal compound muscle action potential (Allen et al., 2015a) and slowed motor 
unit conduction velocities and discharge frequencies (Almeida et al., 2008). The 
mechanisms for the greater fatigability in the lower limb muscles of people with T2D are 
not known.  
Decrements in power during repeated dynamic fatiguing contractions are 
probably of greater functional significance than decrements in torque during isometric 
tasks in people with T2D.  First, at baseline (without fatigue) the difference (reduction) in 
muscle power for people with T2D compared with controls is greater than for maximal 
isometric torque (Hilton et al., 2008; Allen et al., 2016). Second, low power and maximal 
velocity of limb muscles at baseline were the primary variables associated with impaired 
balance and gait in people with T2D (Orr et al., 2006). Whether people with T2D are 
more fatigable during dynamic contractions, which can further exacerbate power 
differences between controls and people with T2D, is relatively unexplored.  One study 
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demonstrated that after 20 moderate-velocity (120 deg·s-1) isokinetic contractions 
performed separately with four lower limb muscle groups, people with T2D (with and 
without diabetic polyneuropathy) were more fatigable than age-matched controls for the 
knee flexor muscles, but not the ankle plantar flexor or dorsiflexor, or knee extensor 
muscles (IJzerman et al., 2012). Another study, showed that people with T2D tended to 
have greater reductions in knee extensor torque over 30 isokinetic contractions at 180 
deg·s-1 than healthy age-matched controls (both lean and weight-matched), although 
these differences in torque reductions did not reach statistical significance, possibly due 
to low subject numbers (n = 8) (Halvatsiotis et al., 2002). There are no other known 
studies determining the fatigability during dynamic fatiguing tasks in people with T2D, 
and furthermore, the mechanisms are unknown. Lastly, despite potential differences in 
fatigability between men and women (Hunter, 2016a), studies of fatigability in people 
with T2D have been underpowered to determine whether there are sex-related differences 
among people with T2D (e.g. (Halvatsiotis et al., 2002; Petrofsky et al., 2005; IJzerman 
et al., 2012; Bazzucchi et al., 2015). 
The mechanisms for any potential increased fatigability of limb muscles in men 
and women with T2D may originate from both neural (supraspinal and spinal) and 
muscular sites. People with T2D may have impaired skeletal muscle energetics (i.e. 
increased inorganic phosphate and hydrogen ion within intracellular milieu) and reduced 
skeletal muscle blood flow during exercise compared with healthy controls 
(Scheuermann-Freestone et al., 2003; Lalande et al., 2008), potentially eliciting greater 
stimulation of afferent feedback (Group III and IV afferents) to supraspinal and spinal 
centers during fatiguing exercise, further exacerbating any exercise-related reductions in 
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neural drive to the muscle (Taylor et al., 2016; Hunter, 2017). Furthermore, because 
people with T2D are at risk of neuropathy, neuromuscular transmission may contribute to 
differences in fatigability between people with and without T2D (Allen et al., 2015a; 
Allen et al., 2016).  In this current study, we used non-invasive stimulation at the motor 
cortex and muscle to determine the contribution of neural (supraspinal and spinal) and 
muscular mechanisms (Todd et al., 2003, 2016) to any differences in fatigability between 
people with T2D and controls.  
The purpose of the study was to: 1) compare fatigability of both men and women 
with T2D (without clinically-evident neuropathy) with age-, BMI- and physical activity-
matched controls in response to a high-velocity dynamic fatiguing task with the knee 
extensor muscles, and 2) determine the contribution of neural and muscular mechanisms. 
Our hypotheses were that: 1) fatigability of the knee extensor muscles would be greater in 
people with T2D compared with healthy controls, and 2) both neural and contractile 
mechanisms would contribute to the greater fatigability in people with T2D compared 
with healthy control participants. Because the age of onset of T2D is inversely related to 
disease complication risk and mortality, we enrolled participants >50 years. Additionally, 
because there is limited understanding of sex differences in fatigability of people with 
T2D, a third aim was to determine whether there were sex-related differences in 
fatigability and mechanisms among people with T2D. Our hypothesis was that there 
would be no sex-related differences in fatigability, as we have observed in a young and 
older adult population previously (Senefeld et al., 2017).  
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3.2 Materials and Methods 
Seventeen people with T2D (10 men: age, 59.7 ± 9.5 years; HbA1c, 6.92 ± 
1.19%; 7 women: age, 59.6 ± 9.0 years; HbA1c, 7.20 ± 1.06%) and twenty-one healthy 
controls (11 men: age, 58.2 ± 10.3 years; HbA1c, 5.42 ± 0.25%; 10 women: age, 61.2 ± 
8.8 years; HbA1c, 5.40 ± 0.21%) participated in the study. Prior to involvement in the 
study, each participant provided written informed consent and the protocol was approved 
by the Marquette University Institutional Review Board (HR-2402) for ethical approval 
in accordance with the Declaration of Helsinki for human experimentation. 
Aside from glycemic control, all participants were healthy. Type 2 diabetes was 
physician-diagnosed and confirmed at study enrolment via fasting glucose and HbA1c. 
Exclusion criteria included: unstable diabetes, prescribed insulin or insulin secretagogue, 
poor glycemic control (glycosylated hemoglobin (HbA1c) >10%), diabetic neuropathy 
(assessed via clinical diagnosis, monofilament and tuning fork sensation tests, and 
sensory questionnaires), peripheral edema, severe obesity (body mass index, BMI, >45 
kg/m2), untreated hypothyroidism, epilepsy, medications that affect cortical excitability, 
possibility of pregnancy and any neurological, cardiovascular or musculoskeletal disease 
that precluded exercise testing. Any potential participants who presented with HbA1c 
>5.7% and <6.5% (and were not diagnosed with T2D) were classified as having pre-
diabetes and not included in the study; thus, all controls had an HbA1c ≤5.6%.  
Participants completed three sessions of testing that included a screening session 
to determine eligibility for the study followed by two experimental sessions. The aim of 
the first experimental session was to familiarize participants with experimental 
procedures and complete a fasting blood draw and questionnaires. The aim of the second 
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experimental session was to complete the fatiguing task. Each session was separated by 
2-7 days.  
Screening Session 
 During the screening session, the following tests were performed: 1) lower limb 
sensation was assessed using a 10-gram monofilament and 128-Hz vibration sensation 
test, 2) autonomic nerve function was assessed using a heart rate variability test and 
blood pressure response to upright posture, and 3) glycemic control was assessed using a 
point-of-care HbA1c instrument. Skeletal muscle mass of the dominant leg and whole-
body fat mass were assessed utilizing DEXA and participants were assigned a triaxial 
accelerometer. Then, peak aerobic capacity was estimated from a submaximal graded 
bicycle ergometer exercise test. 
Diabetic neuropathy screening: Each participant was screened for the presence of 
diabetic polyneuropathy. To assess symptoms and signs of sensory neuropathy 
monofilament screening of the feet, vibration sensation testing (bilateral malleoli and 
heads of the 1st metatarsals) and Achilles tendon reflex testing were performed. 
Participants were excluded if impaired sensation was observed i.e., if the monofilament 
could not be sensed on any site on the foot; if vibrations could be sensed by the examiner 
for more than 10 s longer than the participant; or if the tendon jerk was absent. 
Participants who were suspected of having diabetic polyneuropathy (sensory or 
autonomic) were excluded from the study.  
HbA1c: HbA1c was determined using blood from a fingerstick, analyzed using a point-of-
care instrument assay (Siemens Healthcare Diagnostics, DCA 2000+). 
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Anthropometry and DEXA: Body anthropometry included measurements of height, body 
mass and waist circumference. Skeletal muscle mass of the dominant leg and whole-body 
fat mass (% body weight), were assessed utilizing DEXA (Lunar Prodigy full-body 
scanner, Madison, WI, USA). The scanner was calibrated prior to each scan. The 
analyzed data was recorded offline (Encore 2008 software by GE Health care). In the 
case of participants with artificial joints (n = 4), the artificial joint was excluded via 
encore software.  
Physical Activity Monitor: Accelerometry data were collected using the Actigraph GT3X 
(ActiGraph, Pensacola, FL, USA) that was worn on the hip by each participant for 4 days 
(2 weekdays and 2 weekend days). Sixty-second epochs of data were collected and 
analyzed. Wear-time authentication was performed on each participant’s dataset to 
determine whether data were to be included in the analysis. Acceptable wear-time was set 
a priori and defined as ≥ 3 days of ≥ 9 hours (540 minutes) per day. Step count was 
recorded (ActiLife Software v4) and analyzed.  
Submaximal, Graded Bicycle Test: Participants performed a submaximal graded exercise 
test (Beekley et al., 2004) on a bicycle ergometer (VIAsprint 150P, CareFusion, San 
Diego, CA, USA) to determine estimated oxygen consumption and to screen for exercise-
induced cardiac arrhythmia. Participants were required to maintain cadence of 60 
revolutions per minute that was monitored via LED screen by the participant and a 
researcher, and the cycle load was manipulated to attain three submaximal loads that 
elicited incremental heart rate responses between 40% and 70% of heart rate reserve. The 
participant cycled at each submaximal load for four minutes to attain steady-state. During 
this test, a 12-lead electrocardiogram (CASE, General Electrics, Madison, WI, USA) was 
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monitored to determine if arrhythmias were present. Participants were excluded if 
arrhythmia was detected, even if asymptomatic.  
Experimental Session One 
Participants fasted for at least 8 hours prior to experimental session one. Venous 
blood was obtained via venous draw, after which participants consumed a standardized 
breakfast (8 oz. fruit juice, one cereal bar, and one serving of fruit) prior to undertaking 
the remaining activities in the session. In conjunction with fasting, participants with T2D 
delayed administration of medications until after the venous draw.  
Participants completed a questionnaire to determine handedness/footedness 
(Oldfield, 1971) to assess which leg which would be used for testing. Participants first 
practiced submaximal muscle contractions, maximal voluntary isometric contractions 
(MVICs) and maximal voluntary concentric contractions (MVCCs) of the knee extensor 
muscles while seated in a Biodex System 4 dynamometer (Biodex Medical, Shirley, NY). 
They were also habituated with electrical stimulation of the femoral nerve, percutaneous 
electrical stimulation of the knee extensor muscles and transcranial magnetic stimulation 
(TMS) of the motor cortex.  
Blood Measures: Fasting blood glucose was determined using a point of care instrument 
(Alere Cholestech LDX System, Alere Inc. Waltham, MA, USA). Hemoglobin 
concentration was determined using a point of care instrument (StatSiteM Hemoglobin 
Photometer, Stanbio, Boerne, TX, USA) and hematocrit was determined manually 
(International Micro-capillary Reader, International Equipment Company, Boston, MA, 
USA) per standard instruction of each instrument. Plasma insulin and thyroid-stimulating 
hormone concentrations were quantitatively assayed in duplicate per manufacturer 
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instructions using enzyme-linked immunoassay kits (Quantikine Human Insulin 
Immunoassay (R&D Systems, Minneapolis, MN) and Human TSH (CGA) ELISA Kit 
(Thermo Scientific Pierce (Waltham, MA), respectively).  
Questionnaires: All participants completed questionnaires to assess: clinical symptoms of 
fatigue using the Fatigue Impact Scale (Fisk et al., 1994); sleep quality with the 
Pittsburgh Sleep Quality Index (Buysse et al., 1989); and depression with the short form 
Geriatric Depression Scale (Snowdon, 1990). 
Experimental Session Two 
Participants consumed the same standardized breakfast as during the first 
experimental session; after which participants with T2D administered their diabetes 
medications. In this second experimental session, each participant performed baseline 
MVICs and MVCCs followed by a maximal-velocity fatiguing task and recovery 
contractions with the dominant knee extensor muscles. 
Measurement of Torque, Velocity and Power 
Participants performed isometric and isotonic contractions with the knee 
extensors muscles while seated in a dynamometer. Participants performed all contractions 
on their dominant leg, unless there was any form of disease (e.g. osteoarthritis) or injury 
(e.g. knee reconstruction), in which case the non-dominant leg was tested (n = 2 controls, 
2 people with T2D). Participants were seated with 90º of hip flexion. Padded straps 
mounted on the seat were securely tightened across the shoulders, the waist, and the non-
dominant leg to minimize synergistic movements. The dominant leg was positioned such 
that the axis of rotation of the knee joint was aligned with the axis of rotation of the 
dynamometer. The internal goniometer of the Biodex dynamometer was calibrated using 
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a level to measure 90º flexion of the knee joint. The analog signals corresponding to joint 
angle, torque, and velocity were digitized and recorded through a Power 1401 analog-to-
digital (A-D) converter and Spike2 software (Cambridge Electronics Design, Cambridge, 
UK).   
Electromyography  
Electromyography (EMG) electrodes (Ag–AgCl, 8-mm diameter; 20 mm intra-
electrode distance) were placed on three agonist muscles (rectus femoris, vastus lateralis 
and vastus medialis) in a bipolar arrangement according to recommendations (Hermens et 
al., 2000) with reference electrodes placed over the patella of the dominant knee. The 
EMG signals were amplified (100×) and filtered between 13 - 1000 Hz (Coulbourn 
Instruments, Allentown, PA) and digitized at 2,000 Hz. Mechanical recordings from the 
dynamometer corresponding to torque, velocity and position were recorded online at 
2,000 Hz. All analog signals were digitized using a 1401 A–D converter and Spike 2 
software [Cambridge Electronics Design (CED), Cambridge, UK]. 
Transcranial Magnetic Stimulation (TMS) 
TMS was delivered via a concave double cone coil (Magstim 200, Magstim, 
Whitland, UK, 11.0-cm outside diameter) over the motor cortex area to elicit motor-
evoked potentials (MEPs) and torque during voluntary contractions of the dominant knee 
extensor muscles as described before (Senefeld et al., 2018d). The vertex of the motor 
cortex was identified, and the scalp was marked 1.0 cm lateral to the vertex (over the 
motor area corresponding to the dominant knee extensors) to ensure repeatability of coil 
placement during the experimental protocol. The optimal coil position of the TMS was 
determined during brief contractions of the knee extensor muscles at 20% MVIC. TMS 
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was elicited during the contractions and fine adjustments in the TMS coil position (~0.5 
cm) were made to determine which site evoked the largest superimposed twitch (SIT) 
torque and MEP of the rectus femoris muscle. Optimal stimulator intensity was also 
determined with brief contractions (2-3 s) of knee extensor muscles (50% MVIC), which 
is the intensity that is known to elicit maximal MEPs (Todd et al., 2003). The intensity of 
the stimulation (% maximal of stimulator intensity) was increased by 5% increments until 
maximal twitch torque of the quadriceps and maximal MEP of the rectus femoris muscle 
were elicited. The brief contractions at 50% MVIC were separated by 30-s rest periods to 
avoid fatigue when establishing the intensity of TMS.  
Electrical Stimulation 
 Single-pulse (200 µs duration, 400 V) electrical stimulation was used for femoral 
nerve and percutaneous muscle stimulation (DS7AH; Digitimer, Ltd., Welwyn Garden 
City, UK) to elicit maximal compound muscle action potentials (Mmax) and twitch 
contractions at rest and during MVICs of the knee extensor muscles. 
Femoral Nerve Stimulation: The femoral nerve innervating the knee extensor muscles 
was stimulated supramaximally (120 – 600 mA) with a single pulse to elicit the maximal 
compound muscle action potential (Mmax).  The cathode electrode (Ambu Neuroline 
electrodes, Denmark; 1.5 cm diameter) was placed over the femoral nerve within the 
femoral triangle and the anode was placed over the greater trochanter of the femur. The 
intensity of the nerve stimulation was determined by increasing the current until the 
twitch amplitude plateaued. The stimulation intensity was then increased further by 20% 
to ensure a maximal activation of the muscles within the area of stimulation.  
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Percutaneous Muscle Stimulation: To assess voluntary muscle activation and twitch 
properties, the knee extensor muscles were stimulated with a single pulse (150 – 750 mA) 
via custom-made pad electrodes (6 cm × ~15 cm) placed over the quadriceps muscles. 
The cathode was placed near (within 10 cm) the area of the femoral triangle and the 
anode was placed proximal to the patella without hindering knee flexion/extension of the 
participant. The stimulator intensity was determined by increasing the current until the 
twitch amplitude plateaued, then the stimulation intensity was increased further by 20% 
to ensure a maximal activation of the muscles in the area of stimulation. This stimulation 
intensity was used for the remainder of the session. The twitch amplitude elicited via 
percutaneous and femoral nerve stimulation were linearly correlated (r2 = 0.653, P < 
0.001). Percutaneous muscle stimulation was used throughout the experimental protocol 
for assessment of voluntary activation and twitch properties, because percutaneous 
stimulation was more tolerable than nerve stimulation. Using the supramaximal intensity, 
three muscle stimulations were applied, each separated by ~15 s to assess electrically-
evoked twitch contractile properties in a non-potentiated state.  
Experimental Protocol 
The experimental protocol entailed: 
(1) Baseline MVICs: Participants completed at least three MVICs for ~4 seconds 
each with the knee extensor muscles, positioned in 90° of hip and knee flexion. 
Participants then performed four additional MVICs during which TMS and electrical 
stimulation were superimposed to estimate voluntary activation (see the ‘data analysis’ 
section for calculations). Electrically-evoked, potentiated twitch contractions were also 
elicited at rest immediately after each MVIC to determine contractile properties and 
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voluntary activation of the knee extensor muscles. Each baseline MVIC was separated by 
2.5 minutes, to minimize the effect of fatigue prior to beginning the dynamic fatiguing 
task. 
(2) Baseline Maximal Voluntary Concentric Contractions (MVCCs): Participants 
warmed-up with 10 MVCCs with a load equivalent to 20% of MVIC. These isotonic 
contractions were performed through an ~85º range of motion, from 90°of knee flexion 
until 5°of knee flexion. Participants then rested for 2.5 minutes, before initiating the 
dynamic fatiguing task.  
(3) Dynamic fatiguing task: The fatiguing protocol involved 120 isotonic MVCCs of 
the knee extensor muscles through an ~85º range of motion (as above) with 1 MVCC 
performed every 3 seconds (6-minute task). Participants actively extended the knee, then 
the dynamometer passively returned the leg to the starting position at 90º of knee flexion 
after each MVCC.  
(4) Recovery Contractions: The recovery protocol involved sets of brief contractions 
immediately after the fatiguing task, and then at 5 and 20 minutes of recovery.  Each set 
of contractions involved an MVIC (with a superimposed TMS and percutaneous muscle 
stimulation) followed by an additional electrically-evoked twitch contraction and then 
five successive MVCCs.  
Participants received strong verbal encouragement throughout the maximal effort 
contractions. During all MVCCs, participants were instructed to “kick as hard and as fast 
as possible” and each MVCC was initiated via strong verbal command from the authors: 
“KICK”. The authors provided the verbal cue each 3-s based on a visual cue from a 
custom-designed data collection program, and participants were encouraged to maintain 
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maximal effort throughout the dynamic fatiguing task using several standard statements 
of encouragement.  
Data Analysis 
The torque during the MVICs was quantified as the average value over a 0.1 s 
interval prior to the onset of the TMS pulse. The maximum angular velocity, power and 
resistance torque during MVCCs were quantified during the concentric phase of the 
contraction. The average resistance torque during MVCCs was calculated as the average 
torque during the concentric phase of the knee extension contraction. The duty cycle was 
calculated as: (active contraction time) · (active contraction time + relaxation time)-1. The 
variables from the dynamic fatiguing task are presented as the average from five 
consecutive contractions, at baseline (contractions 1-5) or the end of the fatiguing task 
(contractions 116-120). 
Voluntary activation was assessed with both TMS and electrical stimulation. 
Voluntary activation with TMS was estimated with the SIT expressed as a percentage of 
the total torque i.e. [SIT · (MVIC + SIT)-1 · 100%] (Gandevia, 2001).  For electrically 
evoked contractions, voluntary activation was calculated using the following equation: 
voluntary activation = (1 – SIT · Potentiated Twitch-1) × 100% (Gandevia, 2001; Todd et 
al., 2016). Contractile properties of the knee extensor muscles were quantified from the 
potentiated twitch elicited with percutaneous electrical stimulation.  Variables included 
the peak amplitude of the potentiated twitch, contraction time, and half relaxation time. 
Half relaxation time was determined as the time interval in milliseconds (ms) elapsed 
from the peak twitch amplitude until the torque reached 50% of the peak twitch 
amplitude. Post-activation potentiation (PAP) from electrically-evoked twitch 
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contractions was calculated as: (potentiated twitch amplitude - non-potentiated twitch 
amplitude) · non-potentiated twitch amplitude-1 · 100%.  
Electrophysiological properties of the knee extensors were also assessed with 
peak-to-peak amplitude of the MEPs for the agonist muscles (rectus femoris, vastus 
lateralis and vastus medialis) elicited via TMS during MVICs. Similar results were 
observed for the MEP amplitude and area, thus, only MEP amplitude results are 
presented. The duration of the silent period was determined as the interval from the time 
of the TMS to the return of continuous EMG after the MEP (Taylor et al., 1996). 
Reduction in variables (MVIC torque, MVCC velocity, power, duty cycle, range of 
motion, peak resistance torque, and average resistance torque, voluntary activation, 
twitch amplitude, contraction time, half relaxation time, peak rate of relaxation, EMG 
silent period and MEP (%Mmax)) for before and after the fatiguing task, were calculated 
as [1 – (end value · baseline value-1)] × 100%. Representative traces of raw data are 
presented in Figure 1, for dynamic contractions (Fig. 1A) and MVCs with stimulations 





Figure 3.1. Representative data for maximal voluntary concentric contraction 
(MVCC) power, range of motion and applied torque, maximal voluntary isometric 
contraction (MVIC) torque, superimposed twitch (SIT) torque, potentiated twitch, 
motor evoked potential (MEP) and EMG silent period. A. Calculated power (applied 
torque × half-wave rectified velocity), range of motion and applied torque signals of a 62-
year old control woman performing five MVCCs at the start (black lines) and end (grey 
lines) of the fatiguing task. The torque (B) and EMG (C) signal of the woman performing 
an MVIC with TMS-elicited SIT during the MVIC and electrical stimulation evoked 
twitches during the MVIC and at rest. The TMS-elicited SIT (D), electrically-evoked 
potentiated twitch (E) torque, and vastus lateralis EMG (F) signal displaying the MEP 




Homeostatic model assessment for assessing insulin resistance (HOMA-IR) was 
calculated using the fasting plasma insulin concentration (FPI, mU·L-1) and fasting 
plasma glucose (FPG, mmol·L-1): HOMA-IR = (FPI × FPG) · 22.5-1. 
Statistics 
Values are reported as mean ± SD in the text and displayed as mean ± SE in the 
figures. Participant characteristics and baseline muscle function (Tables 1 and 2) were 
compared across groups using a univariate analysis of variance (ANOVA) with two 
between subject factors (group: T2D vs controls, and sex: male vs. female). 
To determine changes over time during the dynamic fatiguing contraction or 
during the 20-minute recovery period (task end, 5 mins and 20 mins post the dynamic 
contraction), mixed model analysis of variance with group and sex as between subject 
factors and repeated measures over time was used for the various dependent variables 
(MVIC torque, MVCC velocity, power, duty cycle, range of motion, peak applied torque, 
and average applied torque, voluntary activation, twitch amplitude, contraction time, half 
relaxation time, peak rate of relaxation, EMG silent period and MEP (%Mmax)). For each 
ANOVA, the sphericity of data was determined, and technical corrections were 
performed when necessary. If needed, post hoc analysis with Bonferroni corrections were 
applied when an F test was significant. Pearson correlation coefficients (r) were used to 
determine associations between variables including fatigability (reductions in MVIC and 
MVCC), participant characteristics (fasting plasma glucose, HbA1c, estimated VO2 
peak, skeletal muscle mass, daily step count, and questionnaire scores), baseline muscle 
characteristics (MVIC strength, MVCC power, voluntary activation, and potentiated 
twitch amplitude), and measurements of fatigue-related changes in the potentiated twitch 
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and voluntary activation. Linearity of bivariate correlations was verified with visual 
inspection, to confirm there were no violations of the assumptions of normality, linearity, 
and homoscedasticity.  
Significance was determined at P < 0.05 and all analyses were performed using 
IBM Statistical Package for Social Sciences (SPSS, V24). 
3.3 Results 
Baseline Measurements 
 Participant and baseline characteristics are presented in Table 1. The T2D and 
control groups were similar in age (group effect, P = 0.985), BMI (group effect, P = 
0.172), and daily physical activity (step count; group effect, P = 0.895). The control and 
T2D groups had similar body fat (group effect, P = 0.310), estimated VO2 peak (group 
effect, P = 0.231) and skeletal muscle mass in the dominant leg (group effect, P = 0.724).  
As expected, people with T2D had higher HbA1c (group effect, P < 0.001), fasting 
plasma glucose (group effect, P < 0.001), fasting plasma insulin (group effect, P = 0.001) 
and HOMA-IR (group effect, P < 0.001) compared with controls (Table 1). People with 
T2D and controls had similar plasma thyroid-stimulating hormone concentrations (1.86 ± 
0.89 vs. 1.58 ± 0.89 mU·L-1, respectively; group effect, P = 0.306). People with T2D and 
controls demonstrated no signs of anemia, hemoglobin (14.2 ± 1.8 vs. 14.6 ± 1.7 g·dL-1, 
respectively; group effect, P = 0.428) and hematocrit (42.4 ± 3.3 vs. 42.3 ± 4.0%, 
respectively; group effect, P = 0.974) concentrations were similar between the groups. 
Among the people with T2D, 14 people were prescribed metformin and 11 people were 
prescribed a statin medication. Among controls, 0 people were prescribed metformin and 
4 people were prescribed a statin medication. Although not a primary aim of the study, it 
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is noteworthy that people with T2D prescribed to a statin medication had similar 
reductions in MVCC power (time × statin effect, P = 0.458; statin effect, P = 0.729) and 
MVIC torque (time × statin effect, P = 0.742; statin effect, P = 0.571) compared to 
people with T2D not prescribed to a statin medication. See Table 1. 




    (n=17; 10 men) (n = 21, 11 men) 
Age years 59.6 ± 9.0 59.5 ± 9.6 
BMI kg·m-2 29.4 ± 7.0 27.2 ± 4.3 
Body Fat % 36.2 ± 13.8 32.4 ± 7.2 
Duration of Diabetes years 6.83 ± 6.45 0 * 
HbA1c % 7.04 ± 1.11 5.41 ± 0.23 * 
Fasting Plasma Glucose mg·dL-1 126.1 ± 32.1 87.1 ± 6.6 *  
Fasting Plasma Insulin pMol 59.1 ± 25.7 35.1 ± 17.5 *  
HOMA-IR AU 3.08 ± 1.71 1.28 ± 0.63 * 
Estimated VO2 Peak mL/kg/min 27.9 ± 8.3 30.1 ± 7.8 
Leg Muscle Mass kg 8.22 ± 1.75 8.52 ± 2.36 
Daily Step Count n 8334 ± 3446 8295 ± 3218 
Questionnaires       
PSQI AU 4.19 ± 2.61 4.90 ± 2.41 
FIS total AU 24.18 ± 29.65 7.19 ± 14.91 
FIS Cognitive AU 6.38 ± 7.43 3.62 ± 4.42 
FIS Physical AU 7.63 ± 8.02 4.62 ± 5.84 
FIS Psychological AU 11.69 ± 15.53 6.67 ± 11.03 
GDS AU 2.00 ± 0 1.95 ± 0.22 
Table 3.1. Participant characteristics and questionnaire scores. Values are displayed 
as mean ± SD. BMI, body mass index; HbA1c, glycated hemoglobin; HOMA-IR, 
homeostatic model assessment of insulin resistance; AU, arbitrary unit; PSQI, Pittsburgh 
Sleep Quality Index; FIS, Fatigue Impact Scale; GDS, Geriatric Depression Scale. (* 
denotes group difference between controls and T2D, P < 0.05). 
People with T2D and controls had similar knee extensor MVIC torque (group 
effect, P = 0.421), peak angular velocities (group effect, P = 0.949), peak knee extensor 
power (group effect, P = 0.627), electrically-evoked potentiated twitch amplitudes (group 
effect, P = 0.667), and post-activation potentiation (group effect, P = 0.368). See Table 2.  
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Baseline levels of voluntary activation during MVICs were similar between controls and 
people with T2D, quantified with TMS (group effect, P = 0.232) and with electrical 
stimulation (group effect, P = 0.715; Table 2).  
 
Table 3.2. Baseline muscle function before and after the dynamic fatiguing 
contraction in people with T2D and age-and physical activity-matched healthy 
controls without T2D. Values are displayed as mean ± SD. The relative reduction (%) 
shown is from baseline to immediately after the fatiguing tasks (Task End).  People with 
T2D demonstrated greater reductions in MVCC power, MVIC torque, and potentiated 
twitch amplitude compared with healthy controls. (* denotes group difference between 
controls and T2D, P < 0.05; † denotes difference between baseline and task end, P < 
0.05).  
Abbreviations: MVCC, maximal voluntary concentric contraction; MVIC, maximal 
voluntary isometric contraction; VA, voluntary activation; ES, electrical stimulation; SIT, 
superimposed twitch; PAP, post-activation potentiation; RF, rectus femoris; VL, vastus 
lateralis; VM, vastus medialis; Mmax, maximal compound muscle action potential; NS, 
not statistically significant. 
For both groups, men and women were similar in age (58.9 ± 9.8 vs. 60.5 ± 8.7 
years, respectively; sex effect, P = 0.646; group × sex, P = 0.617), BMI (28.9 ± 5.3 vs. 
27.2 ± 6.2 kg·m-2, sex effect, p = 0.447; group × sex, P = 0.205),  daily physical activity 
    Type 2 Diabetes (n = 17)    Control (n = 21)  
    Baseline Task End Δ (%)   Baseline Task End Δ (%) 
MVCC Power Watts 291 ± 139 163 ± 96 -42.8 ± 24.2†   261 ± 85 199 ± 90 -26.4 ± 15.0†* 
MVCC Velocity deg·s-1 330 ± 62 209 ± 74 -36.2 ± 4.5†   333 ± 37 273 ± 61 -18.9 ± 4.6†* 
Duty Cycle % 13.7 ± 1.2 18.0 ± 2.0 +29.5 ± 20.5†   14.5 ± 2.1 18.1 ± 2.8 +25.8 ± 19.7† 
MVIC Torque Nm 176 ± 80 105 ± 46 -37.6 ± 18.2†   160 ± 59 115 ± 45 -26.4 ± 12.1†* 
Twitch Amplitude Nm 41.1 ± 16.8 21.2 ± 10.1 -44.0 ± 20.4†   43.4 ± 20.1 31.1 ± 12.0 -35.4 ± 20.0†* 
Contraction Time ms 83.1 ± 7.0 80.5 ± 14.0  NS   83.7 ± 10.0 82.4 ± 11.5  NS 
Half-relaxation time ms 70.2 ± 20.7 87.8 ± 30.0 +28.0 ± 12.7†   64.2 ± 18.4 74.1 ± 31.2 +27.4 ± 9.5† 
VA (ES) % 93.4 ± 3.4 84.2 ± 9.3 -12.1 ± 2.6†   92.8 ± 5.0 86.4 ± 7.3 -12.4 ± 4.4† 
SIT % MVIC 2.71 ± 1.72 4.76 ± 2.79 +55.8 ± 41.1†   3.19 ± 1.72 5.04 ± 5.73 +47.7 ± 47.2† 
PAP % 63.2 ± 51.8       74.1 ± 47.3     
Mmax Amplitude                 
RF mV 4.88 ± 1.35 5.13 ± 1.32  NS   4.67 ± 0.78 4.47 ± 0.63  NS  
VL mV 6.40 ± 2.40 5.59 ± 1.27  NS   5.88 ± 2.30 5.70 ± 2.18 NS 
VM mV 7.16 ± 3.40 7.52 ± 3.86  NS   6.82 ± 2.20 6.77 ± 1.20  NS  
MEP Amplitude                 
RF %Mmax 39.5 ± 24.0 54.0 ± 33.2 +50.0 ± 71.0†   49.3 ± 38.6 70.9 ± 44.5 +36.5 ± 59.6† 
VL %Mmax 38.2 ± 24.1 42.8 ± 24.7 +11.3 ± 34.3†   29.0 ± 12.6 40.9 ± 24.5 +27.5 ± 37.1† 
VM %Mmax 47.1 ± 28.9 53.6 ± 37.1  NS   47.7 ± 29.8 52.2 ± 37.4  NS 
EMG Silent Period                 
RF ms 149 ± 116 233 ± 167 +59.5 ± 71.2†   134 ± 41 203 ± 96 +61.0 ± 91.4† 
VL ms 150 ± 112 252 ± 169 +70.5 ± 74.7†   138 ± 58 189 ± 94 +47.3 ± 77.0† 




(step count: 8,690 ± 3,220 vs. 7,830 ± 3,400 steps·day-1, respectively; sex effect, P = 
0.499; group × sex, P = 0.608), HbA1c (6.10 ± 1.11 vs. 6.19 ± 1.15%, respectively; sex 
effect, P = 0.612; group × sex, P = 0.568), fasting plasma glucose (106.5 ± 25.7 vs. 102.9 
± 35.2 mg·dL-1, respectively; sex effect, P = 0.614; group × sex, P = 0.786), fasting 
plasma insulin (46.1 ± 21.2 vs. 45.4 ± 29.0 pMol, respectively; sex effect, P = 0.891; 
group × sex, P = 0.118), HOMA-IR (2.06 ± 1.14 vs. 2.17 ± 2.01 AU, respectively; sex 
effect, P = 0.762; group × sex, P = 0.191) and thyroid-stimulating hormone (1.75 ± 1.03 
vs. 1.64 ± 0.68 mU·L-1, respectively; sex effect, P = 0.753; group × sex, P = 0.520).  
Men however, had less body fat than women (28.0 ± 6.6 vs. 38.3 ± 9.6%, 
respectively; sex effect, P < 0.001, group × sex, P = 0.142) and greater skeletal muscle 
mass of the leg (9.81 ± 1.37 vs. 6.54 ± 1.24 kg, respectively; sex effect, P < 0.001; group 
× sex, P = 0.116). For both groups men also had a larger MVIC torque (204.6 ± 63.1 vs. 
116.9 ± 34.7 Nm, respectively; sex effect, P < 0.001, group × sex, P = 0.905), similar 
MVCC peak angular velocity (342.3 ± 56.6 vs. 318.3 ± 41.2 deg·s-1, respectively; sex 
effect, P = 0.184; group × sex, P = 0.620), greater MVCC peak power (329.0 ± 120.4 vs. 
213.1 ± 71.1 Watts, respectively; sex effect, P = 0.004, group × sex, P = 0.453) and a 
larger electrically-evoked twitch amplitude (50.3 ± 21.0 vs. 31.7 ± 4.8 Nm, respectively; 
sex effect, P = 0.004, group × sex, P = 0.670).  Baseline voluntary activation measured 
during the MVICs (92.6 ± 5.2 vs. 93.6 ± 2.7%, respectively; sex effect, P = 0.529, group 
× sex, P = 0.955) and post-activation potentiation (60.0 ± 26.7 vs. 84.6 ± 69.9%, 




Men and women did not differ in estimated VO2 peak (31.0 ± 7.2 vs. 26.0 ± 8.6 
mL·kg-1·min-1, respectively; sex effect, P = 0.060; group × sex, P = 0.063), although 
there was a trend toward significance. Closer examination showed that the control men 
and women had similar estimated VO2 peak (30.1 ± 7.0 vs. 30.1 ± 9.7 mL·kg
-1·min-1; sex 
effect, P = 0.99); however, among people with T2D, men had greater estimated VO2 peak 
compared to women (32.0 ± 7.7 vs. 22.0 ± 5.1 mL·kg-1·min-1; sex effect, P = 0.010).  
 Perception of Fatigue, Depression, and Sleep Quality: People with T2D had 
similar reports of perceptions of daily fatigue on cognitive function (FIS cognitive; group 
effect, P = 0.216), physical function (FIS physical; group effect, P = 0.302), and 
psychological function (FIS psychological; group effect, P = 0.328) compared with 
controls. See Table 1. 
People with T2D and controls reported low but similar scores on the depression 
scale (group effect, P = 0.301), with no one reporting a clinically significant level of 
depression (GDS score > 5). Sleep quality was similar in people with T2D and controls 
(group effect, P = 0.415). See Table 1. The mean scores were consistent with assessments 
of ‘healthy control’ sleepers; however, some individuals reported ‘poor’ sleep quality 
(PSQI score > 5) (Buysse et al., 1989).  
Fatigability and Recovery 
 MVCC angular power and velocity: Both the control group and people with T2D 
had reductions in MVCC power during the dynamic fatiguing task (time effect, P < 
0.001), but this reduction was greater in people with T2D (time × group, P < 0.001; 
Figure 2A). Recovery, however, was similar for both groups (time effect, P < 0.001; 
group effect, P = 0.291; time × group, P = 0.548). 
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People with T2D demonstrated greater reductions in MVCC peak angular velocity 
compared with controls during the dynamic fatiguing task (time effect, P < 0.001; group 
effect, P = 0.688; time × group, P = 0.03). During recovery, both groups demonstrated 
increases in MVCC angular velocity after the dynamic fatiguing task (time effect; P < 
0.001), however, people with T2D had lower MVCC angular velocity than controls 
throughout the recovery period (R05 & R20: group effect, P = 0.012) with no interaction 
(time × group, P = 0.865).  
 
Figure 3.2. Fatigability of the maximal voluntary concentric contraction (MVCC) 
power (% baseline) (A) and maximal voluntary isometric contraction (MVIC) 
torque (% baseline) (B) in response to a dynamic fatiguing task. Values are displayed 
as mean ± SEM. A. The T2D group had greater reductions in the mean MVCC power (% 
baseline power of the mean of first 5 contractions) than controls by the last five 
contractions of the dynamic fatiguing task. Recovery of power during the MVCCs at 5 
min (R05) and 20 mins (R20) was less for the T2D than control group.  B.  MVIC torque 
(% baseline) declined more for the T2D than the control group by the end of the dynamic 
fatiguing task (Task End).  Recovery of MVIC was similar between people with T2D and 
controls for MVIC torque up to 20 mins after the fatiguing task (R20). (* group 
differences at P < 0.05). 
The reduction of MVCC power during the fatiguing task was not different 
between men and women (last 5 contractions: 29.2 ± 20.1% vs. 38.7 ± 16.8% reduction, 
respectively; time × sex, P = 0.524) for either group (time × group × sex, P = 0.762; sex 
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effect, P = 0.104). During recovery (R05 & R20), the increase in MVCC power (time 
effect, P < 0.001) was similar for men and women (sex effect, P = 0.634; time × sex, P = 
0.473; time × group × sex, P = 0.276).  
Men and women demonstrated a similar reduction in MVCC velocity during the 
fatiguing task (last 5 contractions: 23.6 ± 18.8% vs. 31.9 ± 21.2% reduction, respectively; 
time × sex, P = 0.542; time × group × sex, P = 0.621) and similar recovery after the 
fatiguing task (time × sex, P = 0.268; time × group × sex, P = 0.669).  
Duty Cycle: The duty cycle (work:rest ratio) was similar between people with 
T2D and controls during the first five dynamic contractions (group effect, P = 0.146). 
The duty cycle increased during the fatiguing task (due to slower contraction velocity), 
but this increase was similar between people with T2D and controls (time effect, P = 
0.031; time × group, P = 0.663). The duty cycle was similar for men and women at the 
start of the fatiguing task (13.9 ± 1.8% vs. 14.6 ± 1.7%, respectively; sex effect, P = 
0.419; group × sex, P = 0.601), and the increase in duty cycle at the end of the fatiguing 
task was similar (27.1 ± 19.5% vs. 28.4 ± 21.3% increase, respectively; time effect, P < 
0.001; time × sex, P = 0.903). 
Range of Motion:  People with T2D and controls performed the concentric knee 
extension through a similar range of motion (baseline: 79.9 ± 9.0 vs. 80.2 ± 10.9 deg; 
group effect, P = 0.898) at the start of the fatiguing task, and the range of motion 
decreased similarly for both groups at the end of the fatiguing task (last 5 contractions: 
74.1 ± 8.6 vs. 78.4 ± 10.8 deg; time effect, P = 0.006; time × group, P = 0.137). Men and 
women performed the concentric knee extension through a similar range of motion at the 
start of the fatiguing task (80.9 ± 8.3 vs. 79.0 ± 11.6 deg; sex effect, P = 0.587) and had 
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similar reductions in range of motion (last 5 contractions: 76.5 ± 7.1 vs. 75.9 ± 12.5 deg; 
time × sex, P = 0.711; time × group × sex, P = 0.974). 
Applied Torque: The peak applied torque during the concentric knee extension 
was similar for people with T2D compared with controls at the start of the fatiguing task 
(66.9 ± 24.8 vs. 62.7 ± 16.5 Nm, respectively; group effect, P = 0.772).  Similarly, the 
average applied torque did not differ between the T2D and control groups (47.9 ± 19.0 
vs. 43.4 ± 13.3 Nm, respectively; group effect, P = 0.563). The applied torque decreased 
during the dynamic fatiguing task more for people with T2D compared with healthy 
controls, for both the peak torque (19.5 ± 8.6% vs. 13.4 ± 10.3% reduction, respectively; 
time effect, P < 0.001; time × group, P < 0.001) and the average torque (17.3 ± 11.6% vs. 
12.0 ± 8.9% reduction, respectively; time effect, P < 0.001; time × group, P < 0.001).  
Because men were stronger than women, the peak applied torque (75.6 ± 21.6 vs. 
62.7 ± 16.5 Nm, respectively; sex effect, P = 0.001) and the average applied torque (53.9 
± 16.9 Nm vs. 35.9 ± 8.7 Nm, respectively; sex effect, P = 0.001) during the concentric 
phase of the dynamic knee extension was greater for men at the start of the fatiguing task. 
Men and women had a similar reduction in both peak (14.5 ± 11.0% vs. 18.9 ± 7.8% 
reduction; time effect, P < 0.001; time × sex, P = 0.136) and average torque (12.9 ± 
11.4% vs. 16.8 ± 9.3% reduction; time effect, P < 0.001; time × sex, P = 0.236) at the end 
of the fatiguing task. 
 MVIC Torque: The reduction in MVIC torque after the dynamic fatiguing 
contraction (time effect, P < 0.001) was greater in the T2D group than controls (time × 
group, P = 0.04; Figure 2B). MVIC torque increased during the 20 minutes of recovery 
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(time effect, P < 0.001), and the increase was similar between the T2D and control 
groups (R05 & R20: group effect, P = 0.120; time × group, P = 0.186).  
 Men and women had similar reductions in MVIC torque after the dynamic 
fatiguing contraction (End Task: 31.5 ± 20.1% vs. 31.4 ± 9.6% reduction, respectively; 
time effect, P < 0.001; sex effect, P = 0.917; time × sex, P = 0.995; time × group × sex, P 
= 0.725). Men and women also had similar increases in MVIC torque during recovery 
(R05 & R20: time effect, P < 0.001; sex effect, P = 0.774; time × sex, P = 0.951; time × 
group × sex, P = 0.110). See Figure 2B.  
Contractile Properties for the Electrically-Evoked Potentiated Twitch 
 Twitch Amplitude: The electrically-evoked potentiated twitch amplitude was 
reduced for all participants during and immediately after the fatiguing contraction (time 
effect, P < 0.001); however, people with T2D had greater reductions than controls (time 
× group, P = 0.010). Similarly, the twitch amplitude increased during recovery (time 
effect, P < 0.001) but people with T2D recovered more slowly and the twitch was more 
depressed, even at 20 mins post exercise, compared with controls (R05 & R20: group 
effect, P = 0.027). See Figure 3A. 
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Figure 3.3. Electrically-evoked potentiated twitch amplitude (A) and voluntary 
activation (B) during and after the dynamic fatiguing task.  Values are displayed as 
mean ± SEM. A. The electrically-evoked potentiated twitch amplitude (% baseline) was 
reduced more for the T2D group than controls and remained depressed during the 20 
mins recovery (P < 0.05). B. Voluntary activation (assessed with electrical stimulation) 
declined in both people with T2D and controls (P < 0.05) but did not differ between 
groups (P > 0.05). 
Men and women had similar reductions in potentiated twitch amplitude by the end 
of the fatiguing task for both the T2D and control groups (40.3 ± 27.6% vs. 39.8 ± 18.0% 
reduction; time effect, P < 0.001; sex effect, P = 0.267; time × sex, P = 0.702; time × 
group × sex, P = 0.337).  During recovery, men and women demonstrated similar relative 
increases in potentiated twitch amplitude (R05 & R20: time effect, P < 0.001; sex effect, 
P = 0.233; time × sex, P = 0.555; time × group × sex, P = 0.487).  
 Half Relaxation Time: People with T2D and controls, both men and women, had 
similar increases in half relaxation time of the potentiated twitch after the fatiguing 
contraction (time effect, P = 0.001; sex effect, P = 0.568; time × group, P = 0.511; time × 
sex, P = 0.368; time × group × sex, P = 0.982; group effect, P = 0.321). During the 20-
minutes of recovery (task end, and at 5 and 20 minutes post exercise), the half relaxation 
time decreased in all groups (time effect, P = 0.002; group effect, P = 0.115; sex effect, P 
= 0.696; time × group, P = 0.458; time × sex, P = 0.440; time × group × sex, P = 0.747).  
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Contraction Time: People with T2D and controls, both men and women, 
demonstrated no change in contraction time of the electrically-evoked potentiated twitch 
during the fatiguing task (time effect, P = 0.377; group effect, P = 0.792; sex effect, P = 
0.110; time × group, P = 0.564; time × sex, P = 0.212; time × group × sex, P = 0.717), or 
during the 20-minute recovery (task end and at 5 and 20 minutes post exercise) (time 
effect, P = 0.532; group effect, P = 0.717; sex effect, P = 0.126; time × group, P = 0.732; 
time × sex, P = 0.158; time × group × sex, P = 0.996). See Table 2.   
Voluntary Activation 
 Voluntary Activation (Electrical Stimulation): Voluntary activation decreased in 
people with T2D and controls during the fatiguing contraction (End Task: 84.2 ± 9.3% 
vs. 86.4 ± 7.3%, respectively; time effect, P < 0.001), but this decrease did not differ 
between groups (time × group, P = 0.840; Figure 3B). Men and women showed similar 
reductions in voluntary activation by the end of the fatiguing contraction (87.5 ± 7.6% vs. 
81.8 ± 8.1%, respectively; sex effect, P = 0.456; time × sex, P = 0.247; time × group × 
sex, P = 0.506). Voluntary activation remained depressed during the recovery period after 
the fatiguing task for all groups (time effect, P = 0.408; time × group, P = 0.420; time × 
sex, P = 0.260; time × group × sex, P = 0.348; sex effect, P = 0.792). 
 Superimposed Twitch Amplitude (TMS): The SIT increased (i.e. voluntary 
activation decreased) in both people with T2D and controls (time effect, P = 0.015) and 
this effect was similar for both groups (time × group, P = 0.995, Table 2) and for men 
and women across the groups (sex effect, P = 0.490, time × sex, P = 0.625; time × group 
× sex, P = 0.717). During the 20-minute recovery, the superimposed twitch amplitude 
decreased (voluntary activation increased) (time effect, P = 0.039), similarly for people 
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with T2D and controls (time × group, P = 0.600, Table 2) and similarly for men and 
women (sex effect, P = 0.944; time × sex, P = 0.146; time × group × sex, P = 0.443).  
EMG Response to Stimulation: Mmax, MEP, Silent Period 
Maximal compound muscle action potential (Mmax): The Mmax did not change 
during the fatiguing task for participants with T2D or controls for the rectus femoris (time 
effect, P = 0.212; time × group, P = 0.176; group effect, P = 0.392; group × sex, P = 
0.805; time × sex, P = 0.357; time × group × sex, P = 0.741), vastus lateralis (time effect, 
P = 0.697; time × group, P = 0.688; group effect, P = 0.825; group × sex, P = 0.804; time 
× sex, P = 0.294; time × group × sex, P = 0.989), or vastus medialis (time effect, P = 
0.403; time × group, P = 0.449; group effect, P = 0.885; group × sex, P = 0.278; time × 
sex, P = 0.187; time × group × sex, P = 0.503). See Table 2.   
The Mmax did not change during the 20-minute recovery period for participants 
with T2D or controls for the rectus femoris (time effect, P = 0.588; time × group, P = 
0.628; group effect, P = 0.880; group × sex, P = 0.906; time × sex, P = 0.623; time × 
group × sex, P = 0.901), vastus lateralis (time effect, P = 0.653; time × group, P = 0.763; 
group effect, P = 0.727; group × sex, P = 0.803; time × sex, P = 0.830; time × group × 
sex, P = 0.973), or vastus medialis (time effect, P = 0620; time × group, P = 0.736; group 
effect, P = 0.997; group × sex, P = 0.254; time × sex, P = 0.940 time × group × sex, P = 
0.157). See Table 2.   
Motor evoked potential (MEP): The MEP amplitude (%Mmax) evoked during the 
MVC increased after the fatiguing task for the men and women with T2D and controls 
for the rectus femoris (time effect, P = 0.001; time × group, P = 0.876; group effect, P = 
0.422; group × sex, P = 0.910; time × sex, P = 0.955; time × group × sex, P = 0.142) and 
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vastus lateralis (time effect, P = 0.037; time × group, P = 0.260; group effect, P = 0.949; 
group × sex, P = 0.252; time × sex, P = 0.324; time × group × sex, P = 0.231), but not for 
the vastus medialis (time effect, P = 0.139; time × group, P = 0.796; group effect, P = 
0.777; group × sex, P = 0.747; time × sex, P = 0.144; time × group × sex, P = 0.728). See 
Table 2.   
The MEP amplitude (%Mmax) reduced during recovery for men and women with 
T2D and controls for the rectus femoris (time effect, P < 0.001; time × group, P = 0.156; 
group effect, P = 0.176; group × sex, P = 0.986; time × sex, P = 0.588; time × group × 
sex, P = 0.965) and vastus lateralis (time effect, P = 0.042; time × group, P = 0.521; 
group effect, P = 0.494; group × sex, P = 0.266; time × sex, P = 0.153; time × group × 
sex, P = 0.305), but not for the vastus medialis (time effect, P = 0.126; time × group, P = 
0.958; group effect, P = 0.726; group × sex, P = 0.859; time × sex, P = 0.678; time × 
group × sex, P = 0.952).  
Silent Period: The EMG silent period, assessed during the MVIC, increased 
during the fatiguing task for the rectus femoris (time effect, P < 0.001; time × group, P = 
0.615; group effect, P = 0.632; group × sex, P = 0.731; time × sex, P = 0.502; time × 
group × sex, P = 0.133), vastus lateralis (time effect, P = 0.001; time × group, P = 0.187; 
group effect, P = 0.393; group × sex, P = 0.803; time × sex, P = 0.406; time × group × 
sex, P = 0.245) and vastus medialis (time effect, P = 0.002; time × group, P = 0.103; 
group effect, P = 0.189; group × sex, P = 0.516; time × sex, P = 0.406; time × group × 
sex, P = 0.278). See Table 2.   
The EMG silent period decreased during recovery from the fatiguing task for men 
and women with T2D and controls for the rectus femoris (time effect, P < 0.001; time × 
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group, P = 0.800; group effect, P = 0.722; group × sex, P = 0.893; time × sex, P = 0.453; 
time × group × sex, P = 0.585), vastus lateralis (time effect, P = 0.002; time × group, P = 
0.391; group effect, P = 0.447; group × sex, P = 0.660; time × sex, P = 0.275; time × 
group × sex, P = 0.368), and vastus medialis (time effect, P = 0.042; time × group, P = 
0.249; group effect, P = 0.799; group × sex, P = 0.922; time × sex, P = 0.644; time × 
group × sex, P = 0.409). 
Associations 
The following variables were associated with reductions in MVIC performed after 
the fatiguing task: the relative reduction in potentiated twitch amplitude (r2 = 0.364, P = 
0.002; Figure 4A), baseline MVIC torque (r2 = 0.140, P = 0.032), HbA1c (r
2 = 0.145, P = 
0.029), fasting glucose (r2 = 0.130, P = 0.042), and HOMA-IR (r2 = 0.126, P = 0.046).  
The following variables were associated with reductions in MVCC power at the 
end of the fatiguing task: estimated VO2peak (r
2 = 0.494, P <0.001; Figure 4B), reduction 
in potentiated twitch amplitude (r2 = 0.345, P = 0.002), HOMA-IR (r2 = 0.130, P = 
0.042), and HbA1c (r
2 = 0.154, P = 0.024).  
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Figure 3.4. Associations with fatigability. A.  The reduction in MVIC torque (%) was 
associated with the reduction in potentiated twitch amplitude (%) (A; r = 0.603, r2 = 
0.364, P = 0.002). B. The reduction in MVCC power (%) was associated with estimated 
peak aerobic capacity (eVO2) (B; r = -0.703, r
2 = 0.494, P < 0.001).  
3.4 Discussion 
 The novel findings of this study were that people with T2D were more fatigable 
for a high-velocity dynamic fatiguing task with the knee extensor muscles than healthy 
controls who were matched for age, BMI and physical activity, with no differences 
between men and women. People with T2D demonstrated greater reductions in MVCC 
power, MVIC torque and twitch amplitude after the dynamic fatiguing contraction 
compared with the healthy controls, indicating fatigability and impairments in muscle 
contractile properties were greater for people with T2D. Voluntary activation was 
reduced, and the superimposed twitch amplitude and EMG silent period increased after 
the dynamic fatiguing task, demonstrating reduced neural drive and possibly increased 
intracortical and spinal inhibition; however, these changes were similar for people with 
T2D and controls of both sexes. Thus, both muscular and neural mechanisms (including 
supraspinal fatigue) contributed to knee extensor fatigability of men and women after 
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single limb dynamic exercise, however, contractile mechanisms were responsible for the 
greater fatigability of people with T2D compared with controls. Accordingly, the primary 
measures of fatigability, both the reduction in MVCC power and in the MVIC torque, 
were correlated with the reduction in potentiated twitch amplitude. Estimated maximal 
oxygen consumption (VO2) at baseline and metabolic factors (HbA1c, fasting plasma 
glucose and insulin) were also associated with reduction in MVCC power during the 
dynamic fatiguing task.    
 A strength of this study was that we designed it to understand the effects of T2D 
on fatigability of lower limb muscles, while controlling for confounding effects of age, 
diabetic polyneuropathy, daily physical activity levels, and participant anthropometrics, 
by excluding any people with clinical signs of diabetic polyneuropathy and by matching 
groups based on age, physical activity, estimated aerobic fitness, and BMI. Additionally, 
people with T2D reported similar daily levels of perceived fatigability, sleep quality and 
depression as the controls, indicating there was minimal influence of perceptions of 
fatigue that is often associated with advanced diabetes (Fritschi & Quinn, 2010) and that 
may confound exercise-induced fatigue of the lower limb. These findings however may 
underestimate the group-related differences in fatigability and the contributing 
mechanisms may have been different if people with T2D who have diabetic 
polyneuropathy were included in the study. For example, after a 20-repetition, moderate-
velocity (120 deg·s-1) isokinetic fatiguing task with the knee extensors (IJzerman et al., 
2012), there was a progressive, albeit not significant, increase in fatigability in people 
with T2D and diabetic polyneuropathy (37 ± 13% reduction of muscle work) compared 
with people with T2D and no signs of polyneuropathy (34 ± 13%) and healthy controls 
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(30 ± 8%). Additionally, people with T2D and diabetic polyneuropathy demonstrated 
reduced motor unit number estimates, mean motor unit firing rates, and impaired 
neuromuscular propagation in upper and lower limb muscles compared to controls (Allen 
et al., 2014a), which indicates impairments along the motor pathway from corticospinal 
centers to the interface of the nerve and muscle. These data provide a rationale for an 
increased role of central mechanisms contributing to fatigability of limb muscles in 
people with T2D and polyneuropathy, although this has not been examined. 
Greater Fatigability in People with T2D 
The greater fatigability of the knee extensors in people with T2D than controls 
was evidenced by markedly greater reductions in MVCC power (42.8% vs. 26.4% 
reduction) and MVIC torque at the end of the dynamic tasks (37.6% vs. 26.4% reduction) 
(Fig. 2).  During the dynamic fatiguing task, there was a reduction in range of motion and 
rest time between contractions (increased duty cycle) but this was similar for both groups. 
However, the average applied torque declined more during the fatiguing task for people 
with T2D than the controls (17.3% vs. 12.0% reduction), thus, each MVCC required 
relatively less torque for participants with T2D compared to controls at the end of the 
fatiguing task. Despite this, the participants with T2D showed larger losses in power than 
controls. Thus, our study may have underestimated the magnitude of the difference in 
loss of power between the groups by up to ~5%. These results are consistent with 
previous research demonstrating greater fatigability for isometric contractions of people 
with diabetes mellitus (Type 1 or Type 2) of the handgrip (Petrofsky et al., 2005), 
dorsiflexor (Allen et al., 2015a), and knee extensor muscles (Almeida et al., 2008). 
Importantly, our results clearly indicate that the knee extensor muscles are more fatigable 
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for dynamic contractions in people with T2D, although these results are not consistent 
with that seen for low repetition (20 – 30 repetitions), moderate velocity (120 – 180 
deg·s-1) isokinetic contractions for this muscle group (Halvatsiotis et al., 2002; IJzerman 
et al., 2012). The greater fatigability of people with T2D in our study, but not others, 
could be due to faster contraction velocities or more repetitions in our protocol. Close 
examination of the muscle power during the fatiguing task (Fig. 2A) demonstrates that 
the differences in fatigability between people with T2D and controls did not become 
apparent until after ~60 repetitions. Thus, greater fatigability of people with T2D may 
only occur with more repetitions or faster contraction velocities, and the magnitude of the 
difference in fatigability between people with T2D and controls likely increases as a 
function of exercise time.  
A unique aspect of our study was that our cohort of T2D participants did not have 
advanced stages of the disease, yet lower limb fatigue was greater than in controls 
matched for age, BMI and physical activity.  Many of the processes associated with 
advancing severity of T2D will exacerbate fatigability of the lower limb even further, 
including diabetic polyneuropathy (Allen et al., 2016) and loss of muscle mass (Allen et 
al., 2014b), impaired microcirculation (Petrofsky et al., 2005) and cardiovascular disease.  
We showed however, that even prior to detectable clinical signs of polyneuropathy and 
loss of muscle mass, people with T2D display greater fatigability of the knee extensor 
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muscles that are important for daily function, and as discussed below, was due to 
contractile mechanisms. 
Neural Mechanisms of Fatigability 
After the fatiguing task, there was a reduction in voluntary activation (assessed 
via electrical stimulation) (Fig. 3B), an increase in superimposed twitch amplitude 
(assessed via TMS), an increase in EMG silent period and a modest increase in MEP 
amplitude, each of which were similar between the people with T2D and control (Table 
2). The reduction in voluntary activation elicited with electrical stimulation after the 
fatiguing task demonstrated a suboptimal output from the motor pathway, between 
activation of the motor cortex and excitation of the α-motor neuron (Gandevia, 2001).  
Because there was an increase in superimposed twitch amplitude elicited with TMS 
during the MVIC, the reduced neural drive was in part due to a failure to generate output 
from the motor cortex (Todd et al., 2003). However, this failure was similar across all 
groups, and thus did not explain the difference in fatigability in the people with T2D 
(either the increased reduction in the MVIC or power).   
The increase in silent period reflects intracortical inhibition evoked by the TMS 
during the maximal volitional effort which temporarily halts voluntary descending drive 
(Todd et al., 2007) and recent data suggests the silent period may also reflect spinal 
inhibitory circuitry up to at least 150 ms after the stimulation (Yacyshyn et al., 2016). 
Thus, among our participants, there was an increase in intracortical inhibition, which 
involves the γ-aminobutyric acid (GABAB) receptors (Taylor et al., 1996), and possibly 
greater spinal inhibition (Yacyshyn et al., 2016), but this increase in inhibition was 
similar across the groups. Although there was a reduction in voluntary activation, there 
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was a modest increase in the MEP amplitude elicited by TMS observed in the rectus 
femoris and vastus lateralis muscles, indicating a net increase in corticomotor excitability 
(Todd et al., 2006), in part due to an increase in cortical excitability, increased spinal 
excitability or reduced corticospinal inhibition (Kennedy et al., 2016). An increase in 
MEP amplitude is often observed with fatiguing exercise (e.g. (Hunter et al., 2006)) and 
may reflect increased descending drive despite a failure to increase the motor output. 
Despite the concomitant increases in excitability and inhibition of the motor pathway 
during the fatiguing task, these neural adjustments did not directly explain the greater 
fatigability in the men and women with T2D compared with controls.  
Contractile Mechanisms Primarily Explain Fatigability in People with T2D 
The reduction in MVCC power and MVIC torque were associated with the 
decline of the electrically-evoked potentiated twitch amplitude, indicating muscle 
contractile mechanisms largely explain (~35%) the greater fatigability of people with 
T2D.  In both groups, a reduction in twitch amplitude reflected fatigue in the muscle that 
may be due to disturbances in excitation-contraction coupling, accumulation of 
metabolites, and/or impaired calcium handling (Fitts, 2008; Debold et al., 2016), that 
ultimately reduce the torque that is able to be produced by the muscle fibers. Volitional 
and electrically-evoked contractile function, and lean mass of the knee extensor muscles 
was not different between the groups (T2D, control) at baseline, thus, baseline skeletal 
muscle morphology and function likely did not contribute to greater fatigability in people 
with T2D. However, there is evidence of contractile slowing and reduced muscle strength 
in people with diabetes who have polyneuropathy (Allen et al., 2014b).  
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There are several factors thought to affect the exercising muscle specifically in 
people with diabetes which may contribute to the larger fatigue-related reductions in the 
twitch amplitude, including: i) impaired neuromuscular transmission (Allen et al., 
2015a), ii) impaired calcium kinetics and cross-bridge detachment, iii) impaired 
phosphorylation of myosin regulatory light chains (Allen et al., 2014b), and iv) motor 
unit loss (Allen et al., 2013; Allen et al., 2014a). Among this cohort of people with T2D 
who had no signs of diabetic polyneuropathy, there was no reduction in Mmax amplitude, 
providing evidence of preserved integrity of the sarcolemma and neuromuscular junction 
propagation properties in our cohort of men and women with T2D.  There are relatively 
few examples of decreased Mmax amplitude after a fatiguing contraction; however, 
reduced Mmax has been observed during sustained isometric contractions of healthy young 
adults (first dorsal interosseous) (Fuglevand et al., 1993) and in people with type 1 
diabetes and diabetic polyneuropathy (ankle dorsiflexors) (Allen et al., 2015a).  
Additionally, there was a similar increase in half-relaxation time between groups in our 
study, indicating similar slowing of calcium reuptake into the sarcoplasmic reticulum and 
slowing of cross-bridge detachment in the skeletal muscle fibers.  In addition, our data 
indicates that post-activation potentiation, assessed by comparing electrically-evoked 
twitches during a non-potentiated (no muscular effort within 30 s of the stimulation) and 
a potentiated state (MVIC performed within 2-s prior to evoked twitch), was similar 
between groups. Thus, there was probably similar phosphorylation of myosin regulatory 
light chains (Baudry & Duchateau, 2004) between people with T2D and controls at 
baseline. Motor unit loss at baseline or impairments of active motor units in people with 
T2D may also underlie the greater impairments in contractile properties compared with 
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controls. However, the people with T2D had no clinical signs of diabetic polyneuropathy 
and similar characteristics (age, strength, muscle mass and contractile properties) 
compared with controls, indicating no strong rationale for differences in motor unit 
numbers between the groups.  
 The greater reduction in knee extensor power across both groups, was associated 
with estimated fitness level, the gold standard indicator of glycemic control over the 
preceding two-to-three months (HbA1c) and a proxy of insulin resistance (HOMA-IR).  
Although the T2D and controls groups were matched for fitness, participants with lower 
estimated fitness had greater fatigability during the dynamic fatiguing task, indicating 
that a lower capacity of the cardiovascular system (systemic blood flow and skeletal 
muscle oxygen delivery) may contribute to greater fatigability across both groups. The 
association of fatigability with HbA1c and the HOMA-IR indicate that fatigability was 
greater in people with poorer glycemic control and greater insulin resistance. The greater 
insulin resistance (particularly in those with advanced T2D), may be associated with 
greater vascular constriction due to increased expression of endothelin-1 and reduced 
nitric oxide phosphorylation (Reynolds et al., 2017), resulting in reduced skeletal muscle 
blood flow during exercise and more perturbed metabolic milieu during exercise in 
people with T2D compared to controls. For example, there is evidence of impaired 
potassium handling and calcium regulation (Harmer et al., 2014), and increased lactate 
concentrations (Metz et al., 2005; Harmer et al., 2008) in people with T1D and T2D after 
exercise compared with controls. It is therefore probable that people with T2D and 
diabetic polyneuropathy or other complications of advanced T2D may have even more 
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severe fatigability of lower limb muscles than evidenced among our cohort, and these 
associations warrant further investigation.  
No Sex Differences in Fatigability with T2D  
A unique finding of this study was there were no sex-related differences in 
fatigability of the knee extensor muscles in a middle-to-older aged cohort of healthy 
controls or people with T2D for a high velocity dynamic fatiguing task. Typically, there 
are sex differences in fatigability for isometric and slow-to-moderate velocity fatiguing 
tasks, particularly in the upper limb in young healthy and older adults (Hunter, 2016a, b). 
However, the magnitude of the sex differences in fatigability of young and old adults was 
diminished for high-velocity fatiguing contraction tasks with both the elbow flexor and 
knee extensor muscles (Senefeld et al., 2017), and we found this to be the case in the 
middle-to-older aged adults in this study.  We also observed no sex difference in the 
reduction in the MVIC measured immediately after the dynamic tasks and during 
recovery.  However, in several other studies, men showed greater reductions than women 
in the MVIC immediately after the dynamic fatiguing contraction (Senefeld et al., 2013; 
Senefeld et al., 2017; Senefeld et al., 2018d). The mechanism for the sex difference in the 
slower recovery of the men than the women in that study was due to contractile 
mechanisms with no sex difference in reductions in voluntary activation (Senefeld et al., 
2018d). The sex difference in fatigability can diminish for older adults for both isometric 
tasks and dynamic tasks (Hunter, 2016b, a; Sundberg et al., (in review)). The lack of sex 
difference in fatigability between our current cohorts could be due to the age of our 
participants, whose average age was 60 years, which is older compared to previous 
reports demonstrating sex differences (Senefeld et al., 2013; Senefeld et al., 2018d). The 
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lack of sex differences in fatigability within our cohort could be secondary to our a priori 
participant matching criteria, including similar estimated maximal aerobic capacity (VO2 
peak). Women are expected to have a lower maximal aerobic capacity than men due to a 
number of physiological factors including smaller hearts, less haemoglobin, greater body 
fat (Hunter et al., 2015; Hunter, 2016a); thus, the women in our cohort could be relatively 
more fit than the men.  
Conclusion 
 Men and women with T2D who exhibited no clinical signs of diabetic 
polyneuropathy, were more fatigable during and in recovery from a high-velocity 
dynamic fatiguing task with the knee extensors muscles than controls without diabetes 
who were matched for age, body mass index, and physical activity. This difference in 
fatigability occurred when measured as a loss of power and the reduction of MVIC 
torque. Furthermore, there was no sex-based differences in fatigability for the people with 
T2D and controls. The greater fatigability was associated with glycemic control and 
contractile mechanisms, with no observed impairments in neuromuscular transmission. 
Although neural mechanisms of fatigability contributed to reductions in knee extensor 
power, the lower neural drive was moderate relative to the larger contribution of 
contractile mechanisms that explained the greater fatigability of the lower limb in the 




CHAPTER 4: PERFORMANCE FATIGABILITY IN PEOPLE WITH TYPE 2 
DIABETES AND PREDIABETES IS ASSOCIATED WITH CONTRACTILE 
FUNCTION AND GLYCEMIC CONTROL 
This manuscript is currently in review. 
Senefeld J, Harmer AR, Hunter SK. Performance Fatigability in People with 
Type 2 Diabetes and Prediabetes is Associated with Contractile Function and 
Glycemic Control. 
4.1 Introduction 
Type 2 diabetes mellitus (T2D) and prediabetes have become global pandemics 
(Ogurtsova et al., 2017) and are estimated to currently affect 13% and 37% of 
Americans, respectively (Menke et al., 2015). Exercise training is a cornerstone of T2D 
management, and T2D prevention for those with prediabetes, and along with diet, is the 
first intervention used to treat or delay the onset of T2D. Among a cohort of people with 
prediabetes, the incidence of T2D was reduced 58% with lifestyle interventions (diet, 
weight loss and exercise) over a three-year period, and these lifestyle interventions were 
almost twice as effective as pharmacological treatment with metformin (Knowler et al., 
2002). Although exercise training is important in the management and prevention of 
T2D, reduced exercise capacity in people with T2D and prediabetes may be associated 
with numerous signs and symptoms, such as metabolic dysregulation, depression and 
impaired muscle performance (Fritschi & Quinn, 2010; Poitras et al., 2018).  However, 
there is minimal knowledge on the mechanisms for the reduced exercise capacity in a 
single bout of exercise in people with prediabetes, despite the significant impact that 




The disabling symptoms contributing to reduced exercise capacity are globally 
termed fatigue and can be categorized into two domains: perceived fatigability and 
performance fatigability (Kluger et al., 2013; Enoka & Duchateau, 2016). Performance 
fatigability is the decline in an objective measure of performance over a discrete period 
that limits human performance (Kluger et al., 2013; Enoka & Duchateau, 2016). In the 
controlled laboratory setting, it is often measured as the decline in expected force or 
power of limb muscles during a single bout of limb exercise such as repeated contractions 
(Kluger et al., 2013; Hunter, 2017).  
People with diabetes (types 1 and 2) and diabetic polyneuropathy have greater 
performance fatigability compared with controls (Almeida et al., 2008; IJzerman et al., 
2012; Allen et al., 2015a). Similarly, we recently found that people with T2D and no 
clinical signs of neuropathy had greater reductions in knee extensor power and maximal 
voluntary isometric contraction (MVIC) torque after a six-minute dynamic exercise test 
than healthy controls matched for age, sex, body fat and physical activity (Senefeld et al., 
2018c). Greater fatigability of the knee extensor muscles was directly associated with 
reductions in contractile function and glycemic control (HbA1c), providing evidence that 
those individuals with poorer glycemic control (higher HbA1c) exhibit greater 
performance fatigability, partly due to greater fatigue originating within the muscle 
(Senefeld et al., 2018c). HbA1c is also elevated in prediabetes (although not to the extent 
of type 2 diabetes); therefore, it may be anticipated that people with prediabetes will 
exhibit greater fatigability than controls but less than people with T2D. However, no 
studies have evaluated performance fatigability of the limb muscles in people with 
prediabetes.   
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 Performance fatigability can be exacerbated by perceived fatigability, particularly 
in clinical populations (e.g. prediabetes and T2D) (Kluger et al., 2013). Perceived 
fatigability, defined as self-reported symptoms of exertion, exhaustion, and enervation, 
can be assessed at rest or during exercise performance, and may exacerbate the changes 
in sensations that regulate exercise performance. Perceived fatigability, even at rest, is a 
common symptom in people with T2D, and has been associated with limitations in 
physical exercise and a lack of motivation to perform exercise (Fritschi & Quinn, 2010). 
The mechanisms for perceived fatigability in people with T2D in the rested state are 
unknown but may be related to several factors including poor glucose control (hypo- or 
hyper-glycemia or glucose fluctuations) (Sommerfield et al., 2004), diabetic 
polyneuropathy (Rijken et al., 1998), impaired sleep quality (Cuellar & Ratcliffe, 2008), 
emotional distress from daily disease management (de Sonnaville et al., 1998), 
depression (Anderson et al., 2001b), and obesity (Pickup, 2004). Perceived fatigability in 
people with T2D can be ameliorated with improvements in disease-management and 
glycemic control (Fritschi & Quinn, 2010; Park et al., 2015), suggesting an association 
between perceived fatigability and glycemic control. Although increased perceptions of 
fatigability may contribute to impaired physical function (Singh et al., 2016), the 
association between perceived and performance fatigability in people with T2D and 
prediabetes is unknown.   
The purpose of the study was to: 1) compare performance fatigability and the 
contribution of neural and contractile mechanisms for a high-velocity dynamic fatiguing 
task with the knee extensor muscles in people with T2D, prediabetes, and healthy 
controls matched for age, BMI and physical activity, 2) compare perceived fatigability in 
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people with T2D, prediabetes and controls, and 3) determine the association between 
perceived fatigability and performance fatigability. Our hypotheses were that: 1) 
performance fatigability of the knee extensor muscles would be greater in people with 
prediabetes compared with healthy controls, but less than in people with T2D, 2) greater 
performance fatigability would be associated with greater HbA1c and greater reductions 
in contractile function; 3) perceived fatigability in the rested condition would be greater 
in people with prediabetes compared with healthy controls, but less than in people with 
T2D, and associated with HbA1c; and 4) higher perceived fatigability would be associated 
with greater performance fatigability in people with prediabetes and T2D. Although we 
have previously demonstrated no sex-related differences in fatigability in people with 
T2D (Senefeld et al., 2018c), we tested sufficient men and women in each cohort, as 
recommended by the National Institutes of Health for all clinical research (NOT-OD-15-
102), to determine whether there were any sex differences in perceived or performance 
fatigability. 
4.2 Materials and Methods 
Thirty-nine people with T2D (61.2 ± 8.5 years, 23 men and 16 women), 20 people 
with prediabetes (63.1 ± 6.0 years, 11 men and 9 women), and 27 healthy controls (58.1 
± 9.4 years, 13 men and 14 women) participated in the study. Data from a subset of the 
people with T2D (n = 17) and controls (n = 20) have been reported previously (Senefeld 
et al., 2018c). Prior to involvement in the study, each participant provided written 
informed consent and the protocol was approved by the Marquette University 




Presence of T2D was physician-diagnosed and was known prior to study 
enrolment. Potential control participants who presented with an HbA1c 5.7%-6.5% 
without a diagnosis of T2D were classified as having prediabetes, and all controls had an 
HbA1c ≤5.6%. Exclusion criteria included HbA1c >10%, prescribed insulin or insulin 
secretagogue, diabetic neuropathy (assessed via clinical diagnosis, monofilament and 
tuning fork sensation tests, sensory questionnaires, and electrocardiogram during bicycle 
ergometer exercise test), peripheral edema, severe obesity (body mass index, BMI >45 
kg·m-2), untreated hypothyroidism, epilepsy, medications that affect cortical excitability, 
current smoking, possibility of pregnancy and any neurological, cardiovascular or 
musculoskeletal disease that precluded exercise testing. 
Participants completed three sessions of testing that included a screening session 
to determine eligibility for the study, followed by two experimental sessions. In the first 
experimental session, after overnight fasting (and delay of any diabetes medications), 
venipuncture and subsequent blood analyses were performed, participants then consumed 
a standard breakfast and any diabetes medications, completed assessments of perceived 
fatigability and were familiarized with the experimental procedures (stimulations, static 
contractions and dynamic exercise). Prior to the second experimental session, participants 
consumed a standard breakfast and then completed the dynamic fatiguing exercise with 
the knee extensor muscles upon arrival to the laboratory. Testing was conducted in the 
fed state (post-prandial) in order to simulate conditions encountered in daily life, and thus 
enable assessment of the impact of fatigue under these conditions. Each session was 




 During the screening session the following tests were performed: 1) lower limb 
sensation was assessed using a monofilament and vibration sensation test, 2) autonomic 
nerve function was assessed during bicycle ergometer exercise test, 3) HbA1c was 
assayed, 4) peak aerobic capacity was estimated from a submaximal graded bicycle 
ergometer exercise test, 5) anthropometry (lean muscle mass, fat mass and bone density) 
was assessed using a dual-energy x-ray absorptiometry (DEXA) scan, and 6) daily 
physical activity was assessed using a triaxial accelerometer. 
Diabetic neuropathy screening: Each participant was carefully screened for the presence 
of diabetic polyneuropathy. To assess signs of sensory neuropathy, a questionnaire and 
physical evaluation were performed according to standards (Lower Extremity 
Amputation Prevention program) (Anon, 1998). Physical evaluations included 
monofilament screening per standards. Participants were also screened utilizing vibration 
sensation testing. Vibration sensation was assessed using a 128 Hz tuning fork placed on 
the right and left medial malleoli and the head of the 1st metatarsal. Participants were 
excluded if impaired sensation was observed, i.e., if the monofilament could not be 
sensed on any site on the foot or if vibrations could be sensed by the examiner for more 
than 10 seconds longer than the participant.  Achilles tendon reflex testing was 
performed, and participants were excluded if the tendon jerk was absent. Participants who 
were suspected of having diabetic polyneuropathy were excluded from the study.  
Submaximal, Graded Bicycle Test: Participants performed a submaximal graded exercise 
test (Beekley et al., 2004) on a bicycle ergometer (VIAsprint 150P, CareFusion, San 
Diego, CA, USA) to determine exercise tolerance and screen for cardiac arrhythmias. 
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Participants were required to maintain cadence at 60 revolutions per minute (monitored 
via LED screen by the participant and a researcher), and the resistance was manipulated 
to achieve three different submaximal loads that elicited heart rate responses between 
40% and 70% of heart rate reserve. The participant cycled at each submaximal load for 
four minutes to attain a stable heart rate response. During the test, a 12-lead 
electrocardiogram (CASE, General Electrics, Madison, WI, USA) was monitored for 
presence of arrhythmias. Participants were excluded if arrhythmia was present.  
Physical Activity Monitor: Accelerometry data were collected using the Actigraph GT3X 
(ActiGraph, Pensacola, FL, USA) that was worn on the waist by each participant for 4 
days (2 weekdays and 2 weekend days) (Senefeld et al., 2018c). Sixty-second epochs of 
data were collected and analyzed. Wear-time authentication was performed on each 
participant’s dataset to determine whether data were to be included in the analysis. 
Acceptable wear-time was set a priori as ≥ 3 days of ≥ 9 hours (540 minutes) per day. 
Step count was recorded (ActiLife Software v4) and analyzed. 
Anthropometry and DEXA: Height and body mass were assessed with a standard 
stadiometer and scale. Whole body and “tested” leg (leg used for fatiguing task as 
explained for ‘Experimental Session 2’) anthropometrics (total, fat and muscle mass) 
were assessed using DEXA (Lunar Prodigy full-body scanner, Madison, WI, USA). The 
scanner was calibrated prior to each scan. The analyzed data were recorded offline 
(Encore 2008 software by GE Health care). In the case of participants with artificial 
joints (n =3 controls, 0 people with prediabetes and 5 people with T2D), the artificial 
joint was excluded via encore software. In two of the patients with artificial joints, the 
artificial joint was present in the dominant leg.  
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HbA1c: HbA1c was determined using a point-of-care instrument assay (Siemens 
Healthcare Diagnostics, DCA 2000+), certified by the National Glycohemoglobin 
Standardization Program (Bode et al., 2007). 
Experimental Session One 
Participants fasted for at least 8 hours prior to experimental session one, then 
consumed a standardized breakfast (8 oz. fruit juice, one cereal bar, and one serving of 
fruit) prior to undertaking the remaining activities in the session. In conjunction with 
fasting, participants delayed administration of any diabetes medications until after the 
standardized breakfast. Participants then completed a questionnaire to estimate 
handedness/footedness (Oldfield, 1971) to assess which leg which would be used for 
testing, and a familiarization with the protocols used in experimental session two 
(electrical stimulation and practice of MVICs and maximal-effort, high-velocity 
concentric contractions (MVCCs). Participants were also administered a set of 
questionnaires to assess fatigue, sleep quality, and depression.  
Clinical Symptoms of Fatigue: Clinical symptoms of fatigue in the cognitive, 
physical and psychological domains over the previous month were self-reported via the 
Fatigue Impact Scale (Fisk et al., 1994). 
Sleep Quality: Sleep quality over the previous month was self-reported via the 
Pittsburgh Sleep Quality Index (Buysse et al., 1989).  
Depression: Symptoms of depression over the previous month were self-reported 
via the short-form Geriatric Depression Scale (Snowdon, 1990). 
Blood Measures: Fasting plasma glucose and cholesterol (total cholesterol, and 
high- and low-density lipoprotein concentrations) were determined using a point of care 
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instrument (Alere Cholestech LDX System, Alere Inc. Waltham, MA, USA). 
Hemoglobin concentration was determined using a point of care instrument (StatSiteM 
Hemoglobin Photometer, Stanbio, Boerne, TX, USA) and hematocrit was determined 
manually (International Micro-Capillary Reader, International Equipment Company, 
Boston, MA, USA) per standard instruction of each instrument. Plasma insulin and 
thyroid-stimulating hormone concentrations were quantitatively assayed in duplicate per 
manufacturer instructions using enzyme-linked immunoassay kits (Quantikine Human 
Insulin Immunoassay (R&D Systems, Minneapolis, MN) and Human TSH (CGA) ELISA 
Kit (Thermo Scientific Pierce (Waltham, MA), respectively). Homeostatic model 
assessment for assessing insulin resistance (HOMA-IR) was calculated using the fasting 
plasma insulin concentration (FPI, mU·L-1) and fasting plasma glucose (FPG, mmol·L-1): 
HOMA-IR = (FPI × FPG) · 22.5-1. 
Experimental Session Two 
Approximately one hour prior to the second (last) experimental session, each 
participant consumed a standard breakfast. Upon arrival to the laboratory, each 
participant performed a single limb exercise protocol with the knee extensor muscles that 
included baseline MVICs and MVCCs followed by a high-velocity fatiguing task and 
recovery contractions. Following is a description of the experimental procedures and the 
protocol. 
Measurement of Torque, Velocity and Power 
Participants performed single-limb isometric and isotonic contractions using a 
Biodex System 4 dynamometer (Biodex Medical, Shirley, NY). Participants were asked 
to perform all contractions using their dominant leg, unless there was any form of 
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osteoarthritis (or other joint disease or presence of joint implant) present in the dominant 
limb. In those cases (n=2), the non-dominant leg was tested. Participants were positioned 
on the dynamometer seat with 90º of hip flexion. Padded straps mounted on the seat were 
securely tightened across the shoulders, the waist, and the leg not tested during the 
fatiguing task to prevent synergistic movements by the participants. The tested leg was 
positioned such that the axis of rotation of the knee joint was aligned with the axis of 
rotation of the dynamometer. The internal goniometer of the Biodex dynamometer was 
calibrated using a spirit level. The analog signals corresponding to joint angle, torque, 
and velocity were extracted from the Biodex system using custom-built cables digitized 
at 2,000 Hz and recorded through a Power 1401 analog-to-digital (A-D) converter and 
Spike2 software (Cambridge Electronics Design, Cambridge, UK).   
Electrical Stimulation 
 Single-pulse (200 µs duration, 400 V) electrical stimulation was used for femoral 
nerve (100 – 700 mA) and percutaneous muscle stimulation over the quadriceps (150 – 
750 mA; DS7AH, Digitimer, Ltd., Welwyn Garden City, UK). A single stimulation of 
the femoral nerve was used to elicit a compound muscle action potential (M wave) of 
three agonist muscles and a single pulse of percutaneous stimulation of the muscle belly 
was used to elicit twitch torque to quantify contractile function and to estimate voluntary 
activation of the knee extensor muscles.  
Peripheral Nerve (Femoral) Stimulation: Nerve stimulation was performed to elicit the 
maximal M wave (Mmax) of the three agonist muscles (rectus femoris, vastus lateralis and 
vastus medialis).  After baseline MVICs, the femoral nerve was stimulated using 
supramaximal intensities, with the cathode electrode (Ambu Neuroline electrodes, 
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Denmark; 1.5 cm diameter) placed over the femoral nerve within the femoral triangle and 
the anode placed over the greater trochanter of the femur. The intensity of the nerve 
stimulation was determined by increasing the current until the amplitude of the M wave 
of all three knee extensor muscles plateaued. The stimulation intensity (80 – 500 mA) 
was then increased further by 20% to ensure maximal excitation of the femoral nerve. 
The amplitude of the bi-phasic wave elicited with the supramaximal femoral nerve 
stimulation (Mmax) was used to estimate the integrity of neuromuscular propagation 
(Fuglevand et al., 1993).  
Percutaneous Muscle Stimulation: The knee extensor muscles were stimulated 
percutaneously with custom-made pad electrodes (6 cm × ~15 cm). The cathode was 
placed near (within 10 cm) the femoral triangle and the anode was placed proximal to the 
patella without hindering knee flexion/extension of the participant. The stimulator 
intensity used to elicit the twitch amplitude was determined by increasing the current in 
20-50 mA increments until the resting twitch amplitude plateaued. The stimulation 
intensity (100 – 650 mA) was then increased further by 20% to ensure the greatest 
activation possible with the pad electrodes over the knee extensor muscles.  
State Perceptions: Participants reported ratings of perceived exertion (RPE) of the 
exercising leg using a modified 11-point Likert scale (Borg, 1982). Verbal and written 
anchors denoted that a rating of 0 indicated no exertion and a rating of 10 indicated 
maximal possible exertion. Participants were asked to report RPE at baseline, and if 
participants did not indicate 0, the scale was explained again. Participants reported state 
perceptions of muscle cramps, pain, weakness, soreness and fatigue of the exercising leg 
using separate 10-cm visual analog scales (VAS). 
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Blood glucose concentration: Blood glucose concentration was determined using a point-
of-care glucometer (OneTouch Ultra 2, LifeScan, Inc. Chesterbrook, PA) immediately 
before, and after the five-minute and 20-minute recovery muscle contractions. Blood 
sampling was commenced approximately 90 minutes after the standard breakfast and 
administration of diabetes medication— breakfast was completed 60 minutes before 
arrival of the participant and 30 minutes was allotted for preparation of each participant. 
Experimental Protocol 
The experimental protocol involved the following procedures: 
(5) Baseline MVICs: Participants completed at least three MVICs of knee extensor 
muscles for ~4 seconds each with 90 s between trials. Participants then performed four 
additional MVICs. Percutaneous muscle stimulation was superimposed before (to elicit a 
twitch contraction at rest) and immediately after each MVIC (to determine contractile 
function and voluntary activation of the knee extensor muscles). Electrical stimulation of 
the femoral nerve was also performed within 10 s after each MVIC to determine 
neuromuscular junction propagation.  
(6) After baseline MVICs, state perceptions and blood glucose were assessed.  
(7) Baseline MVCCs: Participants performed 10 MVCCs with a load equivalent to 
20% of MVIC as a warm-up. These isotonic contractions were performed through an 80º 
range of motion, from 90°of knee flexion to 10°of knee flexion. The participant then 
rested for 2.5 minutes, before initiating the dynamic fatiguing task.  
(8) Dynamic fatiguing task: The fatiguing exercise task involved 120 isotonic 
MVCCs of the knee extensor muscles at a rate of 1 MVCC every 3 seconds (6-minute 
task). Participants only performed the contractions for knee extension and the 
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dynamometer motor passively returned the limb to the starting position at 90º of knee 
flexion. After 60 and 120 (task completion) MVCCs, participants performed one MVIC.  
(9) Recovery Contractions: The recovery protocol involved sets of brief contractions 
immediately after the fatiguing task, and then at 5 and 20 minutes of recovery.  Each set 
of contractions involved one MVIC (with superimposed percutaneous muscle 
stimulation) followed by an electrically-evoked twitch contraction and then five 
successive MVCCs.  
(10) After the first recovery protocol immediately after the dynamic fatiguing task and 
within three minutes of completion of the dynamic fatiguing task, state perceptions and 
blood glucose were assessed.  
Each participant received strong verbal encouragement throughout the maximal 
effort contractions. During all MVCCs, participants were instructed to “kick as hard and 
as fast as possible” and each MVCC was initiated via strong verbal command from the 
authors, “KICK”. The authors provided the verbal cue each 3 s, based on a visual cue 
from a custom-designed data collection program, and participants were encouraged to 
maintain maximal effort throughout the dynamic exercise task with several standard 




Figure 4.1. Representative data for a maximal voluntary isometric contraction 
(MVIC) with electrical stimulation and two sets of five maximal-effort, high-velocity 
concentric contractions (MVCCs) and study diagram. A. Torque signal from a 62-
year old woman with prediabetes who performed an MVIC before (Baseline; black line) 
and immediately after (Task End; grey) the dynamic fatiguing task, with electrical 
stimulation superimposed to assess voluntary activation and contractile function. B. 
Calculated power (applied torque × half-wave rectified velocity), range of motion and 
applied torque signals from the 62-year old woman with prediabetes who performed five 
MVCCs at the start (black lines) and end (grey lines) of the fatiguing task. C. A diagram 
of the study protocol as described in Materials and Methods. 
Data Analysis 
Performance Fatigability: MVIC torque, MVCC power, and MVCC speed were the 
primary metrics of performance fatigability, although duty cycle, range of motion, and 
MVCC average and peak applied torque directly contribute to these metrics. The MVIC 
was quantified as the average torque over a 0.1 s interval around the maximal torque prior 
to eliciting the electrically-evoked superimposed twitch. The maximum angular velocity, 
power and torque during MVCCs were quantified as the maximum value during the 
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concentric phase of the contraction. The average torque during MVCCs was calculated 
during the concentric phase of the knee extension contraction. In addition, the duty cycle 
was calculated as: (active contraction time) · (active contraction time + relaxation time)-1 
(Sundberg & Bundle, 2015).  
Contractile Function: Contractile function of the knee extensor muscles was quantified 
from the resting twitch elicited with electrical stimulation of the quadriceps muscles.  
Variables included the peak amplitude of the resting twitch, contraction time, and half 
relaxation time. Half relaxation time was determined as the time interval in milliseconds 
(ms) elapsed from the peak twitch amplitude until the torque reached 50% of the peak 
twitch amplitude.  
Voluntary Activation: Voluntary activation was assessed with electrical stimulation and 
calculated using the following equation: voluntary activation = (1 – SIT · Resting Twitch-
1) × 100% (Gandevia, 2001; Todd et al., 2016).  
Fatigue and Recovery Calculations: The changes in variables during and immediately 
after the fatiguing task (fatigue) were calculated as: (xtask end–xbaseline) · (xbaseline)
-1 · 100%. 
Task end was considered the average of the last 5 contractions (contractions 116-120) of 
the dynamic fatiguing task for MVCC variables (power, speed, duty cycle, range of 
motion, peak torque and average torque) but task end values for all other variables. The 
changes in variables during the 20-minute recovery were calculated (relative to baseline) 
as: (xRecovery 20 – xtask end) · (xbaseline)
-1 · 100%. 
Statistics 
Values are reported as mean ± SD in the text and displayed as mean ± SE in the 
figures. Participant characteristics, baseline muscle function, questionnaire scores and 
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baseline dynamic contraction characteristics were compared across groups using a two-
way univariate analysis of variance (ANOVA) with two between-subject factors (group: 
T2D vs prediabetes vs. controls; sex: men vs. women). To verify changes across time for 
the dynamic fatiguing task with the knee extensor muscles or recovery after the dynamic 
fatiguing task, two-way repeated measures ANOVAs with group and sex as between-
subject factors were used to compare dependent variables of MVIC torque, MVCC 
velocity, power, duty cycle, range of motion, peak applied torque and average applied 
torque, electrically-evoked twitch amplitude, half relaxation time, contraction time, and 
voluntary activation. To determine the time effect of fatigue, variables were compared 
between baseline and immediately after the fatiguing task (Task End), while recovery 
was the time effect from immediately after the fatiguing contraction (Task End) until the 
end of the 20-minute recovery period (R20). Thus, two repeated measures ANOVAs 
were performed: one including baseline through the end of the fatiguing task (task end; to 
assess fatigue) and the other including task through recovery (R20; to assess recovery). 
Post hoc analysis (Tukey’s Honest Significant Difference (HSD)) was used to test for 
differences among groups (T2D vs prediabetes vs controls) when significant main effects 
of group or interactions across time were identified, with Bonferroni corrected P-values 
for multiple comparisons (P < 0.025). Separate Pearson correlation analyses were used to 
determine associations between primary measures of performance fatigability (reduction 
in MVCC power and MVIC torque) and participant characteristics (BMI, body fat, 
estimated VO2, physical activity, HbA1c, fasting plasma glucose, HOMA-IR, TSH, HDL, 
LDL and total cholesterol), clinical symptoms of fatigue (Fatigue Impact Scale), sleep 
quality index, depression scale, state perceptions (muscle cramps, pain, weakness, 
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soreness, and fatigue, and rating of perceived exercise), depression, electrically-evoked 
contractile function (amplitude, contraction time, and half-relaxation time), and activation 
of the knee extensors (voluntary activation and neuromuscular junction propagation). 
Three separate linear correlation analyses between performance fatigability and 
characteristics expected to be different between the groups (HbA1c,
 fasting plasma 
glucose, insulin, and HOMA-IR) were performed: separate regressions for each group, 
one regression including people with T2D and prediabetes, and one regression for the 
entire cohort. Linearity of bivariate correlations was verified with visual inspection. 
Preliminary and correlation analyses confirmed there were no violations of the 
assumptions of normality, linearity, or homoscedasticity. Significance was determined at 
P ≤ 0.05 except post hoc testing (P < 0.025), and all the analyses were performed in IBM 
Statistical Package for Social Sciences (SPSS) version 24. 
4.3 Results 
Participant Characteristics 
The three groups (T2D, prediabetes, controls) were similar in age (P = 0.165), 
height (P = 0.329), weight (P = 0.085), BMI (P = 0.129), relative body fat (P = 0.398), 
estimated maximal aerobic capacity (P = 0.224), daily physical activity (P = 0.868) and 
leg lean mass of the leg used for the dynamic fatiguing exercise (P = 0.514; Table 1).  
Medications: Among people with T2D, all (n = 39) participants were prescribed 
Metformin and 34 participants were prescribed a statin medication. Among people with 
prediabetes and controls, no participants were prescribed Metformin, but 5 people with 
prediabetes and 8 controls were prescribed a statin (Table 1). Although not an aim of the 
study, it is noteworthy that people prescribed a statin medication had similar reductions in 
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MVCC power compared to people not prescribed a statin among people with T2D (time 
× statin, P = 0.444), prediabetes (time × statin, P = 0.190) and controls (time × statin, P = 
0.142).  
 Blood Measures: Compared to controls, people with T2D had higher HbA1c (P < 
0.001), fasting plasma glucose (P < 0.001), insulin (P = 0.006) and HOMA-IR (P < 
0.001). Compared to people with prediabetes, people with T2D had higher HbA1c (P < 
0.001) and fasting plasma glucose (P = 0.004); however, fasting plasma insulin (P = 
0.514) and HOMA-IR (P = 0.325) were not different between the groups. Controls had 
lower HbA1c (P = 0.023) and HOMA-IR (P = 0.040) compared to people with 
prediabetes; however, fasting plasma glucose (P = 0.107) and insulin (P = 0.419) were 
not significantly different between the control and prediabetes groups. People with T2D, 
prediabetes and controls had similar fasting plasma thyroid stimulating hormone (TSH; P 
= 0.672), high density lipoprotein (HDL; P = 0.522), low density lipoprotein (LDL; P = 




Table 4.1. Participant characteristics and matching criteria. Each group (type 2 
diabetes, prediabetes and control) were similar in age, height, weight, BMI, body fat, 
estimated VO2, physical activity and leg lean mass (in the leg used for the dynamic 
fatiguing task). Values are displayed as mean ± standard deviation. BMI, body mass 
index; VO2, estimated maximal aerobic capacity; O2, oxygen. Tukey’s HSD post-hoc: *, 
T2D vs. control, P < 0.05; #, prediabetes vs. control, P < 0.05; †, T2D vs. prediabetes; ‡, 
sex difference, P < 0.05. 
Clinical Symptoms of Fatigue, Sleep Quality and Depression 
FIS: Total score (P = 0.509) and scores for each component of the FIS (cognitive 
(P = 0.537), physical (P = 0.254), and psychological (P = 0.586)) did not differ 
significantly between groups (T2D, prediabetes, control).  
Sleep and Depression: Sleep quality (P = 0.483) and depression scale scores (P = 
0.628) were not different between the three groups (T2D, prediabetes, control). 
      Control   Prediabetes   
Type 2 
Diabetes   
      (n = 27)   (n = 20)   (n = 39)   
Age years   58.1 ± 9.4   63.1 ± 6.0   61.2 ± 8.5   
Height m   1.72 ± 0.10   1.69 ± 0.08   1.73 ± 0.08 ‡ 
Weight kg   80.9 ± 17.4   77.5 ± 15.3   88.2 ± 22.5 ‡ 
BMI kg·m2   27.3 ± 4.3   26.9 ± 4.2   29.4 ± 6.4   
Body Fat %   31.5 ± 9.4   32.8 ± 6.0   33.8 ± 9.5 ‡ 
estimated VO2 mLO2·kg
-1·min-1   27.5 ± 8.7   36.9 ± 16.0   30.3 ± 10.2   
Physical Activity steps·day-1   8,400 ± 3,000   8,030 ± 3,110   8,440 ± 4,220   
Leg Lean mass kg   8.51 ± 2.37   8.25 ± 1.88   8.87 ± 2.40 ‡ 
Duration of Diabetes years   --   --   7.72 ± 6.87   
Metformin  n   0   0   39   
Metformin Dosage mg·day-1   --   --   1,155 ± 586   
Duration of Prescription years   --   --   4.6 ± 5.1   
Statin  n   8   5   34   
Duration of Prescription years   5.5 ± 6.0   7.2 ± 4.3   4.8 ± 4.9   
HbA1c %   5.40 ± 0.19   5.89 ± 0.29   7.15 ± 1.18 *#† 
Fasting Plasma Glucose mg·dL-1   85.9 ± 6.5   98.8 ± 18.2   123.5 ± 31.7 *† 
Insulin pMol   32.8 ± 20.3   47.2 ± 27.4   61.8 ± 42.0 * 
HOMA-IR AU   22.9 ± 13.9   42.8 ± 25.4   52.3 ± 30.4 *# 
TSH µIU·mL-1   1.58 ± 0.82   1.83 ± 1.05   1.75 ± 0.83   
HDL mg·dL-1   53.6 ± 17.2   52.7 ± 16.1   47.8 ± 16.0   
LDL mg·dL-1   103.5 ± 30.6   102.8 ± 38.9   89.1 ± 25.9   




 State Perceptions 
 VAS reports of muscle cramps, pain, weakness, soreness and fatigue at baseline 
were 0 among all people with T2D, prediabetes and controls. People with T2D, 
prediabetes and controls did not report an increase in muscle cramps (time, P = 0.054) 
after the dynamic fatiguing exercise; and the reported increase in muscle pain (time, P = 
0.008; time × group, P = 0.349), weakness (time, P < 0.001; time × group, P = 0.541), 
soreness (time, P = 0.028; time × group, P = 0.342) and fatigue (time, P < 0.001; time × 
group, P = 0.264) was not different between the three groups. Similarly, all participants 
reported 0 RPE at baseline and the increase in RPE after the dynamic fatiguing exercise 
(time, P < 0.001; time × group, P = 0.169) was not different between the three groups 




Table 4.2. Metrics contributing to perceived fatigability. Clinial symptoms of fatigue 
(Fatigue Impact Scale; cognitive, physical, psychological and total), sleep quality index 
and depression scale score were not different between groups (T2D, prediabetes, control). 
Reports of muscle cramps, pain, weakness, soreness and fatigue and rating of perceived 
exertion were 0 at baseline among all participants.  After the dynamic exercise, muscle 
cramps did not increase; however, the increase in muscle pain, weakness, soreness, 
fatigue and rating of perceived exertion (RPE) was not different between the three groups 
(type 2 diabetes vs. prediabetes vs. controls). Values are displayed as mean ± standard 
deviation. ‡, sex difference, P < 0.05. 
Performance Fatigability 
 At baseline, people with T2D, prediabetes and controls had similar values for 
MVIC torque (P = 0.465), MVCC power (P = 0.649), MVCC speed (P = 0.623), duty 
cycle (P = 0.228), range of motion (P = 0.322), peak applied torque (P = 0.538) and 
average applied torque (P = 0.728) (Table 3).  
 During the dynamic fatiguing task, the increase in duty cycle (time, P < 0.001; 
time × group, P = 0.175) and reduction in average applied torque (time, P < 0.001; time × 
group, P = 0.361) did not differ between groups (T2D, prediabetes, controls). People with 
T2D however, had greater reductions in MVCC power (time, P < 0.001; time × group, P 
< 0.001), MVCC speed (time, P < 0.001; time × group, P < 0.001), and range of motion 
    Control   Pre-Diabetes   Type 2 Diabetes   
    (n = 27)   (n = 20)   (n = 39)   
FIS Cognitive   3.19 ± 4.15   4.25 ± 5.09   4.74 ± 5.90 ‡ 
FIS Physical   3.89 ± 5.45   3.35 ± 4.79   6.08 ± 6.40 ‡ 
FIS Psychological   5.48 ± 9.99   4.90 ± 6.87   8.00 ± 11.49 ‡ 
FIS Total   12.6 ± 18.6   12.5 ± 15.1   18.3 ± 22.7 ‡ 
Sleep Quality Index   4.67 ± 2.60   3.90 ± 2.13   4.74 ± 2.30   
Depression Scale   0.92 ± 1.09   0.65 ± 0.93   1.10 ± 1.74   
State after Fatiguing Task               
Muscle Cramps   0 ± 0.1   0.3 ± 1.2   0.4 ± 1.4   
Muscle Pain   0.2 ± 0.6   0.3 ± 0.8   0.5 ± 1.3   
Muscle Weakness   0.9 ± 1.2   1.5 ± 2.2   1.2 ± 2.4   
Muscle Soreness   0.4 ± 0.9   0 ± 0.1   0.6 ± 1.5   
Muscle "Fatigue"   2.0 ± 1.8   3.2 ± 2.6   2.2 ± 2.2   




(time, P < 0.001; time × group, P < 0.001) than people with prediabetes (P < 0.001), and 
both groups had greater reductions in MVCC power than controls (P < 0.001). The 
reduction in peak applied torque was greater for people with T2D compared to healthy 
controls (T2D vs control, P = 0.014), however, both groups had similar reductions 
compared to prediabetes (T2D vs prediabetes, P = 0.185; Tukey’s post hoc, prediabetes 
vs control, P = 0.346). After the dynamic fatiguing task, the reductions in MVIC torque 






Figure 4.2. Maximal-effort, high-velocity concentric contractions (MVCC) power 
(% Baseline) (A), reductions (%) in measures of performance fatigability (B), and 
associations between MVCC power reduction (%) and electrically-evoked twitch 
torque reduction (C) and HbA1c (D). A. People with T2D had greater reductions in 
MVCC power than people with prediabetes, and people with T2D and prediabetes had 
greater reductions in MVCC power than controls during the dynamic exercise task. B. 
People with T2D had greater performance fatigability (reductions in MVCC power, 
speed, range of motion and peak applied torque) compared to controls. The reduction in 
MVCC power was associated with the reduction in electrically-evoked twitch amplitude 
(C; r = 0.592, r2 = 0.350, P < 0.001) and HbA1c (D; r = 0.477, r
2 = 0.228, P < 0.001). 
All the metrics of performance fatigability recovered during the 20-minute 
recovery (time, P < 0.001 for each metric).  There was no difference between groups in 
recovery of MVIC torque (time × group, P = 0.189), MVCC power (time × group, P = 
0.954), MVCC speed (time × group, P = 0.304), duty cycle (time × group, P = 0.872), 
range of motion (time × group, P = 0.751), peak applied torque (time × group, P = 0.863) 




Table 4.3. Performance fatigability. People with type 2 diabetes (T2D), prediabetes and 
healthy controls had similar volitional muscle performance at baseline. People with T2D 
had greater performance fatigability - greater reductions in MVCC power, MVCC speed, 
and range of motion - compared to people with prediabetes, and both groups (T2D, 
prediabetes) had greater performance fatigability compared to controls. Values are 
displayed as mean ± SD. MVIC, maximal voluntary isometric contraction; MVCC, 
maximal voluntary concentric contraction. Tukey’s HSD post-hoc: *, T2D vs. control, P 
< 0.05; #, prediabetes vs. control, P < 0.05; †, T2D vs. prediabetes, P < 0.05. 
Blood Glucose 
At baseline, and as anticipated, post-prandial blood glucose was higher for people 
with T2D compared to people with prediabetes (P = 0.001) and healthy controls (P < 
0.001); and there was no difference between people with prediabetes and controls (P = 
0.475). The absolute reduction in blood glucose after the dynamic exercise (time, P < 
    Control  Prediabetes  
Type 2 
Diabetes   
Baseline   (n = 27)  (n = 20)  (n = 39)   
MVIC Torque Nm 151.3 ± 59.1  139.8 ± 58.9  164.7 ± 70.0   
MVCC Power Watts 275.2 ± 86.1  254.0 ± 98.4  293.7 ± 132.0   
MVCC Speed degs·s-1 336.2 ± 44.0  336.3 ± 40.0  330.1 ± 56.1   
Duty Cycle % 14.1 ± 1.9  15.1 ± 2.0  14.8 ± 2.5   
Range of Motion deg 74.6 ± 8.7  78.7 ± 7.2  77.1 ± 10.2   
MVCC peak Torque Nm 65.5 ± 15.8  60.1 ± 20.1  67.4 ± 22.6   
MVCC average Torque Nm 44.3 ± 12.6  42.0 ± 15.0  47.0 ± 18.0   
Fatigue at Task End          
MVIC Torque % -26.2 ± 12.6  -29.1 ± 18.9  -37.7 ± 16.4   
MVCC Power % -22.1 ± 21.1  -31.8 ± 22.6  -44.8 ± 21.9 *†# 
MVCC Speed % -15.4 ± 16.0  -22.8 ± 21.1  -37.5 ± 22.0 *†# 
Duty Cycle % +23.3 ± 20.9  +20.5 ± 18.6  +35.0 ± 20.9   
Range of Motion % -0.8 ± 6.3  -8.5 ± 12.3  -14.7 ± 19.9 *† 
MVCC peak Torque % -11.8 ± 13.6  -14.9 ± 13.9  -19.4 ± 8.4 * 
MVCC average Torque % -8.3 ± 13.2  -12.8 ± 12.4  -13.4 ± 10.8   
Recovery at 20 minutes          
MVIC Torque % +18.4 ± 12.2  +20.1 ± 13.9  +23.2 ± 12.7   
MVCC Power % +38.9 ± 19.5  +36.8 ± 21.4  +42.0 ± 25.4   
MVCC Speed % +22.8 ± 14.5  +26.3 ± 18.6  +33.9 ± 24.9   
Duty Cycle % -18.5 ± 14.1  -19.7 ± 15.4  -22.5 ± 23.0   
Range of Motion % +4.9 ± 5.4  +12.0 ± 11.3  +14.0 ± 11.2   
MVCC Peak Torque % +24.7 ± 15.1  +22.4 ± 22.8  +23.2 ± 13.5   




0.001; time × group, P = 0.033) was greater for people with T2D compared to 
prediabetes (Tukey’s HSD, P = 0.002) and controls (Tukey’s HSD, P < 0.001), but not 
different for prediabetes and controls (Tukey’s HSD, P = 0.359). However, the relative 
reduction in blood glucose ((glucosebaseline – glucoserecovery5minutes)· glucosebaseline
-1·100%) 
was not different between the groups (group, P = 0.137). Blood glucose did not change 





Table 4.4. Electrically-evoked contractile function and activation of knee extensors. 
At baseline, contractile function was similar between people with type 2 diabetes (T2D), 
prediabetes and healthy controls. At fatigue, people with T2D had greater reductions in 
potentiated twitch amplitude and blood glucose compared to people with prediabetes and 
controls; however, impairments in contraction time and half-relaxation time were similar 
between groups (T2D, prediabetes, control). People with type 2 diabetes (T2D) and 
prediabetes and controls had a similar reduction in voluntary activation and no significant 
change in Mmax amplitude of the vastus lateralis. Values are displayed as mean ± SD. ¥, 
task end blood glucose levels were determined after the five-minute recovery 
contractions. Tukey’s HSD post-hoc: *, T2D vs. control, P < 0.05; †, T2D vs. 
prediabetes, P < 0.05. 
Electrically-Evoked Twitch Contractile Function 
Before the dynamic fatiguing task, the electrically-evoked twitch amplitude 
(group, P = 0.908), contraction time (group, P = 0.162), and half-relaxation time (group, 
P = 0.821) were not different between groups (T2D, prediabetes, control). After the 
dynamic fatiguing exercise (task end), the reduction in electrically-evoked twitch 
amplitude (time, P < 0.001; time × group, P = 0.027) was greater for people with T2D 
    Control  Prediabetes  Type 2 Diabetes   
Baseline (n = 27)  (n = 20)  (n = 39)   
Potentiated Twitch Nm 41.6 ± 18.5  43.9 ± 15.8  44.1 ± 18.5   
Contraction Time ms 85.9 ± 9.7  92.7 ± 15.5  89.5 ± 10.8   
Half-Relaxation Time ms 84.8 ± 24.2  84.8 ± 49.0  85.1 ± 25.3   
Blood glucose mg·dL-1 106.1 ± 17.3  114.3 ± 28.5  158.0 ± 46.7  *† 
Voluntary Activation % 92.8 ± 5.8  93.4 ± 11.6  94.5 ± 4.8   
Mmax Amplitude mV 12.04 ± 8.61  12.63 ± 1.76  10.61 ± 4.65   
Fatigue at Task End          
Potentiated Twitch % -21.3 ± 33.0  -32.5 ± 24.9  -44.0 ± 23.4 *† 
Contraction Time % -2.8 ± 10.4  +5.8 ± 14.1  +2.0 ± 14.2   
Half-Relaxation Time % +20.4 ± 37.8  +28.5 ± 46.5  +45.4 ± 46.7   
Blood glucose ¥ mg·dL-1 96.5 ± 11.1  105.0 ± 11.5  131.1 ± 37.4 *† 
Voluntary Activation % -6.17 ± 8.13  -6.63 ± 9.60  -5.48 ± 8.75   
Mmax Amplitude % +16.01 ± 23.12  +16.53 ± 18.96  +13.58 ± 33.49   
Recovery at 20 minutes        
Potentiated Twitch % +21.5 ± 39.8  +31.7 ± 45.0  +45.8 ± 44.3   
Contraction Time % -3.7 ± 11.6  +2.4 ± 11.6  -3.1 ± 9.0   
Half-Relaxation Time % -38.4 ± 35.8  -42.3 ± 56.1  -53.0 ± 49.7   
Blood glucose mg·dL-1 95.6 ± 11.9  104.8 ± 10.9  139.5 ± 39.3   




compared to controls, but not different between people with prediabetes and T2D or 
prediabetes and controls (control vs. T2D, P = 0.006; prediabetes vs. T2D, P = 0.297; 
control vs. prediabetes, P = 0.370). The increase in half relaxation time of the 
electrically-evoked twitch was not different between the three groups (T2D, prediabetes, 
control) (time, P < 0.001; time × group, P = 0.413), and the contraction time of the 
electrically-evoked twitch did not change after the dynamic fatiguing exercise (time, P = 
0.208).  
Electrically-evoked twitch amplitude (time, P < 0.001; time × group, P = 0.271) 
and half-relaxation time (time, P < 0.001; time × group, P = 0.457) recovered similarly 
for the three groups (T2D, prediabetes, controls) during the 20 minutes of recovery.  
There were no changes in electrically-evoked twitch contraction time during recovery 
(time, P = 0.906). See Table 4. 
Voluntary Activation 
 Voluntary Activation: At baseline, voluntary activation did not differ between 
groups (group, P = 0.587). Similarly, the reduction in voluntary activation after the 
dynamic fatiguing exercise was not different between groups (time, P = 0.001; time × 
group, P = 0.931). Voluntary activation did not increase (remained depressed) during the 
20-minute recovery period for any participant (time, P = 0.452).  
Neuromuscular Junction Propagation 
 Mmax: The Mmax amplitude and area for the vastus lateralis did not differ between 
groups at baseline and did not change after the fatiguing task. Similar results (no group 
differences and no change after the fatiguing task) were observed for the Mmax amplitude 
and area of each agonist muscle (rectus femoris, vastus lateralis, and vastus medialis). 
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Given the similar results between measurements (Mmax amplitude and area) and muscles, 
only the Mmax amplitude results for the vastus lateralis are presented (Table 4). 
Associations 
The reduction in MVCC power during the fatiguing exercise was associated with 
several baseline measurements, including HbA1c (r = 0.477, r
2 = 0.228, P < 0.001), 
estimated VO2peak (r = -0.394, r
2 = 0.155, P = 0.001), body fat (r = 0.293, r2 = 0.086, P 
= 0.008), HOMA-IR (r = 0.289, r2 = 0.084, P = 0.050), and diabetes duration for people 
with T2D (r = 0.247, r2 = 0.061, P = 0.038). Reductions in MVCC power were also 
associated with the declines in the range of motion (r = 0.685, r2 = 0.469, P < 0.001), 
duty cycle (r = 0.630, r2 = 0.397, P < 0.001), resting twitch amplitude (r = 0.592, r2 = 
0.350, P < 0.001), and MVIC torque (r = 0.505, r2 = 0.256, P < 0.001).   
Reductions in MVIC torque after the fatiguing exercise were associated with: 
range of motion reduction (r = 0.578, r2 = 0.334, P < 0.001), resting twitch amplitude 
reduction (r = 0.542, r2 = 0.294, P < 0.001), HbA1c (r = 0.361, r
2 = 0.130, P = 0.001), 
HOMA-IR (r = 0.294, r2 = 0.086, P = 0.050), voluntary activation reduction (r = 0.258, 
r2 = 0.067, P = 0.045), and fatigue impact scale physical (r = 0.244, r2 = 0.060, P = 
0.030).  
 In analyses separated by group (T2D, prediabetes, control), HbA1c was associated 
with reductions in MVCC power (r = 0.379, r2 = 0.144, P = 0.017) but not reductions in 
MVIC torque (P = 0.191) for people with T2D. In analyses of data from people with 
prediabetes, HbA1c was associated with reductions in MVIC torque (r = 0.554, r
2 = 
0.307, P = 0.021) but not reductions in MVCC power; (P = 0.319). For controls, HbA1c 
was not associated with reductions in MVIC torque (P = 0.863) or reductions in MVCC 
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power (P = 0.646). In analyses pooled for people with prediabetes and T2D, HbA1c was 
associated with reductions in MVCC power (r = 0.424, r2 = 0.180, P < 0.001) and 
reductions in MVIC torque (r = 0.310, r2 = 0.100, P = 0.024).   
Sex Differences 
 There were anticipated sex-related differences in several baseline measurements.  
Men were taller (P < 0.001), had greater body mass (P < 0.001), less percentage body fat 
(P < 0.001), and greater lean mass (P < 0.001).  Perceived fatigability differed between 
the sexes because men reported higher values on FIS for the cognitive (P = 0.033), 
physical (P = 0.025), psychological (P = 0.029) and total score of the FIS (P = 0.017).  
Men were also stronger and more powerful than women (P < 0.001) and had greater 
electrically-evoked twitch amplitude than women (P < 0.001) for the knee extensor 
muscles. However, there were no sex-related differences (main effects or interactions) in 
any measurements of performance fatigability or perceived fatigability (P > 0.05). 
4.4 Discussion 
The novel finding of this study was that people with prediabetes had greater 
performance fatigability during and after a dynamic task with the knee extensor muscles 
compared with controls who were matched for physical activity, age, sex, and body mass 
index. Furthermore, performance fatigability was even greater for people with T2D than 
prediabetes and controls. There was no impairment in neuromuscular propagation at the 
neuromuscular junction and only modest reductions in neural drive from the motor cortex 
(~6%) which were similar for all groups. Thus, the group-related differences in 
performance fatigability were not due to muscle activation or neural drive to the knee 
extensor muscles. However, there were observed reductions in electrically-evoked 
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contractile function of the knee extensors and greater reductions in contractile function 
were associated with greater performance fatigability, such that people with T2D had the 
greatest reduction in knee extensor power and twitch amplitude.  Accordingly, people 
with prediabetes exhibited an intermediate decline in both knee extensor power during 
the dynamic fatiguing exercise and electrically-evoked contractile function after the 
dynamic fatiguing task.  Collectively, these results suggest that although there were 
(similar) reductions in voluntary activation, greater fatigability for people with T2D and 
prediabetes was primarily due to mechanisms impairing contractile function of the 
skeletal muscle.  
Although there were expected and observed sex-related differences in body mass, 
body size and baseline muscle function, there were no observed sex-related differences in 
fatigability or recovery among people with T2D, prediabetes or controls. These data 
confirm our previous findings in male and female controls and people with T2D 
(Senefeld et al., 2018c). Maximal knee extensor power (MVCC) and assessments of 
contractile function demonstrated substantial recovery during the 20 minutes after the 
dynamic fatiguing exercise for each group, providing evidence that the exercise did not 
induce muscle damage which typically lasts for up to 72 hours post exercise (Cheung et 
al., 2003). Although each group (T2D, prediabetes and control) demonstrated recovery of 
MVIC torque, there were lasting reductions in MVIC torque (~10%) and voluntary 





 The average participant in this cohort was ~60 years, overweight (BMI, ~28 
kg·m-2; body fat ~32%) and relatively active with ~8,200 steps·day-1 (Tudor-Locke et al., 
2011). Despite the relatively high physical activity, the prevalence of prediabetes among 
the potential control participants who enrolled in the study was ~42%, which is similar to 
the estimated proportion of older adults with prediabetes in the US - 48% (Prevention, 
2017). People with prediabetes had greater HbA1c, estimated insulin resistance (HOMA-
IR) and performance fatigability compared with controls, but lower HbA1c and 
performance fatigability than people with T2D (Table 1). The reductions in MVCC 
power were approximately 100% greater for people with T2D than controls (42% vs. 
22%) and 50% greater for people with prediabetes than controls (32% vs. 22%). These 
data demonstrate clear and incremental differences in performance fatigability (reduction 
in MVCC power and MVIC torque) between the groups; and these differences were 
associated with HbA1c and HOMA-IR. We speculate that the association between HbA1c 
and HOMA-IR and greater fatigability could be due to the associated impairments in 
metabolic function (Abdul-Ghani & DeFronzo, 2010) (e.g. reduced glucose-uptake, fat 
oxidation, and oxidative phosphorylation) or vascular function (Montero et al., 2013; 
Poitras et al., 2018) (e.g. decreased endothelial-dependent vasodilation, capillary 
rarefaction, and reduced cardiac output) secondary to insulin resistance. 
Performance Fatigability 
 The fatigue-related reduction of knee extensor power during the high-velocity 
dynamic exercise was progressively greater according to group - controls (22%), people 
with prediabetes (32%), and people with T2D (45%). Despite these differences, the 
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results likely underestimate the magnitude of greater performance fatigability for people 
with prediabetes and T2D, because there were greater reductions in the range of motion 
during the dynamic fatiguing task for people with T2D (14%) and prediabetes (9%) 
compared with the controls (1%). The reduction in range of motion demonstrates reduced 
knee extensor work during the dynamic fatiguing task and was associated with 
performance fatigability (r2 = 0.469). Our findings of greater fatigability are consistent 
with previous research demonstrating greater fatigability of people with type 1 diabetes 
mellitus and diabetic polyneuropathy compared to controls for isometric contractions of 
the dorsiflexors (Allen et al., 2015a) and knee extensors (Almeida et al., 2008), and 
greater fatigability of people with T2D and no clinically-evident diabetic polyneuropathy 
compared to controls for isometric contractions of the finger flexors (Petrofsky et al., 
2005). However, our data are the first to demonstrate greater limb fatigability in people 
with prediabetes compared with healthy controls matched for age, body size and physical 
activity; and people with T2D (and no clinically-evident diabetic polyneuropathy) had 
even greater limb fatigability than people with prediabetes.  
Mechanisms of Performance Fatigability 
 The mechanisms contributing to both the reductions in knee extensor power and 
MVIC torque with the dynamic fatiguing task included a loss in voluntary activation 
within the motor cortex (~6%) and reduction in contractile function (twitch amplitude 
and half-relaxation time) of the knee extensor muscles (~20% for controls, ~30% for 
people with prediabetes and ~40% for people with T2D).  However, there was no 
observed decline in the neuromuscular transmission of the action potentials from the 
alpha motor neuron to the sarcolemma (M wave).  
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The exercise-induced reduction in voluntary activation was not different between 
the groups (control, prediabetes, T2D), was weakly associated with the reduction in 
MVIC torque (r2 = 0.067) and was not associated with the reduction in MVCC power, 
suggesting that neural mechanisms played a minor role in the difference between groups 
in the reduction in MVIC torque and probably the reduction in MVCC power. It is 
notable, however, that assessment of voluntary activation during these high-velocity 
(>350 deg·s-1) dynamic contractions was not performed in this study because of the 
methodological limitations in assessment of voluntary activation during high-velocity 
contractions (Rozand et al., 2017). Voluntary activation was assessed during maximal 
static contractions immediately after the dynamic fatiguing task and given the moderate 
correlation between the reduction in MVIC torque and MVCC power (r2 = 0.256), the 
reduction in voluntary activation during static contractions may not accurately reflect the 
reduction in voluntary activation during dynamic contractions. 
 There is evidence that diabetes is associated with changes in the activation of the 
motor unit, including reduced motor nerve conduction velocities (Almeida et al., 2008), 
reduced and more variable motor unit discharge rates (Almeida et al., 2008; Watanabe et 
al., 2013), and disrupted neuromuscular transmission (Allen et al., 2015a). Additionally, 
greater impairments in neuromuscular transmission were associated with greater 
fatigability of maximal strength contractions after an isometric fatiguing task among 
people with T1D and diabetic polyneuropathy (Allen et al., 2015a). Neuromuscular 
transmission was quantified in our cohort with amplitude and area of the M wave (Mmax) 
of the vastus lateralis, vastus medialis and rectus femoris; however, there were no group-
related differences nor any reductions of neuromuscular transmission. The difference 
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between studies probably is due to the absence of clinically-evident diabetic 
polyneuropathy in our cohort.   
 The greater performance fatigability of people with prediabetes and T2D was 
associated with larger impairments in muscle contractile properties, quantified with the 
electrically-evoked twitch amplitude. The magnitude of the reduction of MVCC power 
and electrically-evoked twitch amplitude were remarkably similar for people with T2D 
(44.8 vs. 44.0%), people with prediabetes (31.8 vs. 32.5%) and healthy controls (22.1 vs. 
21.3%), providing evidence of the close relationship between performance fatigability 
and muscle contractile properties. The reductions in twitch amplitude reflect a decline in 
the number of high-force cross-bridges formed and the amount of force per cross-bridge 
(Debold et al., 2016). However, the kinetics of the electrically-evoked twitch - the 
contraction time and half-relaxation time - were not different between the groups after the 
fatiguing task. The kinetics of the twitch are likely reflective of intracellular calcium and 
cross-bridge cycling (Kent-Braun et al., 2012). Considered together, the primary 
mechanisms contributing to greater fatigability of the knee extensor muscles in people 
with prediabetes and T2D were likely due to impaired force production from the cross-
bridge formation of actin and myosin, secondary to a lower number of cross-bridges or 
less force per cross-bridge. Accumulation of metabolic by-products (particularly 
hydrogen ion and inorganic phosphate) could be responsible for inhibition of cross-bridge 
force production (Fitts, 2008, 2016), suggesting that people with prediabetes and T2D 
may have experienced greater intracellular accumulation of or greater sensitivity to 
myocellular metabolites.  
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The association between larger HOMA-IR and impairments in contractile 
function after the fatiguing task may suggest that the downstream manifestations of 
insulin resistance may result in greater impairments in contractile function of people with 
prediabetes and T2D. Insulin resistance affects many tissues (e.g. liver, coronary arteries, 
brain) (Rask-Madsen & Kahn, 2012), and the effects of insulin resistance on muscle and 
peripheral vasculature would most likely contribute to greater impairments in contractile 
function during exercise. Insulin resistance can induce impairments in peripheral 
vasculature including impaired vasodilation (Montero et al., 2013; Phillips et al., 2015; 
Mahmoud et al., 2016), capillary density or recruitment (Serne et al., 1999), endothelial 
function  and skeletal muscle blood flow (Reynolds et al., 2017; Poitras et al., 2018; 
Senefeld et al., 2018b) and impaired metabolic function in skeletal muscle including 
reduced insulin-stimulated glucose uptake (Holloszy, 2003; Szendroedi & Roden, 2008) 
and reduced mitochondrial quality or quantity (Porter & Wall, 2012; Montgomery & 
Turner, 2015), and these mechanisms may contribute to greater fatigability in people with 
insulin resistance (i.e. prediabetes and T2D). These potential mechanisms warrant future 
investigations. 
To simulate typical life conditions, participants performed dynamic fatiguing 
exercise ~90 minutes after consuming a standard breakfast. A recent systematic review 
concluded that among people with diabetes, exercise conducted postprandially blunts 
hyperglycemia and improves various measures of glycaemia more than exercise 
conducted in the fasted state (Borror et al., 2018). As anticipated, postprandial blood 
glucose levels were greater for people with T2D compared to the other groups 
(prediabetes, control); however, each group demonstrated a similar relative decline in 
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blood glucose (~10%) after the dynamic fatiguing exercise. Postprandial (insulin-
stimulated) glucose transport is impaired among people with insulin resistance (DeFronzo 
& Tripathy, 2009), largely accounting for the greater postprandial blood glucose in 
people with T2D, however, use of metformin after breakfast would have facilitated 
muscle glucose uptake.  Exercise stimulates glucose flux into skeletal muscle via a 
separate pool of intracellular glucose transporters (GLUT4) and this process is not 
impaired in diabetes (Goodyear & Kahn, 1998). Hence it is reasonable to assume that the 
reductions in blood glucose concentration during and after exercise in all groups were 
due to the combination of exercise- and insulin-stimulated glucose disposal; the latter 
being facilitated by metformin among those with T2D. In terms of potential influences on 
fatigue, we cannot partition relative contributions of the longer-term effects of prevailing 
glycaemia (indicated by HbA1c) and acutely elevated blood glucose concentration.  
Metrics Contributing to Perceived Fatigability 
 Although perceived fatigability is common among people with T2D and could 
perhaps contribute to increased rates of depression, anxiety and fatigue in people with 
T2D compared to controls (Fritschi & Quinn, 2010), our cohort had minimal evidence of 
perceived fatigability. Our metrics of clinical symptoms of fatigue (Fatigue Impact 
Scale), sleep quality, depression, and state perceptions (rating of perceived exertion and 
muscle cramps, pain, weakness, soreness and fatigue) that can contribute to perceived 
fatigability were similar across the groups (T2D, prediabetes and control). Thus, among a 
cohort with homogeneous and low reports of perceived fatigability, there were no 
associations between perceived fatigability and performance fatigability. We speculate 
that the negligible reports of perceived fatigability are due to minimal levels of co-
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morbidities in our cohort— participants had relatively low rates of obesity (30% 
participants), relatively good glycemic control (HbA1c ≤ 7.0%; 75% of people with T2D), 
and there were high numbers of participants with physical activity greater than 7000 
steps·day-1 (70% participants). Even so, this “healthy” cohort of people with T2D or 
prediabetes who volunteered for this exercise study (and hence are likely to be more 
active and well-disposed towards exercise) had poorer glycemic control, greater 
performance fatigability and greater impairments in knee extensor contractile function 
compared to controls, and our results likely underestimate the magnitude of these issues 
in the “average” person with T2D or prediabetes. 
Conclusion 
 For the first time, we demonstrated that the knee extensor muscles of people with 
prediabetes were 50% more fatigable than controls for a dynamic fatiguing task even 
when matched for physical activity levels, body mass index, age and sex. We also 
showed that people with T2D were more fatigable than people with prediabetes, and this 
was evidenced as a greater reduction in knee extensor power and maximum isometric 
strength. Perceived fatigability did not differ between the groups and appeared to have 
minimal influence on performance fatigability.  Reductions in voluntary activation 
contributed to the reduction in maximal force for each group; however, the greater 
fatigability of people with prediabetes and diabetes compared to controls was primarily 
due to muscle contractile mechanisms. Although exercise is a cornerstone of T2D 
management and prevention, the greater performance fatigability among people with 
prediabetes and T2D (with minimal reports of perceived fatigability and co-morbidities) 
may be a significant physiological barrier to exercise tolerance in this clinical population. 
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However, exercise training can improve glycemic control, enhance skeletal muscle blood 
flow and capillary density, improve insulin sensitivity and insulin-stimulated glucose 
uptake in skeletal muscle and increase mitochondrial quantity (Marwick et al., 2009; 
Stanford & Goodyear, 2014).  Such adaptations could reduce or offset the greater 
performance fatigability and reductions in contractile function in people with prediabetes 




CHAPTER 5: EXERCISE-INDUCED HYPEREMIA IS ASSOCIATED WITH 
FATIGABILITY IN HUMAN TYPE 2 DIABETES 
This manuscript is currently in review. 
Senefeld J, Limberg JK, Lukaszewic KM and Hunter SK. Exercise-Induced 
Hyperemia is Associated with Knee Extensor Fatigability in Human Type 2 
Diabetes. 
5.1 Introduction 
 The Diabetes Prevention Program demonstrated that a 3-year lifestyle 
intervention, including diet, weight loss and regular exercise, lowered the risk of 
developing type 2 diabetes mellitus by 58% among an at-risk population (Knowler et al., 
2002). A 10-year follow-up of this study estimated that lifestyle intervention resulted in 
the delay of development of type 2 diabetes by 4 years (Diabetes Prevention Program 
Research et al., 2009). Lifestyle therapy has therefore become the first line of medical 
intervention for management of type 2 diabetes (Garber et al., 2018), with physical 
exercise serving as the cornerstone of lifestyle therapy.  
Physical exercise can result in fatigability of limb muscles.  Fatigability of limb 
muscles is a reversible, short-term, activity-induced reduction in muscle strength or 
power (Gandevia, 2001), and when followed by adequate recovery, induces appropriate 
physiological adaptations of the neuromuscular system (Kraemer & Ratamess, 2004). 
Excessive fatigability or inadequate recovery however, may contribute to exercise 
intolerance and reduced adherence to exercise training. Greater fatigability has been 
shown to limit the performance of repeated contractions of limb muscles that are 
common during daily tasks (Hunter, 2017). We recently demonstrated that the knee 
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extensor muscles of patients with type 2 diabetes are more fatigable compared with age-, 
(body mass index) BMI-, and physical activity-matched controls after a six-minute, 
dynamic exercise due to impairments within the contractile properties of the muscles 
(Senefeld et al., 2018a; Senefeld et al., 2018c). Such deficits in contractile function could 
be mediated by impaired oxygen kinetics in skeletal muscle of patients with type 2 
diabetes (Poitras et al., 2018). 
 Although there is no definitive conclusion that muscle oxygen delivery is 
diminished in patients with type 2 diabetes (for review, see (Poitras et al., 2018)), there is 
strong evidence to support impaired skeletal muscle blood flow regulation in this 
population, possibly contributing to greater fatigability than healthy controls (Montero et 
al., 2013; Poitras et al., 2018). The increase of skeletal muscle blood flow during exercise 
(exercise-induced hyperemia) is governed by complex interactions between cardiac and 
muscular pump, sympathetic nervous system control, local vasoactive metabolites and 
autacoids (Joyner & Casey, 2015). Ultimately, however, the control of blood flow is 
largely dictated by vessel diameter of skeletal muscle arterioles which is dependent on 
endothelial response to chemical and metabolic stimuli (Joyner & Casey, 2015). A recent 
meta-analysis (Montero et al., 2013) demonstrated impaired endothelial function, 
commonly assessed with flow-mediated dilation (Thijssen et al., 2011), in non-exercising 
vasculature in patients with type 2 diabetes compared with age-matched controls in 28 
out of 29 studies.  However, there is a dearth of knowledge examining patients with type 
2 diabetes compared with controls when possible confounders are controlled for such as 
age, sex, body size and physical activity levels.  
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The purpose of the study therefore was to compare fatigability, contractile 
function, and exercise-induced hyperemia after dynamic exercise with the knee extensor 
muscles between patients with type 2 diabetes and age-, BMI- and physical activity-
matched controls. Our hypotheses were: 1) fatigability of the knee extensor muscles 
would be greater in patients with type 2 diabetes compared with healthy controls, and 2) 
greater fatigability would be associated with greater reductions in skeletal muscle 
contractile function and reduced exercise-induced hyperemia.  
5.2 Research Design and Methods 
Fifteen patients with type 2 diabetes (7 women) and 15 healthy, age-, BMI, and 
physical activity-matched controls (7 women) participated in the study. Although we 
have previously demonstrated no sex-related differences in fatigability in patients with 
type 2 diabetes (Senefeld et al., 2018a; Senefeld et al., 2018c), biological sex was 
accounted for in the study design and reporting of findings as suggested by the National 
Institutes of Health (NOT-OD-15-102). All women enrolled were post-menopausal. No 
participants were taking hormone replacement drugs or vasoactive medications. All 
patients with type 2 diabetes were prescribed a statin and Metformin; however, control 
participants were prescribed no medications. Prior to involvement, each participant 
provided written informed consent and the protocol was approved by the Marquette 
University Institutional Review Board in accordance with the Declaration of Helsinki. 
Inclusion and Screening Criteria 
Type 2 diabetes was physician-diagnosed. Exclusion criteria included: prescribed 
insulin or insulin secretagogue, glycated hemoglobin (HbA1c)>10%, diabetic neuropathy, 
peripheral edema, BMI>45 kg·m-2, untreated hypothyroidism, current smoking, 
126 
 
cardiovascular or musculoskeletal disease that precluded exercise testing. Participants 
who presented with HbA1c 5.7%-6.5% without a diagnosis of type 2 diabetes were 
classified as having pre-diabetes and not included in the study; thus, all controls had an 
HbA1c≤5.6%. Participants abstained from caffeine and vigorous exercise for the 24 hours 
prior to each session. 
Screening Session 
During a screening session, participants underwent diabetic neuropathy screening, 
HbA1c testing, dual-energy x-ray absorptiometry (DEXA) scan, a graded exercise test, 
completed questionnaires and were issued a physical activity monitor. Participants 
abstained from food for 2 hours prior to the screening session.  
Diabetic neuropathy screening: Participants were screened for the presence of 
diabetic polyneuropathy using 10-g monofilament, 128-Hz vibration, and tendon jerk, as 
performed previously (Senefeld et al., 2018a; Senefeld et al., 2018c).  
HbA1c: HbA1c was determined using blood from a fingerstick (Siemens 
Healthcare Diagnostics, DCA 2000+). 
DEXA: Whole body and dominant leg anthropometrics (total, fat and skeletal 
muscle mass) were assessed using dual x-ray absorptiometry (DEXA; Lunar Prodigy, 
Madison, WI).  
Physical Activity: Accelerometry data were collected (Actigraph GT3X+, 
ActiGraph, Pensacola, FL) via waist monitor worn for 4 days (2 weekdays and weekend 
days) with 60s epochs. Wear-time was set a priori (≥ 3 days of ≥ 9 hours per day) and 
was authenticated (Hart et al., 2011b). 
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Submaximal, Graded Bicycle Test: To assess estimated aerobic capacity (eVO2), 
participants performed a submaximal graded exercise test (Beekley et al., 2004) on a 
bicycle ergometer (VIAsprint 150P, CareFusion, San Diego, CA) with 12-lead 
electrocardiogram (CASE, General Electrics, Madison, WI). The selected protocol was 
designed to elicit incremental heart rate responses between 40% and 70% of heart rate 
reserve during three, steady-state efforts for four-minutes each.  
Questionnaires: Clinical symptoms of fatigue, depression and sleep quality were 
assessed with the Fatigue Impact Scale (Fisk et al., 1994), short form Geriatric 
Depression Scale (Burke et al., 1991), and Pittsburgh Sleep Quality Index (Buysse et al., 
1989), respectively.  
Study Protocol 
 Within one week of the screening session, participants completed three 
experimental sessions. Experimental sessions were performed on different days separated 
by 2 – 7 days. Experiments began in the morning (~8:00 AM) after a 12-hour fast and 
prior to administration of medication. During the first experimental session, participants 
underwent a flow-mediated dilation study of the right brachial artery and were 
familiarized with the lower limb dynamic fatiguing contraction. During the second 
experimental session, participants underwent a flow-mediated dilation study of the right 
superficial femoral artery and performed a six-minute dynamic fatiguing contraction with 
the non-dominant knee extensors. During the third experimental session, participants 
performed a 6-minute dynamic fatiguing contraction with the dominant knee extensors. 




 Flow-mediated dilation (FMD) studies were performed while participants were 
lying supine and afebrile, and the room temperature was ~70°F. After quiet rest, blood 
pressure was manually auscultated in the left arm of the participant every two minutes 
until the mean arterial pressures of two consecutive measurements were within 5% 
(Thijssen et al., 2011).   
 Artery diameter and blood flow velocity were assessed simultaneously using 
duplex mode Doppler ultrasound (Vivid E, General Electrics, Madison, WI) with an 8-
MHz linear array probe with insonation angle of 60°. For arm measurements, the 
ultrasound probe was placed overlying the brachial artery at the mid-point between the 
cubital fossa and axilla, with the arm in ~90 degrees of abduction and forearm held 
midway between pronation and supination. For leg measurements, the ultrasound probe 
was placed overlying the superficial femoral artery, 2.5 cm distal to the bifurcation of the 
common femoral artery; the position was recorded and replicated during exercise-induced 
hyperemia studies. Electrocardiogram was recorded and synced with ultrasonography 
(USB ECG, NORAV medical, Germany).  
 A rapid inflation pneumatic cuff system (Hokanson Rapid Cuff, DE Hokanson, 
Inc., USA) was used to apply a supra-systolic pressure (250 mmHg) to occlude blood 
flow for five minutes, and then immediately release the pressure. Blood flow velocities 
were assessed in the two-minutes before occlusion and for 30s immediately post-
occlusion and arterial diameters were assessed for five minutes post-occlusion (Thijssen 
et al., 2011). Blood flow velocity was assessed as the average maximum velocity of three 
consecutive cardiac cycle segment and averaged across three segments. Arterial diameter 
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was assessed with custom-designed software (AccessPoint Suite, Freeland Systems LLC, 
Georgia) by a single rater blinded to the participants’ diabetes status. Arterial diameter 
was assessed at end diastole over a 2-cm segment. The average diameter before occlusion 
and the maximum diameter after occlusion were used to calculate flow-mediated dilation.  
Exercise-Induced Hyperemia 
 Arterial diameter and blood flow velocity were assessed as described above; 
however, the six-minute exercise replaced the five-minute occlusion.  On separate days, 
the dynamic fatiguing contraction was performed with the dominant and non-dominant 
legs.  Femoral artery blood flow was assessed on the dominant leg femoral artery during 
both experiments.  Thus, when exercise was performed with the non-dominant leg, blood 
flow measures in the dominant leg served as an inactive limb control and a proxy for the 
contribution of central mechanisms of blood flow.  
Dynamic Lower Limb Exercise 
  Participants were seated in a Biodex dynamometer (System 4, Biodex Medical, 
Shirley, NY) with 90º of hip and knee flexion to perform all knee extension torques, 
velocity and power during isometric and dynamic contractions as described before 
(Senefeld et al., 2018c). Padded straps were securely tightened across each shoulder and 
the waist.  
At the beginning of each session, 3-5 brief (~4s) maximal voluntary isometric 
contractions (MVICs) were performed with the knee extensors until two MVIC torque 
values were within 5%. Four additional MVICs were performed in the same manner with 
stimulation within 3s after each MVIC to assess skeletal muscle contractile properties. 
The muscles were stimulated with a single pulse (150 – 750 mA; DS7AH, Digitimer, 
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Ltd., Welwyn Garden City, UK) via custom-made pad electrodes (6 cm×~15 cm). The 
cathode was placed within 10 cm of the femoral triangle and the anode was placed 
immediately proximal to the patella. Stimulator current was increased until the 
electrically-evoked twitch amplitude plateaued, and then the current was increased 20% 
(Senefeld et al., 2018d). 
The maximum MVIC torque value was recorded and used to calculate the 20% 
MVIC load for the dynamic fatiguing exercise. Participants then performed the dynamic 
fatiguing task involving 120 maximal voluntary concentric contractions (MVCCs) once 
every three seconds (six minutes total). One MVCC involved maximal velocity 
concentric knee extension until full extension followed by passive knee flexion (180º·s-1). 
One MVIC was performed after the 60th MVCC, and immediately after the dynamic 
exercise. 
Mechanical recordings from the dynamometer corresponding to torque, velocity 
and position were digitized using a 1401 A–D converter and Spike 2 software 
(Cambridge Electronics Design, Cambridge, UK) with a sampling frequency of 2,000 Hz.  
Data Analysis 
Skeletal Muscle Function and Fatigability: The peak power during the concentric 
phase of each MVCC was determined. Fatigability was determined as the reduction in the 
average peaks of first five contractions of the fatiguing task to the last five contractions. 
Contractile properties that were quantified from electrically-evoked knee extensor 
contractions included the peak amplitude of the resting twitch, its contraction time (time 
elapsed from the rise in the twitch force until the peak twitch), and half relaxation time 
(time elapsed from the peak twitch amplitude until the torque reached 50% of the peak 
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twitch amplitude). The magnitude of change in outcome variables (other than power) was 
calculated: (xtaskend–xbaseline)/xbaseline×100%. 
Normalization of Vasodilation and Hyperemia: Increased blood flow is a 
mechanical stimulus causing increased shear stress to vascular endothelium (Pyke et al., 
2004). Shear rate (the rate of shear stress) can increase vasodilation in a dose-dependent 
fashion (Thijssen et al., 2011), thus FMD responses were normalized to shear rate (i.e. 
FMD×(shear rate)-1×100%). Similarly, because limb size can affect hyperemic responses 
(Limberg et al., 2010), limb skeletal muscle mass was used to normalize skeletal muscle 
blood flow (i.e. (blood flow)×(muscle mass)-1×100%. Shear rate was calculated (Gibbs et 
al., 2011): 4×(mean blood velocity)×(artery diameter)-1. Blood flow was calculated 
(Padilla et al., 2008): (mean blood velocity)×π×radius2×60.  
Statistical Analysis 
Two-way univariate analyses of variance (ANOVAs) with group and sex as 
between subject factors were used to compare physical characteristics and baseline 
measures of skeletal muscle contractile properties. To verify changes after 5-minute 
occlusion and the dynamic exercise, separate two-way repeated measures ANOVAs (pre 
vs. post) with group and sex as between subject factors and repeated measures were used 
to compare the dependent variables, including MVIC torque, MVCC power, peak twitch 
amplitude, contraction time and half relaxation time. For each ANOVA, the sphericity of 
data was verified with Mauchly’s test. After checking for normality of data (Shapiro-
Wilk test), Pearson product-moment correlation coefficient was used determine 
association between the measurement of fatigability (reduction in MVCC power) and 
participant characteristics (HbA1c, estimated VO2 peak, skeletal muscle mass, and daily 
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step count), vascular variables (exercise-induced hyperemia, baseline brachial and 
femoral diameter, and FMD responses) and changes in skeletal muscle contractile 
properties. Significance was determined at P<0.05 and analyses were performed in IBM 
statistical package for social sciences (SPSS) version 24. 
5.3 Results 
For all variables, the main effect of sex or the interactions of sex with time or 
group are only reported if significant, otherwise these statistics are not reported (P>0.05).  
Physical Characteristics and Estimated Aerobic Capacity  
 Patients with type 2 diabetes were not different to controls for age, height, weight, 
BMI, body fat, daily step count, estimated aerobic capacity, and thigh lean mass (P>0.05, 
Table 1). As expected, patients with type 2 diabetes had higher HbA1c compared with 
control subjects (group, P<0.001). 
Men were taller (sex, P<0.001), had lower body fat (sex, P<0.001), higher 
estimated maximal aerobic capacity (sex, P=0.026) and greater thigh lean mass (sex, 




    Type 2 Diabetes   Control   
    n = 15   n = 15   
Baseline Characteristics         
Age years 62.4 ± 9.0   58.4 ± 6.9   
Diabetes duration years 9.2 ± 7.1   -- * 
Height cm 173 ± 9   170 ± 7 † 
Weight kg 92 ± 29   82 ± 15 † 
BMI kg·m-2 30.4 ± 7.7   28.4 ± 4.6   
HbA1c % 7.0 ± 0.8   5.6 ± 0.3 * 
Body Fat % 34.0 ± 10.7   34.6 ± 9.9 † 
Daily Steps n 7200 ± 3200   7900 ± 2300   
eVO2 mL·kg
-1·min-1 36.8 ± 12.2   40.2 ± 20.4 † 
Questionnaires         
Fatigue Impact Scale AU 12.8 ± 14.7   10.9 ± 15.0   
Depression: GDS AU 0.8 ± 1.1   0.7 ± 0.9   
Sleep Quality: PSQI AU 5.3 ± 2.1   4.7 ± 2.4   
Muscle Function         
MVIC Torque Nm 153 ± 67   151 ± 69 † 
MVCC Power Watts 329 ± 53   340 ± 38 † 
Peak Twitch Torque Nm 32.3 ± 12.1   40.3 ± 18.6 † 
HRT Nm 86.1 ± 21.2   74.0 ± 24.0   
CT ms 86.9 ± 8.2   89.4 ± 6.6 † 
Fatigability         
MVIC % 32.0 ± 14.6   36.5 ± 13.9   
MVCC % 30.0 ± 20.1   14.6 ± 19.0 * 
Peak Twitch Torque % 37.6 ± 24.8   31.6 ± 30.1   
HRT % +39.5 ± 46.0   +19.2 ± 29.7   
CT % NS   NS   
Table 5.1. Patient characteristics, questionnaire scores and skeletal muscle function. 
Values are displayed as mean ± standard deviation. Patients with type 2 diabetes and 
controls were similar in characteristics, questionnaire scores and skeletal muscle 
function; however, patients with type 2 diabetes had increased HbA1c compared to 
controls.  BMI, body mass index; HbA1c, glycated hemoglobin; eVO2, estimated aerobic 
capacity; GDS, Geriatric Depression Scale; PSQI, Pittsburgh Sleep Quality Index; 
MVIC, maximal voluntary isometric contraction; MVCC, maximal voluntary concentric 
contraction; HRT, half-relaxation time; CT, contraction time; NS, not significant. *, 
group differences, P < 0.05; †, sex differences, P < 0.05. 
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Fatigue, Depression, and Sleep Questionnaires 
 Patients with type 2 diabetes and controls did not differ for scores on the Fatigue 
Impact Scale (group, P=0.755), depression (group, P=0.726) or sleep quality (group, 
P=0.579). See Table 1. 
Baseline Skeletal Muscle Function  
Patients with type 2 diabetes and controls were not different for baseline measures 
of MVIC torque (group, P=0.754), MVCC power (group, P=0.482), electrically-evoked 
peak twitch amplitude (group, P=0.327), half-relaxation time (group, P=0.232), and 
contraction time (group, P=0.339). However, men had higher MVIC torque (sex, 
P=0.002), MVCC power (sex, P=0.049), twitch amplitude (sex, P=0.028) and shorter 
contraction time (sex, P=0.038) than women, independent of group (Table 1). 
Fatigability 
 Patients with type 2 diabetes had greater reductions in limb power than controls 
by the end of the fatiguing contraction (time, P<0.001; time×group, P<0.001). After the 
fatiguing exercise, both groups had reductions in MVIC torque (time, P<0.001; 
time×group, P=0.675), electrically-evoked twitch amplitude (time, P=0.002; time×group, 
P=0.981), and increases in half-relaxation time (time, P=0.042; time×group, P=0.358). 
The contraction time did not change for either group following exercise (time, P=0.710; 





Figure 5.1. Fatigability and exercise-induced hyperemia in patients with type 2 
diabetes mellitus and healthy controls. Maximal voluntary concentric contraction 
(MVCC) power (% Baseline) (A), reductions in maximal voluntary isometric contraction 
(MVIC) torque and electrically-evoked twitch amplitude (B), and exercise-induced 
hyperemia in the dominant artery after exercise in the dominant and non-dominant legs 
(C). Group data are displayed as mean ± SEM, and women are represented in grey filled 
symbols. A. Patients with type 2 diabetes had greater reductions in MVCC power than 
controls (P<0.05). B. The reductions in MVIC torque and electrically-evoked twitch 
amplitude did not differ between patients with type 2 diabetes and controls (P>0.05). C. 
Patients with type 2 diabetes had a lower exercise-induced hyperemia compared with 




 Dominant Leg Exercise: Patients with type 2 diabetes had smaller femoral artery 
diameter at rest than controls (group, P=0.036) and men had greater femoral artery 
diameter than women (sex, P=0.012), with no interaction of sex and group. Resting 
femoral artery blood flow was not different between groups (group, P=0.762).  However, 
controls had larger increases in femoral artery blood flow (exercise-induced hyperemia) 
than patients with type 2 diabetes after the dynamic exercise with the dominant leg when 
expressed relative to baseline flow (time, P<0.001; time×group, P=0.040), relative to 
thigh lean mass (time, P<0.001; time×group, P=0.047), and for the absolute blood flow 
(time, P<0.001; time×group, P=0.043). See Table 2 and Figure 1C. 
 Non-dominant Leg Exercise: At rest, controls and men had larger femoral artery 
diameter than patients with type 2 diabetes and women respectively (group, P=0.044; 
sex, P=0.020). Baseline femoral artery blood flow was not different between groups 
(group, P=0.662). After the dynamic fatiguing exercise in the non-dominant leg, both 
groups demonstrated similar increases in femoral artery blood flow in the resting limb 
when expressed relative to baseline flow (time, P<0.001; time×group, P=0.770), relative 
to thigh lean mass (time, P<0.001; time×group, P=0.941), and for absolute blood flow 
(group, P=0.683). However, the increased blood flow in the dominant leg artery was 
lower during the resting condition (non-dominant leg exercise; experimental session 2) 
than the exercising condition (dominant leg exercise; experimental session 3) (time×limb, 





Table 5.2: Flow-mediated dilation (FMD) and exercise-induced hyperemia (EIH) for 
patients with type 2 diabetes mellitus and healthy controls. Values are displayed as 
mean ± standard deviation. Patients with type 2 diabetes and controls did not differ in 
flow-mediated dilation of the brachial and femoral arteries, and exercise-induced 
hyperemia (EIH) of the non-dominant limb (Non). However, controls had greater EIH 
compared to patients with type 2 diabetes after the fatiguing contraction with the 
dominant (Dom) leg. FMD, flow-mediated dilation; Δ, change; ks, kilosecond; Norm., 
normalized. *, group differences, P < 0.05; †, sex differences, P < 0.05. 
    Type 2 Diabetes   Control   
    n = 15   n = 15   
Brachial FMD         
Diam. Max Time s 90.7 ± 37.8   80.2 ± 23.9   
Resting Diam. mm 3.62 ± 0.56   3.79 ± 0.44 † 
Resting Shear s-1 171.3 ± 93.1   202.5 ± 93.0   
Shear End s-1 788.4 ± 243.2   826.1 ± 232.8   
Shear Δ % 418.2 ± 165.4   341.5 ± 135.0   
FMD μm 32.7 ± 16.6   33.7 ± 12.6   
FMD % 9.52 ± 6.08   9.88 ± 3.19   
FMD %·ks-1 14.8 ± 3.4   14.3 ± 4.1   
Femoral FMD         
Diam. Max Time s 114.9 ± 47.8   97.3 ± 3.3   
Resting Diam. mm 5.92 ± 0.80   6.61 ± 0.70 *† 
Resting Shear s-1 132.2 ± 54.2   118.4 ± 58.9   
Shear End s-1 324.9 ± 137.2   363.3 ± 116.1   
Shear Δ % 156.3 ± 86.8   219.3 ± 170.6   
FMD μm 45.1 ± 24.1   36.0 ± 21.5   
FMD % 7.31 ± 3.29   6.39 ± 2.99   
FMD %·ks-1 39.4 ± 18.5   32.4 ± 11.8   
EIH Dominant         
Resting Diam. mm 5.91 ± 0.88   6.57 ± 0.83 *† 
Resting Flow mL·min-1 416 ± 137   465 ± 210   
Flow End mL·min-1 994 ± 222   1221 ± 321 * 
Flow Δ mL·min-1 598 ± 181   778 ± 202 * 
Flow Δ % 177 ± 90   194 ± 79 * 
Thigh Lean Mass kg 8.23 ± 2.84   8.15 ± 2.05 † 
Norm. Flow Δ % 169 ± 82.4   198 ± 76.4 * 
EIH Non-Dominant         
Resting Diam. mm 5.96 ± 0.76   6.49 ± 0.68 *† 
Resting Flow mL·min-1 365 ± 141   377 ± 180   
Flow End mL·min-1 604 ± 166   638 ± 310   
Flow Δ mL·min-1 239 ± 104   261 ± 162   
Flow Δ % 77.3 ± 46.9   60.9 ± 41.3   





 Brachial Artery: At rest, brachial artery diameter was not different between 
groups (group, P=0.735); however, men had greater diameter compared to women for 
both groups (sex, P=0.015). After occlusion, patients with type 2 diabetes and controls 
had similar increases in absolute brachial artery diameter (time, P<0.001; time×group, 
P=0.379; group, P=0.735), relative to baseline diameter (group, P=0.651), and relative to 
shear rate (group, P=0.493). Both groups demonstrated similar increases in shear rate 
(time, P<0.001; time×group, P=0.625). See Table 2 and Figure 2E. 
Femoral Artery:  At rest, patients with type 2 diabetes had smaller femoral artery 
diameter than controls (group, P=0.004), and men had greater femoral artery diameter 
compared with women (sex, P<0.001). Diameter was similar across the three trials (FMD 
and two exercise sessions; trial, P=0.903). After occlusion, patients with type 2 diabetes 
and controls did not differ in the increases in absolute femoral artery diameter (time, 
P<0.001; time×group, P=0.203; group, P=0.689), when relative to baseline diameter 
(group, P=0.475), and relative to shear rate (group, P=0.798). Both groups demonstrated 





Figure 5.2: Flow-mediated dilation for patients with type 2 diabetes mellitus and 
healthy controls. Representative data for femoral artery diameter from before (A) and 
after (B) five-minute occlusion for flow-mediated dilation (FMD) studies and blood flow 
velocity curves before (C) and after (D) FMD, and group data for FMD studies of the 
brachial (E) and femoral (F) arteries. Group data are displayed as mean ± SEM, and 
women are represented in grey filled symbols. Femoral artery diameter and blood flow 
velocity of a 55-year old man with type 2 diabetes. Patients with type 2 diabetes and 
controls demonstrated similar FMD of the brachial artery (E) and femoral artery (F) 
diameter after the 5-minute bout of occlusion (P>0.05). 
Correlation and Regression Analysis 
 The reduction in MVCC power at the end of dynamic exercise was associated 
with the following: the reduction in resting twitch amplitude (r=0.645, r2=0.416, 
P=0.001), baseline femoral artery diameter (r=-0.631, r2=0.398, P=0.003), change in 
blood flow after the dominant leg dynamic exercise (r=-0.557, r2=0.310, P=0.009), and 
HbA1c (r=0.544, r




The novel findings of this study were that patients with type 2 diabetes had 
greater lower-limb fatigability and a lower hyperemic response to dynamic fatiguing 
exercise with the knee extensor muscles than healthy controls who were matched for age, 
BMI and physical activity. There were no sex differences for either variable. Greater limb 
fatigability was associated with a greater loss in contractile function, higher HbA1c, a 
reduced exercise-induced hyperemic response and smaller baseline artery diameter 
suggesting that impairments in peripheral tissue (vascular and contractile) mediate the 
greater limb fatigability in people with type 2 diabetes.  
There is a growing evidence indicating that patients with type 1 or type 2 diabetes 
have greater fatigability of skeletal muscle (Petrofsky et al., 2005; Almeida et al., 2008; 
Allen et al., 2015a; Senefeld et al., 2018a; Senefeld et al., 2018c). We have previously 
shown that greater fatigability of people with type 2 diabetes is due to mechanism(s) 
originating in the muscle (Senefeld et al., 2018a; Senefeld et al., 2018c). Although neural 
mechanisms contribute to fatigability in patients with type 2 diabetes and controls, the 
reductions in neural drive were similar for both groups (Senefeld et al., 2018a; Senefeld 
et al., 2018c), and group differences were due to greater changes in contractile function 
in the patients with type 2 diabetes than the controls. This current investigation provides 
evidence that a reduced hyperemic response in skeletal muscle blood flow could be a 
primary contributing factor to that loss of contractile function and large lower limb 
fatigability in people with type 2 diabetes during repeated dynamic contractions.  
Although there is substantial evidence of impaired endothelial/smooth muscle 
function in people with type 2 diabetes (Montero et al., 2013), we demonstrated that in 
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the individuals studied, patients with type 2 diabetes and controls had similar flow-
mediated dilation of the brachial and femoral arteries. This unique finding is likely due to 
study design because our participants (with and without type 2 diabetes) on average were 
not obese, were relatively active, had well-controlled blood glucose, relatively high 
aerobic fitness, minimal reports of clinical symptoms of fatigue. These data suggest that 
despite healthy macrovascular endothelial function and limited co-morbidities, patients 
with type 2 diabetes have microvascular impairments, reduced exercise-induced 
hyperemia and greater fatigability.  Such deficits may reduce exercise training tolerance 
and impair performance of activities of daily living.  
Exercise-Induced Hyperemia  
The reduced exercise-induced hyperemia response in patients with type 2 diabetes 
after the dynamic fatiguing exercise are consistent with findings that patients with type 2 
diabetes have reduced femoral blood flow during repeated knee extension exercise 
compared with controls (Lalande et al., 2008). However, we also observed a small 
exercise-induced hyperemic response after non-dominant limb exercise that was similar 
between patients with type 2 diabetes and controls, providing evidence that systemic 
changes to the cardiovascular system did not contribute to lesser exercise-induced 
hyperemic response after dominant limb exercise in patients with type 2 diabetes.  
Instead, these data suggest that the impairments in exercise-induced hyperemia in patients 
with type 2 diabetes was primarily due to mechanisms within the exercising limb. The 
down-stream implications of reduced exercise-induced hyperemia in patients with type 2 
diabetes as assessed in the present investigation may include: attenuated perfusion, 
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oxygenation and blood flow kinetics in skeletal muscle and microcirculation (Padilla et 
al., 2006; Bauer et al., 2007; Zheng et al., 2014).  
Doppler ultrasound is a measure of blood flow which is a proxy for supply of 
oxygen to skeletal muscle, but not an assessment of oxygen demand within the muscle. 
The attenuated blood flow response could be secondary to a smaller physiological 
stimulus to increase oxygen delivery to skeletal muscle in patients with type 2 diabetes. 
However, mechanisms contributing to increased oxygen demand in the skeletal muscle 
(e.g. increased concentrations of hydrogen ion and inorganic phosphate) (Korthuis, 2011) 
also cause reductions in twitch amplitude (Debold et al., 2016). Because patients with 
type 2 diabetes and controls had similar reductions in twitch amplitude after the fatiguing 
exercise, the greater attenuated blood flow response after exercise was likely not due to 
reduced metabolic demand in patients with type 2 diabetes. Thus, we speculate that the 
reduced exercise-induced hyperemic response (possibly indicating impairments in 
skeletal muscle microcirculation) likely contributed to the greater reductions of 
contractile function and fatigability in patients with type 2 diabetes. These mechanisms 
however, warrant future investigations. 
Flow-Mediated Dilation 
 Flow-mediated dilation was similar for patients with type 2 diabetes and healthy 
controls for both the brachial artery and femoral artery, even when normalized to shear 
rate. Patients with type 2 diabetes commonly have reduced FMD which may be indicative 
of impaired microvascular and macrovascular endothelial health and vascular smooth 
muscle function (for review, see (Montero et al., 2013)). Our data demonstrate that 
attenuated FMD-response may not be an obligatory consequence of type 2 diabetes per se 
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but may occur in the presence of additional co-morbidities or worsened symptoms of type 
2 diabetes (e.g. poor glycemic control or diabetic polyneuropathy).  
Importantly, despite similar thigh mass and position of recording relative to 
common femoral artery bifurcation, the controls repeatedly demonstrated a larger resting 
femoral artery diameter compared to patients with type 2 diabetes for three separate 
measurements (femoral FMD and both dynamic fatiguing exercises). This group-related 
difference in artery diameter likely reflects increased vasoconstrictor tone in patients with 
type 2 diabetes, possibly secondary to an imbalance of vasoconstrictors (e.g. endothelin-
1) and vasodilators (e.g. nitric oxide) (Phillips et al., 2015; Mahmoud et al., 2016). 
Although vascular remodeling could induce a physiologically-limited artery size 
(Kozakova & Palombo, 2016), our data demonstrated a robust flow-mediated dilation 
response in patients with type 2 diabetes, suggesting the reduced artery size is due to 
vascular tone versus remodeling. The increased vasoconstrictor tone has been associated 
with upregulation of smooth muscle endothelin receptors, and both are implicated in the 
pathogenesis of hypertension and atherosclerosis (Mahmoud et al., 2016). Thus, although 
the functional measure of FMD was similar to controls, there may be an underlying 
impairment in vascular health in patients with type 2 diabetes.  
Correlations with Fatigability 
 Our data suggest vascular dysfunction as a mechanism underlying greater 
fatigability in patients with type 2 diabetes. Vascular dysfunction was observed as 
increased resting vasoconstrictor tone and an attenuated hyperemic response to dynamic 
exercise. These impairments in vascular function may contribute to reduced O2 delivery 
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and ultimately transport within the microvasculature, which may disrupt skeletal muscle 
contractile function.   
Clinical Importance 
 Patients with type 2 diabetes have greater lower limb fatigability than controls 
during dynamic exercise, independent of the effects of obesity, diabetic polyneuropathy, 
poor glycemic control, and physical activity. We showed for the first time that this 
greater limb fatigability was associated with reduced skeletal muscle blood flow and 
contractile function [the latter as we have observed previously (Senefeld et al., 2018a; 
Senefeld et al., 2018c)]. Greater limb fatigability can promote exercise intolerance, 
possibly resulting in reduce exercise training adherence. Importantly, exercise training is 
primary to type 2 diabetes management and there is evidence that vascular function and 
fatigability can improve with exercise training in patients with type 2 diabetes (Maiorana 
et al., 2001; Hamdy et al., 2003; Green et al., 2006; Laughlin, 2016). These data suggest 
treatments focused on improving vascularization and/or blood vessel tone may be 
effective in enhancing perfusion and reversing impairments in fatigability and contractile 




CHAPTER 6: CONCLUSIONS & FUTURE DIRECTIONS 
 The purpose of this dissertation was to determine the difference in fatigability 
during and in response to high-velocity dynamic contractions between people with T2D 
compared to controls matched for age, sex, anthropometry and physical activity, and 
identify the contributing mechanisms. The studies in this dissertation clearly and 
repeatedly demonstrated greater fatigability in people with T2D compared to matched 
controls. For the first time, we demonstrated that people with prediabetes have less 
fatigability than people with T2D but greater fatigability than matched controls. These 
studies provide evidence that impaired muscle contractile function and skeletal muscle 
blood flow were associated with the greater fatigability after the dynamic contractions. 
This chapter provides a summary of the key findings of this dissertation and proposes 
future studies to continue to address limitations in knowledge. The set of descriptive 
studies included in this dissertation demonstrated that people with T2D (Chapter 3-5) and 
prediabetes (Chapter 4) have greater fatigability due to impairments in muscular 
mechanisms, particularly the blood flow response during exercise (Chapter 5), rather than 
greater impairments in neural mechanisms.  
These data add to the current body of literature that demonstrate across several 
contraction types and tasks, people with diabetes mellitus (type 1 or type 2; with or 
without diabetic polyneuropathy) have greater fatigability during single limb exercise 
(isometric and low-to-moderate velocity and high-velocity contractions) for several 
muscles groups (dorsiflexors, plantar flexors, knee extensors, knee flexors, and finger 
flexors) compared with controls—even when matched for lean mass, body size, and 
physical activity levels, see Figure 6.1.  
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 Collectively with other data from the literature (see Figure 6.1), it is clear that 
people with T2D have greater limb fatigability across different contraction types and 
contraction intensities, and this dissertation indicates that the primary mechanisms 
responsible for these differences are due to greater fatigue within the exercising muscle 
among people with T2D. The primary mechanisms could be related to diabetic 
polyneuropathy-related reductions in muscle contractile function, metabolic dysfunction, 
endothelial dysfunction and impaired motor unit properties. However, previous studies 
have predominantly compared fatigability in people with T2D compared to controls with 
low BMI (lean controls) and physical activity has not been objectively assessed to 
describe participants. Thus, the greater fatigability in people with T2D compared to 
controls may have been attributed to higher BMI or lower physical activity levels in 
people with T2D compared with controls. Crucially, the studies in this dissertation 
matched people with T2D to controls based on BMI and objectively assessed physical 
activity (accelerometer)—in addition to matching according to age and sex. This 
dissertation demonstrated that people with T2D and prediabetes have greater fatigability 
than matched controls, providing evidence that T2D per se contributes to increased 
fatigability outside of the detrimental effects of increased BMI and reduced physical 
activity.  
These findings have important application to exercise training and activities of 
daily living.  These findings highlight potential mechanisms (muscular and peripheral 
blood flow) for increased exercise intolerance and reduced adherence to exercise training 
in people with T2D (Poitras et al., 2018). Future interventional studies should focus on 
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mitigating the impairments in metabolic build-up or sensitivity and the vascular (macro-, 
micro-vascular or both) response during exercise. 
 
Figure 6.1. Forest Plot of standard mean differences in fatigability between controls 
and people with T2D. Represented are mean data from high-velocity, isotonic (studies 
from this dissertation), isometric and isokinetic (120 & 180°·s-1) contraction studies. The 
group difference in fatigability (% controls) is plotted and calculated as the mean 
difference (equation 1.1). Collectively, across all tasks represented in these plotted 
studies, people with diabetes mellitus were more fatigable across several limb muscles 
than controls. 
 In Chapter 3, people with T2D and no signs of diabetic polyneuropathy 
demonstrated greater fatigability of the knee extensor muscles compared to healthy, 
matched controls after a dynamic contraction. In this study, transcranial magnetic 
stimulation and electrical stimulation of the muscles were used to determine the site 
along the motor pathway which contributed to the group-related differences in 
fatigability. This study addressed two important limitations in the current body of 
literature: 1) matching people with T2D and controls based on age, sex, anthropometrics 
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and physical activity and 2) examining fatigability during high-velocity dynamic 
contractions. The findings demonstrated that people with T2D have greater reductions in 
muscle power (i.e. greater fatigability) than controls matched for age, sex, body size and 
physical activity. Although there was no group-related difference in the reduction of 
voluntary activation nor impairments in neuromuscular propagation, people with T2D 
had greater reductions in electrically-evoked muscle contraction amplitude and this was 
positively correlated with fatigability. These data suggest that people with T2D have 
greater fatigability than healthy controls—even when closely matched— and that 
impaired contractile function was the primary mechanism. Whether people with T2D 
have greater fatigability for isometric and low-to-moderate velocity contractions than 
controls matched for age, sex and physical activity is not known and warrants future 
investigation.  
 In Chapter 4, three cohorts of people were recruited and matched according to 
age, sex, anthropometry and physical activity—people with T2D and no signs of diabetic 
polyneuropathy, people with HbA1c levels in a prediabetes range (>5.6% and  <6.5%) and 
healthy controls. Electrical stimulation of the knee extensors was used to determine the 
site along the motor pathway which contributed to fatigability after high-velocity 
dynamic contractions. This study determined difference in fatigability between people 
with prediabetes compared to people with T2D and controls, a novel investigation. The 
findings demonstrated a progressive increase in fatigability in people with prediabetes 
and T2D than controls. The findings supported Study 1 and provided repeatable evidence 
of greater fatigability in people with T2D compared to controls, and reductions in 
electrically-evoked twitch amplitude were associated with fatigability, but reductions in 
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voluntary activation were not. These data replicated findings from Study 1 and provided 
evidence that people with prediabetes have greater fatigability than controls but less 
fatigability than people with T2D.  
 In Chapter 5, Doppler ultrasonography was used to assess flow-mediated dilation 
of the brachial and femoral arteries (as a proxy for endothelial function) and exercise-
induced hyperemia after a dynamic exercise task with the knee extensors in people with 
T2D and no signs of diabetic polyneuropathy compared to healthy, matched controls. 
This study was used to determine the contribution of vascular impairments to greater 
fatigability in people with T2D. The findings supported that people with T2D have 
greater reductions in muscle power (greater fatigability) and smaller increases in skeletal 
muscle blood flow after dynamic fatiguing contraction (exercise-induced hyperemia) 
compared to matched controls, as observed in Study 1 and 2. Greater knee extensor 
muscle fatigability was associated with lesser exercise-induced hyperemia at the end of 
the dynamic contractions, suggesting that an impaired ability to adequately increase 
blood flow in response to exercise may contribute to greater fatigability in people with 
T2D. Whether precise mechanisms of vascular function during exercise that may mediate 
greater fatigability in people with T2D during dynamic contractions is unknown and 
warrants future investigation.   
6.1 Contractile and Metabolic Function Contribution to Fatigability 
 Each study in this dissertation demonstrated a strong association between greater 
reductions in electrically-evoked contraction amplitude and power during dynamic 
contractions of the knee extensor muscles, suggesting that skeletal muscle regulation 
during exercise may be impaired in people with T2D. Impaired contractile function of 
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skeletal muscle after fatiguing exercise is thought to reflect disturbances in excitation-
contraction coupling, accumulation of metabolites, and/or impaired calcium handling 
(Fitts, 2008; Debold et al., 2016), that ultimately reduce the torque that is able to be 
produced by the muscle fibers. As discussed in Chapter 3, people with T2D have 
maintained neuromuscular transmission, half-relaxation time of the electrically-evoked 
contraction and post-activation potentiation suggesting that impaired contractile function 
is due to metabolic by-products in the skeletal muscle (e.g. hydrogen ion and inorganic 
phosphate). These data lead to two logical hypotheses: 1) people with T2D have greater 
accumulation of metabolic by-products or 2) the muscle fibers of people with T2D have 
greater sensitivity to metabolic by-products.  
6.2 Skeletal Muscle Blood Flow Contribution to Fatigability 
 Study 3 demonstrated an association between fatigability and blood flow at the 
end of the high-velocity dynamic contractions, suggesting that skeletal muscle blood flow 
during exercise may be blunted in people with T2D. The blunted blood flow response 
would be secondary to dysfunction in the micro- and/or macro-vasculature. There is 
evidence of impaired microvascular and macrovascular function in people with T2D, and 
this is one of the primary mechanisms implicated to cause poor exercise tolerance in 
people with T2D (Poitras et al., 2018). As discussed in Chapter 5, people with T2D have 
maintained macrovascular function in the femoral artery, suggesting microvascular 
dysfunction may contribute to greater fatigability in people with T2D. These data provide 
rationale to closely examine microvascular function and the potential association with 
greater fatigability in people with T2D.  
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 The similar flow-mediated dilation of both the femoral and brachial arteries 
between people with T2D compared to controls observed in Aim 3 (Chapter 5) strikingly 
contrasts a robust difference in flow-mediated dilation between people with T2D and 
controls observed in the literature (Montero et al., 2013). Data were extracted from 11 
different studies (black bars in Figure 6.2) assessing flow-mediated dilation of the 
brachial artery  in people with T2D compared to controls, and each study demonstrated 
less flow-mediated dilation in people with T2D—see Figure 6.2 (Enderle et al., 1998; 
Anderson et al., 2001a; Ma et al., 2001; Ihlemann et al., 2002; Tan et al., 2002; 
Woodman et al., 2002; Ifrim & Vasilescu, 2004; Karabag et al., 2007; Bruno et al., 
2012). Importantly, however, the group average of flow-mediated dilation from the 469 
people with T2D was 5.1 ± 2.9% (grey bar in Figure 6.2), which was nearly 50% of the 
response of the observed cohort in Aim 3 (white bar in Figure 6.2). This marked 
difference between the data from Aim 3 and previous data is likely reflective of the 
characteristics of the participants with T2D recruited for Aim 3—these participants with 
T2D had well-controlled HbA1c (7.0 ± 0.8%), were highly physically active (7,200 ± 
3,200 steps per day), were relatively aerobically fit (36.8 ± 12.2 mL·kg-1·min-1), had no 
prescription to insulin, and had no signs of diabetic polyneuropathy. Importantly, the 
mean flow-mediated dilation of the controls from Aim 3 (9.88 ± 3.19%) was not different 
compared to the mean flow-mediated dilation of the 325 control participants from the 11 
studies (7.72 ± 3.76%). The data providing evidence of convergent validity of the flow-
mediated dilation experiments performed for Aim 3 and supporting evidence that the 
striking lack of difference in flow-mediated dilation between people with T2D and 
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controls observed in Aim 3 was due to a difference in the cohort of people with T2D 
participating in Aim 3 relative to the body of literature.  
 
Figure 6.2. Summary of flow-mediated dilation studies in brachial artery of controls 
and people with type 2 diabetes. Each bar graph represents the mean and standard 
deviation of flow-mediated dilation in controls (panel A) and people with T2D (panel B). 
The bars filled with black represent 11 studies (Enderle et al., 1998; Anderson et al., 
2001a; Ma et al., 2001; Ihlemann et al., 2002; Tan et al., 2002; Woodman et al., 2002; 
Ifrim & Vasilescu, 2004; Karabag et al., 2007; Bruno et al., 2012) identified from a 
recent review (Montero et al., 2013), the bar filled with grey represents the mean of the 
11 studies, and the bar filled with white represents data from the brachial artery included 
in Aim 3. 
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6.3 Motor Unit Properties Contribution to Fatigability 
 Although not assessed in this dissertation, there is evidence that impaired 
modulation of motor units during exercise may contribute to greater fatigability in people 
with diabetes mellitus (type 1 and type 2). Previous studies have demonstrated that 
people with diabetes mellitus have disrupted neuromuscular transmission (Allen et al., 
2015a), slower baseline motor nerve conduction velocities (Almeida et al., 2008), 
decreased mean motor unit discharge rates (Almeida et al., 2008; Watanabe et al., 2013), 
and greater variability of motor unit discharge rates (Watanabe et al., 2013) compared to 
controls. This area of study warrants future investigations.  
6.4 Future Directions 
 Three areas of future mechanistic studies were suggested (above)— metabolic 
function, skeletal muscle blood flow and motor unit properties. To determine if people 
with T2D have greater accumulation of metabolic by-products, near-infrared 
spectroscopy (NIRS) and magnetic resonance spectroscopy (31P-MRS) can be used to 
evaluate baseline mitochondrial function and accumulation of metabolic by-products in 
vivo during dynamic contractions with the knee extensors in people with T2D and 
controls. NIRS can be used to determine recovery kinetics of concentrations 
oxyhemoglobin and deoxyhemoglobin after a sustained perturbation (brief occlusion or 
exercise) and subsequent occlusion/perfusion sequence using a portable, superficial probe 
(Ryan et al., 2012), and compare the time constant of a recovery curve (plotting the slope 
of each curve as a function of time) to quantify mitochondrial function in people with 
T2D and controls. The 31P-MRS can be used in vivo during dynamic exercise to estimate 
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relative concentrations of metabolic by-products (e.g. hydrogen ion and inorganic 
phosphate) to directly compare accumulation of metabolic by-products between people 
with T2D and controls. 
 To examine skeletal muscle blood flow, NIRS could be used to determine skeletal 
muscle oxygenation during exercise (REF) and microvascular function could be 
determined in response to flow-induced dilation and vasoactive reagents to determine the 
reactivity of the microvasculature—which is indicative of endothelial and vascular 
smooth muscle function (Mahmoud et al., 2016). To examine motor unit properties, high-
density, surface EMG with multichannel linear array electrodes could be used in 
conjunction with blind source separation and decomposition algorithms to assess motor 
unit properties during isometric exercise (Farina et al., 2014; De Luca et al., 2015; 
Muceli et al., 2015; Negro et al., 2016).  
6.5 Summary 
 In summary, this dissertation demonstrated that people with T2D have greater 
fatigability of the knee extensor muscles during a high-velocity exercise compared to 
people with prediabetes, and both groups (T2D, prediabetes) had greater fatigability than 
controls, with each group matched for age, sex, anthropometry and physical activity. 
Specifically, this dissertation provided evidence of 2-fold greater reductions in muscle 
power during a six-minute task for people with T2D (Chapters 3 - 5) than controls and 
1.5-fold greater fatigability in people with prediabetes compared with controls (Chapter 
4). The greater fatigability was associated with impairments in electrically-evoked 
muscle contractile properties (T2D and prediabetes, Chapter 3 - 5) and impaired blood 
flow response during exercise (T2D, Chapter 5). These findings may: 1) direct 
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mechanistic studies to examine the properties within the muscle that contribute to greater 
fatigability, 2) inform longitudinal studies to improve fatigability in people with T2D and 
prediabetes, which may reduce the incidence of T2D and prediabetes, and 3) provide a 
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